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1 Summary 
 
Human immunodeficiency virus (HIV-1) particles assemble and bud at the host cell plasma 
membrane and are released as immature, noninfectious particles. Concomitant with release, 
the viral protease (PR) cleaves Gag and GagProPol polyproteins into single proteins, leading 
to a major structural rearrangement of the virion. Temporal control of proteolytic cleavage with 
respect to particle assembly appears crucial for the maturation of infectious particles. The order 
of Gag processing is tightly regulated by utilization of different proteolytic cleavage sites with 
specific binding affinities to HIV-1 PR. However, the precise mechanism and kinetics of PR 
activation, as well as the time course of proteolytic maturation are currently unclear.  
Since many virus particles are formed in an infected cell and the time course of formation is 
asynchronous – not only between individual cells but also on the surface of a single cell - bulk 
biochemical analyses are not suitable for analysis of PR activation. Therefore, the aim of my 
thesis was to monitor and quantitate the HIV-1 PR activity during virus particle assembly by 
live-cell microscopy. Live-cell analysis of HIV-1 assembly site formation using fluorescence 
microscopy was already established in the lab. Previous studies from our and other groups, 
imaging fluorescently labeled virus assembly by total internal fluorescence microscopy (TIRF), 
showed that formation of viral assembly sites proceeds over 1-2 h, and Gag assembly for an 
individual bud is completed within 10-20 min. Here, I designed and explored various 
approaches for single virus tracking of PR activity in parallel to Gag assembly. For this purpose, 
I developed and tested different sensors to detect (i) PR enzymatic activity at the nascent 
assembly site, (ii) Gag polyprotein processing mediated by PR, or (iii) the generation of mature 
HIV-1 PR by autoprocessing from the GagProPol precursor. 
To measure PR activity at the assembly site, I designed Förster resonance energy transfer 
(FRET) reporter molecules which were targeted to nascent assemblies. For this, a FRET pair 
of autofluorescent proteins was linked via a Gag-derived PR cleavage site and fused to the 
viral protein r (Vpr) to mediate incorporation into particles. We could show the incorporation, 
and proteolytic processing of the FRET-based sensor was observed. The PR-dependent 
changes in FRET signal were analyzed in purified virus-like particles (VLPs) and viral assembly 
sites at the plasma membrane of HeLa Kyoto cells. While sensor co-expression with wild-type 
HIV-1 PR caused a decrease of the FRET values by two-fold upon proteolytic processing, 
during time-lapse measurements of the assembly process we could not detect a change in 
FRET signal over time. 
In order to detect Gag cleavage as readout for HIV-1 PR activity, I attempted different 
approaches. Initially, I applied a previously established system for distinguishing immature and 
mature particles by STED nanoscopy to the analysis of particles formed at the cell surface in 
live-cell experiments. While STED nanoscopy is unsuitable for following assembly and 
maturation by live cell imaging, I could show that Gag processing and particle arrangement did 
occur under conditions and in the time frame of intended measurements.  
I then tested two approaches for live-cell measurements of Gag processing. A first attempt to 
utilize a split fluorescent protein-based method was not successful, since fluorescence was 
found to be independent of the Gag processing state. This approach was therefore abandoned.  
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In an alternative approach, I explored the use of changes in eCFP fluorescence lifetime 
depending on fluorophore concentration via homo FRET. For this, eCFP molecules were 
inserted within the Gag polyprotein. Local Gag concentrations increase during the assembly 
process and should thus lead to a decrease of fluorescence lifetime. Proteolytic processing 
should release the fluorophore for free diffusion within the virus particle and thereby cause an 
increase in fluorescence lifetime. Indeed, Gag.eCFP cleavage by HIV-1 PR resulted in 
changes in fluorescence lifetime measured in purified VLPs and at the plasma membrane of 
HeLa Kyoto cells. Time-lapse experiments visualized differences in fluorescent lifetime during 
viral assembly. So far, only few events that may correspond to proteolytic processing were 
detected. Further adaptation of the system to live cell measurements is under way. 
 
Finally, I studied the formation of active HIV-1 PR during assembly using an innovative 
approach based on the binding of a fluorogenic inhibitor. Various sensors, designed to 
fluoresce upon binding to the PR active site, were provided by our collaboration partners who 
coupled the fluorogenic dye silicone-rhodamine (SiR) to the PR inhibitor Ritonavir (RTV). 
Specific signal increase upon binding to active PR was shown in vitro and on assembly sites 
at the plasma membrane of HeLa Kyoto cells. The sensor SiR-C6-RTV was identified to feature 
the highest signal-to-noise ratio and best allowed the detection of active HIV-1 PR during viral 
assembly. 
 
Using this compound, I successful established conditions for time-resolved detection of mature 
PR at nascent assembly sites. Different SiR recruitment patterns with respect to progression 
of Gag assembly were observed. Early signal increase was detected after 10-20 min, 
suggesting PR activation at late stages of assembly. Later events were observed after ~ 40 
min, suggesting formation of active PR after viral release. Further improvement of signal-to-
noise ratio would be beneficial and is currently under way. An extensive analysis of the 
frequency of the different phenotypes, also in conjunction with recruitment of the cellular 
protein Vps4 recruited shortly before HIV-1 release, will yield insight into the sequence of 
events at nascent assembly sites in following studies.  
 
  
Zusammenfassung  3 
 
2 Zusammenfassung 
 
An der Plasmamembran der Wirtszelle gebildete Partikel des menschlichen Immunschwäche-
Virus (HIV-1) schnüren sich von der dieser ab und werden als unreife, nicht infektiöse Partikel 
freigesetzt. Gleichzeitig spaltet die virale Protease (PR) Gag und GagProPol-Polyproteine in 
einzelne Proteine, was zu einer größeren strukturellen Neuordnung des Virion führt. Die 
zeitliche Kontrolle der proteolytischen Spaltung in Bezug auf die Partikelbildung ist 
entscheidend für die Reifung infektiöser Partikel. Die Reihenfolge der Gag Prozessierung wird 
durch die Nutzung verschiedener proteolytischer Schnittstellen mit spezifischen 
Bindungsaffinitäten zu HIV-1 PR präzise geordnet. Allerdings sind der genaue Mechanismus 
und die Kinetik der PR-Aktivierung sowie der zeitliche Verlauf der proteolytischen Reifung 
derzeit unklar.  
Da viele Viruspartikel in einer infizierten Zelle gebildet werden und der zeitliche Verlauf der 
Bildung – nicht nur zwischen mehreren Zellen, sondern auch auf der Oberfläche einer 
einzelnen Zelle – asynchron ist, sind biochemische Analysen nicht für die Untersuchung der 
PR-Aktivierung geeignet. Daher war das Ziel meiner Arbeit, die HIV-1 PR-Aktivität während 
der Viruspartikelentstehung mittels Lebendzellmikroskopie zu überwachen und zu 
quantifizieren. Die Lebendzellanalyse der HIV-1 Partikel-Assemblierung mittels 
Fluoreszenzmikroskopie wurde zuvor bereits im Labor etabliert. Frühere Studien aus unseren 
und anderen Gruppen, die fluoreszenzmarkierte Virusentstehung mittels Total Internal 
Fluorescence Microscopy (TIRF) anschauten, haben gezeigt, dass die Bildung von 
Viruspartikeln an einer Zelle über 1-2 Stunden andauert und die Gag Assemblierung für ein 
einzelnes Partikel innerhalb von 10-20 Minuten abgeschlossen ist. Hier habe ich verschiedene 
Ansätze zur Verfolgung von PR-Aktivitäten in einzelnen Viruspartikeln parallel zu deren Gag-
Assembly entworfen und evaluiert. Zu diesem Zweck habe ich verschiedene Sensoren 
entwickelt und getestet, um alternativ (i) PR-enzymatische Aktivität an der Virusbildungsstelle, 
(ii) Gag-Polyproteinprozessierung, die durch PR vermittelt wird, oder (iii) die Erzeugung von 
reifer HIV-1 PR durch Autoprozessierung aus dem GagProPol-Polyprotein nachzuweisen. 
Um die PR-Aktivität an der Bildungsstelle zu messen, entwarf ich Förster Resonanz Elektronen 
Transfer (FRET) Reportermoleküle, die zur Assemblierungsstelle rekrutiert werden. Dazu 
wurde ein FRET-Paar autofluoreszierender Proteine über eine von Gag abgeleitete PR-
Spaltstelle verknüpft und mit dem viralen Protein r (Vpr) fusioniert, um die Aufnahme in Partikel 
zu vermitteln. Ich konnte die Aufnahme in Viruspartikel zeigen und die proteolytische 
Prozessierung des FRET-basierten Sensors beobachten. Die PR-abhängigen Veränderungen 
im FRET-Signal wurden in aufgereinigten virusähnlichen Partikeln (VLPs) und viralen 
Assemblierungsstellen an der Plasmamembran von HeLa Kyoto-Zellen analysiert. Während 
die Sensor Koexpression mit Wildtyp-HIV-1 PR bei der proteolytischen Spaltung zu einer 
Halbierung der FRET-Werte führte, konnten wir während der Zeitraffer-Messungen des 
Assemblierungsprozesses keine Veränderung des FRET-Signals über die Zeit feststellen. 
Um die Gag Prozessierung als Anzeige für die HIV-1 PR-Aktivität zu erkennen, habe ich 
verschiedene Ansätze untersucht. Zunächst habe ich ein zuvor etabliertes System zur 
Unterscheidung von unreifen und reifen Partikeln mittels STED-Nanoskopie auf die Analyse 
von Partikeln angewendet, die an der Zelloberfläche in Lebendzell-Experimenten gebildet 
wurden. Während die STED-Nanoskopie derzeit für die Verfolgung von Partikelbildung und 
Reifung durch Lebendzell-Mikroskopie ungeeignet ist, konnte ich zeigen, dass die Gag 
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Prozessierung und Partikelumstrukturierung unter Bedingungen und im Zeitrahmen der 
geplanten Messungen erfolgte.  
Im Anschluss habe ich zwei Ansätze für Lebendzell-Messungen der Gag Prozessierung 
getestet. Ein erster Versuch, eine auf Split-Fluoreszenzprotein basierende Methode zu 
verwenden, war nicht erfolgreich, da sich die Fluoreszenz als unabhängig vom Gag 
Prozessierungszustand erwies. Dieser Ansatz wurde daher verworfen.  
In einem alternativen Ansatz untersuchte ich die Verwendung von Änderungen der eCFP-
Fluoreszenzlebensdauer in Abhängigkeit von der Fluorophor-Konzentration über homo FRET. 
Dazu wurden eCFP-Moleküle in das Gag-Polyprotein eingebracht. Die lokalen Gag-
Konzentrationen steigen während des Partikelbildungsprozesses und sollten daher zu einer 
Verkürzung der Fluoreszenzlebensdauer führen. Bei der proteolytischen Prozessierung sollte 
der Fluorophor zur freien Diffusion innerhalb des Viruspartikel freigesetzt werden, was zu einer 
Erhöhung der Fluoreszenzlebensdauer führen würde. Tatsächlich führte die Gag.eCFP-
Spaltung durch HIV-1 PR zu Veränderungen in der Fluoreszenzlebensdauer, die in gereinigten 
VLPs und an der Plasmamembran von HeLa Kyoto-Zellen gemessen wurden. In Zeitraffer-
Experimenten wurden Unterschiede in der Fluoreszenzlebensdauer während der Virusbildung 
visualisiert. Bisher wurden nur wenige Ereignisse erkannt, die der proteolytischen 
Prozessierung entsprechen können. Eine weitere Anpassung des Systems an die Messungen 
in lebenden Zellen ist in Arbeit. 
Schließlich untersuchte ich die Bildung von aktiver HIV-1 PR während der Partikelbildung mit 
einem innovativen Ansatz, der auf der Bindung eines fluorogenen Inhibitors basiert. 
Verschiedene Sensoren, die bei der Bindung an die PR-aktive Stelle fluoreszieren, wurden 
von unseren Kooperationspartnern zur Verfügung gestellt, die den fluorogenen Farbstoff 
Silikon-Rhodamin (SiR) mit dem PR-Inhibitor Ritonavir (RTV) gekoppelt haben. Spezifische 
Signalzunahme bei Bindung an aktive PR wurde in vitro und an Assemblierungsstellen an der 
Plasmamembran von HeLa Kyoto Zellen gezeigt. Der Sensor SiR-C6-RTV wurde mit dem 
höchsten Signal-Rausch-Verhältnis identifiziert und ermöglichte den Nachweis von aktiver 
HIV-1 PR während der Virusbildung. 
Mit dieser Verbindung habe ich erfolgreich Bedingungen für den zeitaufgelösten Nachweis von 
reifer PR an im Entstehen begriffenen Assemblierungsstellen geschaffen. Unterschiedliche 
SiR-Rekrutierungsmuster in Bezug auf das Fortschreiten der Partikelbildung wurden 
beobachtet. Ein früher Signalanstieg wurde nach 10-20 min erkannt, was auf eine PR-
Aktivierung in den späten Phasen der Assemblierung hindeutet. Spätere Ereignisse wurden 
nach ~ 40 min beobachtet, was auf die Bildung einer aktiven PR nach der Virusfreisetzung 
hindeutet. Eine weitere Verbesserung des Signal-Rausch-Verhältnisses wäre von Vorteil und 
wird derzeit durchgeführt. Eine umfangreiche Analyse der Häufigkeit der verschiedenen 
Phänotypen, auch in Verbindung mit der Rekrutierung des kurz vor der HIV-1-Freisetzung 
rekrutierten zellulären Proteins Vps4, wird in künftigen Studien einen Einblick in die Abfolge 
der Ereignisse an entstehenden Partikelbildungsstellen geben.  
  
Table of contents  5 
 
3 Table of contents 
 
1 Summary ....................................................................................................................... 1 
2 Zusammenfassung ....................................................................................................... 3 
3 Table of contents .......................................................................................................... 5 
4 Introduction .................................................................................................................. 9 
4.1 Human Immunodeficiency Virus Type 1 (HIV-1) ...................................................... 9 
4.1.1 Classification, genome and morphology ..........................................................10 
4.1.2 Replication-cycle of HIV-1 ...............................................................................12 
4.1.2.1 Assembly, budding and maturation ..........................................................13 
4.1.3 HIV-1 protease – Key factor of maturation .......................................................15 
4.1.3.1 PR structure and function .........................................................................15 
4.1.3.2 Mechanism of PR function .......................................................................17 
4.1.3.3 PR inhibitors .............................................................................................20 
4.2 Fluorescence labeling of virus-like particles............................................................22 
4.2.1 Fluorescence tags inserted in Gag ..................................................................22 
4.2.2 Fluorescence tags inserted by coupling to Vpr ................................................22 
4.3 Fluorescence-based methods applied in this study ................................................23 
4.3.1 Bimolecular fluorescence complementation assays detect Gag processing ....23 
4.3.2 Förster resonance energy transfer to detect proteolytic activity .......................23 
4.3.3 Fluorescence lifetime-resolved imaging to detect Gag processing ..................24 
4.3.4 Fluorogenic probes to stain active PR .............................................................24 
4.3.5 Single virus tracking at assembly sites ............................................................25 
4.4 Aim of the work ......................................................................................................26 
5 Materials and Methods ................................................................................................27 
5.1 Materials ................................................................................................................27 
5.1.1 Laboratory Equipment .....................................................................................27 
5.1.2 Reagents .........................................................................................................29 
5.1.2.1 Chemicals and consumables ....................................................................29 
5.1.2.2 Protease Inhibitors ...................................................................................31 
5.1.2.3 Reagent Systems (Kits) ............................................................................34 
5.1.2.4 Buffers and Solutions ...............................................................................34 
5.1.2.5 Growth Media ...........................................................................................35 
5.1.2.6 Nucleic acids ............................................................................................36 
5.1.2.7 Plasmid DNA ............................................................................................36 
5.1.2.8 Enzymes ..................................................................................................37 
Table of contents  6 
 
5.1.2.9 Antibodies and dyes .................................................................................38 
5.1.3 Software ..........................................................................................................38 
5.2 Methods .................................................................................................................39 
5.2.1 Biochemical methods ......................................................................................39 
5.2.1.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
Blotting ……………………………………………………………………………………39 
5.2.1.2 Spectrofluorometry ...................................................................................40 
5.2.2 Cell biological methods ...................................................................................40 
5.2.2.1 Cell culture ...............................................................................................40 
5.2.2.2 SNAP and Clip stain .................................................................................41 
5.2.2.3 Staining of cells with fluorogenic PR inhibitor ...........................................41 
5.2.2.4 Flow cytometry .........................................................................................41 
5.2.3 Molecular biological methods ..........................................................................42 
5.2.3.1 Bacterial transformation and plasmid amplification ...................................42 
5.2.3.2 Preparation of plasmid DNA from bacterial mini cultures ..........................42 
5.2.3.3 Gene amplification by polymerase chain reaction (PCR) ..........................43 
5.2.3.4 Agarose gelelectrophoresis ......................................................................43 
5.2.3.5 DNA digest and ligation ............................................................................43 
5.2.4 Cloning procedures .........................................................................................44 
5.2.4.1 Cloning by PCR ........................................................................................44 
5.2.4.2 Subcloning ...............................................................................................44 
5.2.5 Virological methods .........................................................................................46 
5.2.5.1 Preparation of virus-like particles (VLPs) ..................................................46 
5.2.5.2 SNAP labeling of VLPs .............................................................................46 
5.2.6 Imaging methods .............................................................................................46 
5.2.6.1 Total internal reflective fluorescence microscopy (TIRF) ..........................46 
5.2.6.2 Laser scanning confocal microscopy ........................................................47 
5.2.6.3 Stimulated emission depletion (STED) .....................................................47 
5.2.6.4 Fluorescence lifetime imaging microscopy (FLIM) ....................................47 
5.2.7 Image analysis ................................................................................................48 
5.2.7.1 Image processing .....................................................................................48 
5.2.7.2 FRET analysis ..........................................................................................48 
5.2.7.3 Acceptor bleaching ...................................................................................48 
5.2.7.4 FRAP analysis..........................................................................................48 
5.2.7.5 Co-localization analysis ............................................................................48 
5.2.7.6 Single assembly sites kinetics (Tracking via Imaris) .................................49 
5.2.8 Statistical analysis ...........................................................................................49 
Table of contents  7 
 
6 Results .........................................................................................................................50 
6.1 Fluorescence-tagged virus-like particles can be visualized in fluorescence 
microscopy .......................................................................................................................50 
6.2 Live-cell imaging of the viral assembly process ......................................................52 
6.3 Design of sensors to detect HIV-1 PR activity during viral assembly ......................56 
6.3.1 An external FRET-based sensor was specifically cleaved by HIV-1 PR ..........56 
6.3.2 Internal labeling of Gag for detection of Gag processing as a marker for PR 
activity …………………………………………………………………………………………69 
6.3.2.1 Split fluorescent proteins and insertion in Gag does not enable distinction of 
mature and immature VLPs .......................................................................................69 
6.3.2.2 Changes in localization of fluorescence tags in Gag can be visualized by 
STED microscopy ......................................................................................................71 
6.3.2.3 Changes in fluorescence lifetime of eCFP in Gag can be visualized by FLIM 
microscopy ................................................................................................................75 
6.3.3 Design of fluorogenic HIV-1 PR inhibitors to specifically visualize the active PR
 …………………………………………………………………………………………82 
6.3.3.1 Specific fluorogenicity of the probes was validated by spectrophotometry 84 
6.3.3.2 Specific fluorogenicity of the probes detected at HIV-1 assembly sites in 
HeLa Kyoto cells ........................................................................................................89 
7 Discussion ...................................................................................................................95 
7.1 Visualization of the assembly process by fluorescence microscopy .......................95 
7.2 Design of sensors to visualize HIV-1 PR activity during viral assembly by fluorescence 
microscopy .......................................................................................................................96 
7.2.1 An external FRET-based sensor was specifically cleaved by HIV-1 PR ..........96 
7.2.2 Internal labeling of Gag for detection of Gag processing as a marker for PR 
activity …………………………………………………………………………………………98 
7.2.2.1 Split fluorescent proteins and insertion in Gag does not enable distinction of 
mature and immature VLPs .......................................................................................98 
7.2.2.2 Changes in localization of fluorescence tags in Gag can be visualized by 
STED microscopy ......................................................................................................99 
7.2.2.3 Changes in fluorescence lifetime of eCFP in Gag can be visualized by FLIM 
microscopy .............................................................................................................. 100 
7.2.3 Formation of active HIV-1 PR was detected during the viral assembly process
 ………………………………………………………………………………………..101 
7.3 Future implications of the project .......................................................................... 103 
8 Abbreviations ............................................................................................................ 104 
9 Index ........................................................................................................................... 107 
10 Publications and contributions ................................................................................ 109 
10.1 Publications .......................................................................................................... 109 
10.2 Conference contributions...................................................................................... 109 
Table of contents  8 
 
10.3 Contributions to this project .................................................................................. 109 
11 Acknowledgements ................................................................................................... 111 
12 Plasmid Maps ............................................................................................................ 113 
13 References ................................................................................................................. 116 
 
  
Introduction  9 
 
4 Introduction 
 
4.1 Human Immunodeficiency Virus Type 1 (HIV-1)  
 
The human immunodeficiency virus (HIV) is the main causative agent for the immune disease 
acquired immune deficiency syndrome (AIDS). In 2017, globally 36.9 million people were 
infected with HIV and about 1 million people died of AIDS (UNAIDS Global AIDS, 2018). The 
disease was already described in 1981, but HIV-1 was first isolated in 1983 (Gottlieb et al. 
1981; Barré-Sinoussi et al. 1983; Popovic et al. 1984).  
 
The course of an HIV infection can be divided in 3 phases: Acute phase, asymptomatic phase 
and symptomatic phase (Pantaleo et al. 1993; Pantaleo und Fauci 1995). The acute phase is 
characterized by high viral titers, reported symptoms in this time are described as flu-like and 
summarized as mononucleosis-like symptoms. A few days after infection, activated 
lymphocytes produce virus in high quantities (Flint 2015). The high viremia is suppressed 
within a few weeks after infection due to the depletion of the susceptible T cell population and 
to the establishment of a cell-mediated immune response that is observed prior to antibody 
production. The inflammatory response during acute infection stimulates CD4+ T cell 
maturation, therefore the CD4+ T cell population partly recovers.  
After 3 to 4 months viremia declines, in some cases even under the detection level, while viral 
replication continues. Due to the continuous infection, immune activation and cytotoxicity of 
the virus, the CD4+ T cell population decreases over time.  The term “clinical latency” describes 
a lack of symptoms, while there is still viral production and therefore no complete state of 
latency (Pantaleo und Fauci 1995).  
There is a steady but slow disease progression until the CD4+ T cell count drops and the 
deterioration of the immune system results in the inability to fight opportunistic infections e.g. 
atypical pneumonia. This state is called acquired immunodeficiency syndrome (AIDS) (Flint 
2015). 
 
The first drug to treat HIV infection was approved in 1987. AZT was found to impair viral 
replication by inhibiting reverse transcription (Nakashima et al. 1986). Quickly, the virus 
developed resistance to the drug and the necessity to target multiple viral processes 
simultaneously was revealed. 
The virus encoded HIV-1 protease (PR) is known to be crucial for formation of infectious viral 
particles. Design of specific inhibitors of this enzyme enabled combination antiretroviral 
therapy for the first time in 1996, which decreased the potential of drug resistance significantly 
(James 1995). 
In 2017, 1.8 million people became infected with HIV-1 and 21.7 million people accessed 
antiretroviral therapy (UNAIDS Global, 2018). The numbers of new infections are decreasing 
over the years, while the fractions of infected patients treated with combined antiretroviral 
therapy (cART) increases. cART involves at least three drugs, targeting multiple steps of the 
viral replication cycle, that reduces the viral load below the detection limit and enables a 
relatively normal life today (DAH, n=n, 2018).  
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4.1.1 Classification, genome and morphology 
 
HIV-1 and HIV-2 are members of the genus Lentiviridae and belong to the family Retroviridae. 
HIV-2 was isolated from patients in West Africa, but due to its higher clinical relevance, this 
study only focuses on HIV-1 (Sharp und Hahn 2011). 
HIV-1 is divided in three groups that vary in their prevalence. Each arose from independent 
zoonotic transmission from non-human primates infected with simian immunodeficiency virus 
(SIV) to humans in Central and West Africa (Gao und Karin 2005; Plantier et al. 2009). Group 
M (“major”) is responsible for 98% of HIV-1 infections and geographically most spread (Sharp 
und Hahn 2010). Groups O (“outliers”) and N (“non-O, non-M”) are relatively rare and restricted 
to the area of Cameroon and surrounding countries in central Africa (Sharp et al. 1999). 
HIV-1 is a membrane enveloped virus that integrates its genome in the host cell. The spherical 
virus particle has a diameter of ~145 nm (Briggs et al. 2009) and carries two copies of the 
ss(+)RNA genome with a size of 9.7 kilobases (Flint 2015; Coffin 1997; Briggs et al. 2003). 
While HIV-1 displays a high sequence variability, the genomic organization is strongly 
conserved. The coding regions are flanked by long terminal repeats (LTRs) at both the 5’ and 
3’ end of the genome. Nine open reading frames (ORFs)  are divided in three different classes 
of encoded proteins: structural proteins Gag (group specific antigen), Pol (polymerase) and 
Env (envelope protein), regulatory proteins Tat (transactivator of transcription) and Rev 
(regulator of virion), and accessory proteins Vif (virion infectivity factor), Vpr (viral protein R), 
Vpu (viral protein U) and Nef (negative factor) (Fig. 1) (Coffin 1997; Flint 2015; Kirchhoff 2009). 
 
 
Fig. 1: HIV-1 genome and particle structure. A: HIV-1 genomic organization. The coding region is flanked by long 
terminal repeats (LTRs). Nine open reading frames (ORFs) are shown as boxes. Black lines depict proteolytic 
cleavage sites. Three major genes: gag (group specific antigen), pol (polymerase) and env (envelope). Gag protein 
in processed into MA, CA, SP1, NC, SP2 and p6. pol contains PR, RT, RNAse H and IN. Additional genes encode 
for regulatory proteins Tat (transactivator of transcription) and Rev (regulator of virion), and accessory proteins Vif 
(virion infectivity factor), Vpr (viral protein R), Vpu (viral protein U) and Nef (negative factor). Adapted from Kirchhoff, 
2009. B: Schematic illustration of a mature HIV-1 particle. Accessory proteins are omitted in the representation. 
 
Gag encodes capsid proteins that are transcribed and translated as 55 kDa precursor protein 
(Fig. 2A). During maturation of the virion, the precursor protein is processed by the viral 
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protease (PR) into the 17 kDa matrix protein (MA), 24 kDa capsid protein (CA), 9 kDa 
nucleocapsid protein (NC), p6 and spacer peptide (SP) 1 and 2 (Fig. 1B, 2B) (Göttlinger 2002; 
Freed 2015; Sundquist und Kräusslich 2012).  
Pol is expressed as a GagProPol fusion protein with a size of 160 kDa (p160) due to a frame 
shift at the 3’ end of gag, (Fig. 2A). This frameshift occurs in 5% of translation events, causing 
a Gag:GagProPol ratio of 20:1 (Jacks et al. 1988; Garcia-Miranda et al. 2016). In the 
maturation process, the fusion protein is cleaved and Pol is further digested into the functional 
subdomains protease (PR, p10), reverse transcriptase (RT, p66 and p51), RNase H (p15), and 
integrase (IN, p32) (Fig. 1B, 2B, C) (Prescott et al., 1999). The RT p66/p51 dimer provides 
RNA-and DNA- dependent DNA polymerase activity and degrades RNA in RNA-DNA hybrids 
(RNAse H activity). IN drives the integration of the viral genome into the host cell genome 
(provirus) (Farnet et al. 1996).  
 
 
Fig. 2: Gag and GagProPol processing and formation of a mature viral particle. A: Schematic illustration of 
Gag and GagProPol polyproteins and their subunits. Arrows depict protease cleavage sites. Gag is processed into 
MA, CA, SP1, NC, SP2 and p6. GagProPol cleavage into PR, RT and IN. B, C: Schematic illustration and electron 
cryotomograms of (B) immature and (C) mature HIV-1. Spherical virion diameter is about 145 nm. Electron 
cryotomograms from (Mattei et al. 2016). Scale bar: 20nm. 
 
Env encodes a 160 kDa protein that is transported through the secretory pathway to the plasma 
membrane and glycosylated during this process (gp160) (Fig. 1). It is cleaved by cellular 
proteases in two glycoproteins of 120 kDa (gp120) and 41 kDa (gp41). Gp41 is a 
transmembrane protein, while gp120 is located on the membrane surface. The mature 
domains are non-covalently bound (Wyatt und Sodroski 1998). Env forms heterodimeric 
trimers on the viral membrane, that interact with cellular receptors to enter the host cell (see 
4.1.2) (Center et al. 2002). There are about 7-14 trimers per viral particle (Chertova et al. 2002; 
Zhu et al. 2003). 
Regulatory proteins are Tat (transactivator of transcription) and Rev (regulator of virion), vif 
(virion infectivity factor), vpr (viral protein R), vpu (viral protein U) and nef (negative factor) 
encode accessory proteins (Fig. 1).  
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4.1.2 Replication-cycle of HIV-1 
 
To enter the target cell, the HIV-1 envelope protein gp120 binds to the CD4 receptor on the 
cell surface of memory T-cells and macrophages (Fig. 3). This triggers a structural change in 
Env, which allows the interaction of gp41 with the cellular co-receptor (most importantly the β-
chemokine receptor CCR5 or α-chemokine receptor CXCR4 (Sattentau und Moore 1991; Wu 
et al. 1996). The exposure of a hydrophobic fusion peptide due to Env and (co)receptor 
interaction induces the fusion of viral and cellular membranes. The viral contents enter the 
cytoplasm through the formed fusion pore (Rivière et al. 2010; Haffar et al. 2000) (Fig. 3 Entry). 
The viral capsid, the conical cone consisting of CA, that contains the viral genome, NC and 
Vpr, is delivered, but the exact fate of the core in different cell types is still under investigation.  
The RNA genome is reversely transcribed by the reverse transcriptase into double stranded 
DNA with duplicates of long terminal repeats (LTRs) (Chung et al. 2013). The viral dsDNA is 
part of a so-called pre-integration complex containing at least the viral dsDNA genome, IN and 
Vpr (Fig. 3 Reverse Transcription), which is transported to and through the intact nuclear pore, 
allowing infection of non-dividing cells (Fig. 3 Nuclear import). The role of the capsid in this 
process and the mechanism of nuclear entry is currently unclear. 
Reverse transcription yields circular and linear double stranded viral DNA, but only linear DNA 
flanked with duplicates of LTRs can function as a precursor for the integration in the host 
genome. Viral DNA is mostly integrated in active euchromatin where the 5′ LTR is applied as 
a eukaryotic promoter and the 3′ LTR functions as the polyadenylation and termination site 
(Bushman et al. 1990) (Fig. 3 Integration). To increase genomic transcription, the cell is 
activated by Tat, that additionally leads to a higher efficiency of transcription elongation by 
recruitment of cellular factors such as RNA polymerase II (Kao et al. 1987; Karn und Stoltzfus 
2012). Unspliced genomic RNAs are transported into the cytoplasm by Rev (Fig. 3 
Transcription and mRNA Export). Viral proteins are translated in the cytoplasm and regulatory 
proteins are shuttled back into the nucleus (Fig. 3 Translation). Structural proteins and newly 
transcribed RNA genomes then assemble into progeny virions. Assembly and release are the 
main focus of this work and therefore described in more detail in the following chapter 4.1.2.1.  
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Fig. 3: Schematic replication cycle of HIV-1. HIV-1 binds to cellular CD4 and co-receptors on the plasma 
membrane. Viral entry occurs via membrane fusion (Entry). Contents are released in the cytoplasm and the viral 
genome is reverse transcribed from ssRNA to dsDNA (Reverse Transcription). The viral genome is transported into 
the nucleus and integrated in the host chromosomal DNA (Nuclear import and Integration). DNA is transcribed and 
mRNA is exported into the cytoplasm (Transcription and mRNA Export). Spliced mRNA is translated in viral 
proteins, unspliced genome incorporated in the viral particle (Translation). Gag assembles at the plasma membrane 
and recruits viral and cellular proteins (Assembly). The viral bud is pinched off by the cellular ESCRT machinery 
(budding). Gag and GagProPol are cleaved by the viral protease and structural rearrangement leads to formation 
of mature, infectious viral particles (Maturation). From (Ganser-Pornillos et al. 2008).  
 
4.1.2.1 Assembly, budding and maturation 
 
The Gag polyprotein drives viral assembly and is known to be sufficient for formation of non-
infectious virus-like particles (Gheysen et al. 1989). Gag proteins traffic to the cytoplasm as 
monomers and dimers (Bieniasz 2009), while small amounts of Gag protein bind and thereby 
recruit the viral genome to the plasma membrane (Jouvenet et al. 2009). Gag contains an N-
terminal myristoylation site in MA, that triggers the protein localization to the plasma membrane 
(Ghanam et al. 2012; Göttlinger et al. 1989).  Basic residues in MA interact with acidic 
phospholipids at the inner leaflet of the plasma membrane and support membrane binding 
(Fig. 3 Assembly, 4) (Hermida-Matsumoto und Resh 1999; Zhou et al. 1994). 
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Fig. 4: Schematic representation of assembly, budding and maturation of HIV-1. Viral particles assemble at 
the plasma membrane. Gag forms the viral bud and recruits viral and cellular proteins, as well as the viral genome 
to the assembly site. Viral particles are released from the plasma membrane by the ESCRT machinery. Proteolytic 
processing of the structural proteins enables structural rearrangement and formation of mature, infectious viral 
particles. 
 
MA drives the Gag membrane targeting and Env incorporation in the viral particle (Dorfman et 
al. 1994). Binding to the acidic phospholipid phosphatidylinositol 4,5- bisphosphate triggers 
structural changes in MA that expose the myristoyl group (myristoyl switch) and anchor Gag 
to the plasma membrane (Ono et al. 2004). CA-SP1 harbors intermolecular interaction sites 
that drive Gag multimerization to form an immature lattice (Guo et al. 2005; Pak et al. 2017). 
GagProPol is incorporated by the same mechanism as Gag, while viral proteins like Vpr, Vif 
and Nef interact with the C-terminal p6 domain of Gag. The viral Env protein, is integrated in 
the viral membrane by interaction with MA to enable binding and infection of the host cell 
(Wyatt und Sodroski 1998). Released viral particles have a radius of ~63 nm and the immature 
Gag lattice contains ~2400 Gag and ~120 GagProPol molecules (Briggs et al. 2003; Carlson 
et al. 2008). Genesis of the full Gag lattice takes ~5-15 min, as determined by live-cell imaging 
of fluorescently labeled virus derivatives (Jouvenet et al. 2008; Ivanchenko et al. 2009).  
Budding of virus particles form the membrane is mediated by the p6 domain of Gag, which 
recruits the cellular endosomal complex required for transport (ESCRT) machinery and  drives 
Vpr incorporation in the viral particle (Accola et al. 2000; Martin-Serrano und Bieniasz 2003). 
The C-terminal domain of Gag, p6, was found to be crucial for virus release from the plasma 
membrane (Malim und Emerman 2008; Peterlin und Trono 2003). Virus variants lacking p6 
stay attached to the plasma membrane by stalk-like structures (Göttlinger et al. 1991). A so-
called ‘late-domain’ motif in p6 recruits Tsg101 and ALIX, components of the ESCRT complex, 
that further recruit the ESCRT-III complex (Huang et al. 1995). ESCRT-III forms a spiral-like 
structure in the viral bud, supposedly closing off the virus to the plasma membrane. It then 
recruits the AAA ATPase vacuolar protein sorting 4 (Vps4), which enables membrane scission 
and recycles ESCRT components after budding has been completed (Freed 2015).  Super-
resolution microscopy reveals co-localization of the ESCRT complex with the Gag assembly 
site (Baumgärtel et al. 2011; Bendjennat und Saffarian 2016; Bleck et al. 2014). Vps4 ATPase 
is recruited shortly before scission off the plasma membrane and the viral particle is released 
Introduction  15 
 
20-25 min after assembly initiation (Ivanchenko et al. 2009; Jouvenet et al. 2011b; Johnson et 
al. 2018). 
Gag and GagProPol are composed of folded domains separated by flexible linkers that mark 
PR cleavage sites. After the budding process, the immature virion matures by proteolytic 
cleavage of Gag and GagProPol precursor proteins (Fig. 2,3,4) (Sundquist und Kräusslich 
2012). This process is described in more detail in 4.1.3. Shortly, PR dimerizes within 
GagProPol and autoprocesses in a precise order (Pettit et al. 1991; Pettit et al. 2005; Pettit et 
al. 1994; Tessmer und Kräusslich 1998). GagProPol cleavage releases functional PR, RT and 
IN (Louis et al. 1991; Louis et al. 1999; Louis et al. 1994; Wondrak et al. 1996). While the 
sequence of GagProPol processing is still under debate, Gag cleavage order is highly 
conserved (Tözsér 2010; Tözsér et al. 1997; Tözsér et al. 1991). Specific cleavage sites with 
varying susceptibility allow regulations of the scission process. This allows functional formation 
of condensed RNA genome in the assembled conical capsid. NC binds the viral genome and 
forms the condensed ribonucleoprotein particle (RNP). CA forms the conical core that 
encapsidates the RNP (Gorelick et al. 1990). Structural rearrangement of the proteins leads to 
formation of mature, infectious viral particles (Fig. 2B, 2C) (Ganser-Pornillos et al. 2008; Pettit 
et al. 1994; Swanstrom und Wills 1997; Vogt 1997).  
 
4.1.3 HIV-1 protease – Key factor of maturation 
 
Proteolytic processing of Gag and GagProPol polyproteins was found to be required for 
formation of infectious HIV-1. Viral particles lacking PR rendered the virus non-infectious. This 
indicates the significant role of proteolytic processing activity for viral infectivity (Henderson et 
al. 2012; Kohl et al. 1988; Peng et al. 1989). This crucial step in the HIV-1 life cycle is the target 
of important drugs used in HIV therapy. The mechanism of PR is described further in this 
chapter.  
 
4.1.3.1 PR structure and function 
 
The HIV-1 protease (PR) is an aspartyl protease that forms a symmetric homodimer of subunits 
comprising 99 amino acid residues (Fig. 5). Due to the homology to the cellular protease 
pepsin, the retroviral proteases are also called retropepsins (Barrett et al. 2012). The active 
site consists of three amino acids (Asp-Thr-Gly) and is stabilized by non-covalent interactions 
at the interface of the dimer (Pettit et al. 2003; Tessmer und Kräusslich 1998). For the 
proteolytic cleavage, two catalytic aspartic acid residues (D25), one from each subunit, activate 
a water molecule (Louis et al. 1999; Oroszlan und Luftig 1990; Wlodawer und Erickson 1993; 
Konvalinka et al. 2015). Two glycine-rich flexible loops at the top are called flaps, because they 
regulate substrate accessibility by conformational changes that allow substrate entering and 
exiting.  
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Fig. 5: Structure of HIV-1 PR. Subunits are identical but colored in black and grey for better identification. Blue 
residues mark the catalytically active Asp 25 and Asp 25’ residues. Figure was generated using PyMol 
(www.pymol.org). PR structure adapted from from PDB ID: 3el1. 
 
Substrates of PR are bound asymmetrically in an anti-parallel β-sheet conformation, so that 
the scissile bond is located in the center (Fig. 6). Mutation analysis of substrate showed the 
importance of amino acids up- and downstream of the scissile bond (Partin et al. 1990b; Partin 
et al. 1990a). Specificity studies revealed the necessary characteristics of the substrate. P1 
and P1’ were shown be exhibit large hydrophobic residues, while P2 and P2’ contain 
hydrophobic or small polar site chains (Pettit et al. 2002). P3 and P3’ sites were found to tolerate 
variable amino acids (Loeb et al. 1989; Pettit et al. 1991; Tözsér et al. 1997).  
 
Fig. 6: Substrate interaction with the catalytic residues. Substrate is bound asymmetrically so that the scissile 
bond is located in the center. Amino acids on either side of the scissile bond bind to substrate cavity. P enumerates 
amino acid side-chains, S labels subsites of the enzyme cavities. Scissile bond between P1 and P1’. Figure was 
generated with ChemDraw. 
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4.1.3.2 Mechanism of PR function 
 
HIV-1 PR uses an activated water molecule to attack the amide bond carbonyl of the 
substrate's scissile bond (Fig. 7). The activation of the water molecule is achieved by the two 
aspartyl β-carboxy groups at the active site. The water molecule acts as a nucleophile and 
attacks the carbonyl carbon of the scissile bond (James und Sielecki 1985). 
The Asp side chain closer to the nucleophilic water molecule is assigned the negative charge 
(Fig. 7). The negative aspartate side chain activates the water by rendering it nucleophilic to 
attack the carbonyl group in the substrate scissile bond and to generate an oxyanion 
tetrahedral intermediate (“oxyanion hole”). The scissile amide N atom is protonated and 
molecular rearrangement results in the decomposition of the tetrahedral intermediate to the 
hydrolyzed products (Suguna et al. 1987; Berg et al. 2014).  
 
 
Fig. 7: Schematic representation of the mechanism of proteolytic cleavage. Activation of a water molecule by 
two aspartic acid residues to cleave the peptide bond. Figure was generated with ChemDraw. 
 
4.1.3.2.1 PR auto-processing 
 
Monomeric PR is expressed as subunit of the GagProPol polyprotein. It needs to dimerize in 
order to enable proteolytical activity (Pettit et al. 1994; Tessmer und Kräusslich 1998). The 
active sites of both subunits interact only weakly and show low dimer stability but is crucial for 
correct spacial approximation. Then, the N- and C-terminal amino acids of both domains can 
interact strongly and establish a stable dimer (Louis et al. 1991; Hayashi et al. 2014). Auto-
processing of HIV-1 protease was shown to be tightly coupled to protein folding (Louis et al. 
1999). The first cleavage is reported to occur at the SP1-NC cleavage site, followed by 
processing of the transframe region at TFP-p6* and p6*-PR respectively (Pettit et al. 1994; 
Phylip et al. 1992). A mutation in p6* was shown to influence PR activity (Chiu et al. 2006). 
TFP cleavage increases PR activity and is needed to allow proper folding of PR (Chatterjee et 
al. 2005; Huang und Chen 2010; Louis et al. 1991; Wan et al. 1996). PR-RT scission is the 
last step of self-processing and renders a catalytically active dimerized PR that subsequently 
cleaves Gag and GagProPol (Wondrak et al. 1996). 
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Fig. 8: Autocatalysis of HIV-1 PR from GagProPol. PR monomers need to dimerize as part of GagProPol to form 
the active site. PR auto-catalyses by cleaving off the N-terminal TFP and p6* first, PR-RT cleavage is last step of 
self-processing. 
 
4.1.3.2.2 Cleavage of Gag and GagProPol  
 
PR cleavage sites in Gag and GagProPol display different amino acid sequences but are all 
recognized by the viral PR. Sequence variations are thought to regulate cleavage sequence 
and rate by different binding affinities to the PR active site (Fig. 9) (Kräusslich et al. 1989; Pettit 
et al. 1994; Pettit et al. 2005; Wiegers et al. 1998). Most studies were performed by in vitro 
processing of peptides representing different cleavage sites or Gag-derived proteins with 
purified HIV-1 PR. Alternatively, viral particles lacking PR were concentrated and processed 
with purified PR (Konvalinka et al. 1995). Accumulation of cleavage products over time were 
detected by fluorography or immunoblot (Erickson-Viitanen et al. 1989; Konvalinka et al. 1995). 
These studies revealed uncleaved Gag polyprotein (p55) before PR addition. The order of 
cleavage was found to be highly conserved (Tözsér et al. 1997). Cleavage sites were classified 
based on their processing rate (Pettit et al., 1994). Upon proteolytic processing, p40 (MA-CA-
SP1) and p15 (NC-SP2-p6) were detected rapidly (Fig. 9). SP1-NC was shown to be the first 
processing event and therefore determines the Gag cleavage rate (Fig. 9) (Oliveira et al. 2003). 
Intermediate processing was observed for SP2-p6 (9x slower than SP1-NC) and MA-CA (14x 
slower than SP1-NC). Slow, and therefore late cleavage was measured for NC-SP2 (350x 
slower than SP1-NC) and CA-SP1 (400x slower than SP1-NC) (Pettit et al. 1994). Blockage 
of any individual cleavage site except NC-SP2 impaired viral infectivity (Coren et al. 2007; 
Marco et al. 2010; Lee et al. 2012; Müller et al. 2009; Wiegers et al. 1998). 
Free NC binding to the viral genome leads to condensation of the RNP. Free CA assembles 
as the conical capsid and encloses the genome. Regulation of the processing order is therefore 
crucial for formation of functional and formation of infectious viral particles. This is supported 
by studies that observe impaired viral infectivity upon weak protease inhibition and by its 
premature activation (Figueiredo et al. 2006; Kaplan et al. 1994; Müller et al. 2009). An 
obligatory dimeric protease expressed as GagProPol component does not form viral particles 
due to premature Gag and GagProPol cleavage (Kräusslich 1991). A delay of virus release 
from the plasma membrane was found to cause viral particles to lack RT and PR (Bendjennat 
und Saffarian 2016). 
While the processing order of Gag was studied in detail, the proteolytic cleavage in respect to 
virus assembly is not well understood. Due to asynchronous virus assembly between cells and 
differences for individual budding sites, bulk analysis by biochemical approaches is not 
applicable here. The timeframe of Gag processing was studied by induced HIV-1 PR activity 
in purified viral particles (Hanne et al. 2016; Mattei et al. 2014; Schimer et al. 2015). In these 
studies, immature viral particles were produced in the presence of PR inhibitors. In the first 
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study, the inhibitors were washed out and the cleavage products were analyzed over time. 
While Gag processing products were observed by immunoblot, viral infectivity was not 
recovered (Mattei et al. 2014). Delayed processing by slow dissociation of the inhibitor 
dissociation from the HIV-1 active site was discussed to cause the hampered infectivity. 
Therefore, the next studies applied a photodegradable inhibitor, that was rapidly inactivated. 
Here, 30% of mature CA was produced within 15 min, but full Gag cleavage was not achieved 
(Schimer et al. 2015). Visualization of conformational changes by super-resolution microscopy 
and quantification of mature and immature VLPs over time resulted in t1/2 of ~30 min for virus 
maturation (Hanne et al. 2016). 
 
 
Fig. 9: Gag cleavage sites and order of proteolytical processing events. Rapid cleavage ot SP1-NC, 
intermediate processing of SP2-p6 and MA-CA and slow scission of NC-SP2 and CA-SP1. Different cleavage 
sequences are believed to influence binding affinity of the PR active site and therefore regulate proteolytic 
processing.  
 
While the order of cleavage events that are involved in autocatalysis of PR are known, the 
sequence of processing in Pol is not fully elucidated. (Tözsér et al. 1991) support the cleavage 
of RT-IN, followed by PR-RT and RT-RNAseH (Könnyű et al. 2013). Alternatively, a 
simultaneous release of PR, RT, RNAse H and IN was discussed (Craven et al. 1991). 
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Fig. 10: Specific PR cleavage sites in GagProPol. TFP-p6* and p6*-PR cleavage increases proteolytic activity. 
RT-IN may be cleaved prior to PR-RT, which is followed by RT-RNAseH processing. Alternatively, Pol is cleaved 
simultaneously. 
 
4.1.3.3 PR inhibitors 
 
The first PR inhibitor approved by the FDA was saquinavir in 1995 (James 1995). Combination 
of different drugs in antiretroviral therapy (ART) decreased the mortality of AIDS-related deaths 
in the USA from 50000 to 18000 people a year (La Porte 2009). Today, there are nine protease 
inhibitors approved for HIV-1 therapy: saquinavir (SQV), ritonavir (RTV), indinavir (IDV), 
nelfinavir (NFV), amprenavir (APV), lopinavir (LPV), atazanavir (ATV), tipranavir (TPV) and 
darunavir (DRV). Structural and biochemical analyses of the HIV-1 active site were conducted 
for the rational design of the drugs. All protease inhibitors with the exception of DRV are 
competitive inhibitors: they represent non-cleavable peptide analoga, that bind to the active 
site of PR with high affinity and compete with Gag binding but do not prevent auto-processing 
(Fig. 11). DRV was found to additionally prevent PR dimerization (Humpolíčková et al. 2018). 
All together, they bind to the active site of the dimer and prevent cleavage of Gag, and thereby 
maturation, which leads to a release of immature, non-infectious viral particles (Patick und 
Potts 1998). Protease inhibitors are designed to mimic the tetrahedral intermediate formed 
during the cleavage mechanism, but scission of the bond by viral protease does not occur 
(Konvalinka et al. 2015). Drug resistance of the virus is observed upon treatment; it arises 
through mutations in PR, but also in Gag (Côté et al. 2001; Dam et al. 2009; Fun et al. 2012). 
Mutations in HIV-1 proteins are caused by the lack of proof-reading of the viral RT and are 
further selected for reduced inhibitor susceptibility. Initial resistance mutations are also referred 
to as primary mutations because they are the first mutations selected. They usually change 
the structure of the active site cavity, so that the binding of the drug to the viral PR is hampered, 
which results in resistance to PIs (Gulnik et al. 1995). While primary mutations additionally 
reduce HIV-1 PR activity, secondary and tertiary mutations are observed in patients over time, 
that do not reduce binding of the inhibitor to PR but increase proteolytic activity (Nijhuis et al. 
1999). Structural similarities of the inhibitors may lead to cross-resistance. Therefore, new 
drugs need to be designed that address different mechanisms of inhibition. 
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Fig. 11: PR inhibitor bound to the active site of HIV-1 PR. Subunits are identical but colored in black and grey 
for better identification. Blue residues mark the catalytically active Asp 25 and Asp 25’ residues. Red structure 
illustrates inhibitor Atazanavir bound to the active site. Figure was generated using PyMol (www.pymol.org). PR 
structure adapted from from PDB ID: 3el1. 
 
PR inhibitors bind to the active site with varying rate constants. While the association with the 
active site is described by kon (M-1s-1), the dissociation rate with koff (s-1) and t1/2 (s) the halftime 
for the molecule to bind. PR inhibitors in general bind strongly to the active site. Dissociation 
rate are more variable (Dierynck et al. 2007). While DRV does not dissociate form the active 
site, RTV features a short t1/2.  
 
 
 
Fig. 12: Selected PR inhibitor structures and respective kinetic parameters for binding to the active site of 
HIV-1 PR. Ritonavir (RTV), Lopinavir (LPV) and Darunavir (DRV) structures generated with ChemDraw. Rate 
constants and t (1/2) from (Dierynck et al. 2007). 
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4.2 Fluorescence labeling of virus-like particles 
 
In this project, we want to observe the HIV-1 PR activity during the viral assembly. Therefore, 
we need to visualize the formation of new viral particles at the plasma membrane in 
combination with utilization of sensors to detect proteolytic activity or active HIV-1 PR over 
time. 
Fluorescence labeling of viral particles allows detection of dynamic events during the viral life 
cycle. It is crucial that labeling of HIV-1 does not alter functions and infectivity of the virus 
(Campbell und Hope 2008). For visualization of viral assembly, application of fully infectious 
virus is unnecessary. A subviral derivative lacking LTRs and Nef, where reverse transcription 
is disabled to render the virus non-infectious (pCHIV) was generated previously and shown to 
be suitable for studying viral assembly (Lampe et al. 2007) and therefore has been applied in 
this work.  
 
4.2.1 Fluorescence tags inserted in Gag 
 
Insertion of fluorescent proteins in Gag, between MA and CA, was found to be tolerated in viral 
particles (Fig. 13B). eGFP was inserted and designed to stay attached to MA upon proteolytic 
processing (Müller et al. 2004). While the tagged virus formed viral particles with reduced 
infectivity, it was observed that mixing of labeled and unlabeled Gag in an equimolar ratio 
reconstitutes full infectivity of the virus (Müller et al. 2004). Gag labeling with eGFP was shown 
to allow detection of assembly sites at the plasma membrane by fluorescence microscopy 
(Baumgärtel et al. 2012; Ivanchenko et al. 2009; Jouvenet et al. 2011a). These sites were 
tracked, and the signal intensity increase was analyzed over time. The assembly kinetics of 
labeled Gag were observed to exhibit saturating exponential curves (Ivanchenko et al. 2009; 
Jouvenet et al. 2008; Mücksch et al. 2017; Rahman et al. 2014). 
 
4.2.2 Fluorescence tags inserted by coupling to Vpr 
 
Vpr is an accessory protein of HIV-1. It interacts with the p6 domain of Gag and gets 
incorporated in the viral particle by Gag recruitment (see 4.1.1 and 4.1.2.1). A molar ratio of 
Vpr to Gag of 1:7 was determined based on radioactively labeled highly purified virions (Müller 
et al. 2000). Vpr was discovered as tool to introduce foreign proteins in the viral particle by 
fusion to Vpr (Wu et al. 1996). Linkage of a fluorescent protein to Vpr was described in 2002 
to allow visualization of the viral entry (Fig. 13A) (McDonald et al. 2002). Expression of Vpr in 
trans also enables double-labeling of viral particles (Fig. 14) (Lampe et al. 2007). For 
exogenous Vpr incorporation, higher molar ratios of Vpr to Gag of up to 1:2 were described, 
resulting in up to ~1000 Vpr molecules in the viral particle. Incorporation of exogenous Vpr was 
observed in hamper Gag processing; therefore, it needs to be regulated carefully (Lampe et 
al. 2007; Sood et al. 2017).  
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4.3 Fluorescence-based methods applied in this study 
 
In this study, HIV-1 proteolytic activity and formation of active PR was measured during the 
viral assembly process. Light microscopy enables detection of events in living cells. But the 
resolution is limited due to its dependence of the wavelength (λ) and the numerical aperture 
(NA) of the microscope lense: 
𝑅𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 (𝑟) =  
𝜆
2 ∙ 𝑁𝐴
 
Applying a laser with 488 nm wavelength allows for a resolution of ~240 nm. HIV-1 is known 
to have a diameter of 120 nm, so it cannot be resolved. Therefore, fluorescence characteristics 
like FRET are applied to measure changes in the viral particle (see 4.3). Super-resolution 
STED microscopy increases the resolution of fluorescence microscopy to ~20 nm and 
therefore can be applied to resolve viral structures as well (Hell und Wichmann 1994; Hanne 
et al. 2016). 
Either, external sensors were cleaved by the viral PR, Gag processing was observed, or active 
PR was labeled.  
 
4.3.1 Bimolecular fluorescence complementation assays detect Gag processing 
 
BiFC assays are applied for visualization of protein interactions in living cells (Kerppola 2006, 
2008). In this assay, fluorescent proteins are split in two subunits that are non-fluorescent 
individually. GFP-based proteins are β-barrels consisting of eleven β-strands that are all 
necessary for the formation of the fluorophore. They may be split in N- and C-terminal domains, 
or β1-10 and β11 (Cabantous et al. 2005; Cabantous und Waldo 2006), which are both non-
fluorescent; fluorescence is reconstituted by association of both parts upon co-expression in 
the same cell. This has been exploited to monitor protein-protein interactions. β1-10 and β11 
are linked to different target proteins and interaction of the target proteins is detected upon 
generation of fluorescence signal. We have explored a different application in this study, 
incorporating split subunits of the yellow fluorescent protein Venus (Hernandez und Sandri-
Goldin 2011) and sfGFP in Gag between the MA and CA domain. Constraint of the subunits 
within the unprocessed polyproteins was presumed to impair reconstitution of the fluorophore, 
while release by PR mediated processing should allow association (Fig. 26). 
 
4.3.2 Förster resonance energy transfer to detect proteolytic activity 
 
HIV-1 PR activity was measured by fluorescence-based studies since the 1990s. It was 
described, that PR cleaves HIV-1 Gag processing sites independent of the flanking proteins. 
This allowed the design of peptide probes that gain a fluorescent signal upon proteolytic 
processing due to e.g. clipping of a quencher (Baum et al. 1990; Richards et al. 1990). Mostly, 
the measurements were conducted in vitro, e.g. spectrofluorometry. Here, either purified 
proteins of viral particles were subject to proteolytic cleavage by purified HIV-1 PR (Baum et 
al. 1990; Gaber et al. 2013; Müller et al. 2014; Richards et al. 1990).  
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The FRET-based assay utilizes the Förster resonance energy transfer (FRET) technique which 
was initially described by Theodor Förster in 1946 (Förster 1948). FRET relies on the energy 
transfer between a donor and an acceptor fluorophore providing that the emission peak of the 
donor molecule overlaps the excitation peak of the acceptor molecule and that both 
fluorophores are in close proximity of their Förster radius (approximately 10Å) (Lam et al. 2012; 
Gaber et al. 2013). Following excitation of the donor fluorophore, energy is directly transferred 
to the adjacent acceptor fluorophore by dipole-dipole interactions leading to the excitation of 
the latter. Since FRET efficiency directly correlates with the distance of the fluorophores, it is 
an established technique to analyze protein interactions between two fluorescently labeled 
proteins. Different FRET-pairs like mCerulean and mCitrine or GFP and mCherry had been 
applied to observe HIV-1 PR activity in cells (Gaber et al. 2013; Yang et al. 2012). Here, FRET 
was analyzed by fluorescence microscopy, or as FACS-based FRET assay by flow cytometry 
(Banning et al. 2010).  
For a FRET-based analysis of PR activity, the fluorescent proteins Clover and mScarlet were 
coupled via a HIV-1 PR cleavage site (as found in Gag between MA and CA) and linked to Vpr 
to enable its incorporation in viral particles (Lam et al. 2012; Bindels et al. 2017). 
 
4.3.3 Fluorescence lifetime-resolved imaging to detect Gag processing 
 
Fluorescence lifetime measurements (FLIM) are based on monitoring of fluorescence decay 
over time. After excitation, fluorescent proteins require a specific time for transformation from 
the excited to the ground state (Clegg et al. 2003). Different lifetime components of the same 
molecule may form due to variations on molecular species or conformation (Digman et al. 
2008). This lifetime is independent on the signal intensity but changes due to molecular 
interactions, e.g. decreases upon energy transfer of the protein as FRET-donor. eCFP was 
found to form homo-FRET pairs by interacting with surrounding eCFP proteins, and 
dimerization of eCFP led to a decrease of its fluorescence lifetime.  
Here, eCFP was utilized for FLIM measurements, because it performs homo-FRET, which 
reduces the influence of protein incorporation (Poëa-Guyon et al. 2013). Molecular crowding 
induced homo-FRET of eCFP, resulting in a decrease of fluorescence lifetime (Kremers et al. 
2006).  
In this work, eCFP was inserted in Gag between MA and CA, either flanked with PR cleavage 
sites or one cleavage site between the fluorescent protein and CA. Gag multimerization should 
lead to a decrease of fluorescence lifetime due to molecular crowding, while proteolytic 
processing should be detected via increase of fluorescence lifetime. 
 
4.3.4 Fluorogenic probes to stain active PR 
 
The spectrum of fluorescence tags was expanded with the design of self-labeling enzymes 
that covalently bind substrates. SNAP (O6-alkylguanine-DNA-alkyltransferase) and Clip (O6-
alkyl-cytosine-DNA-alkyltransferase) form a covalent bond with tags coupled to silicone-
rhodamine (SiR) (Correa et al. 2013; Gautier et al. 2008; Lukinavičius et al. 2018). The 
resulting fluorescence signal of SiR is in the far-red (excitation maximum: 645 nm, emission 
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maximum: 661 nm) range, enabling multiple labeling of viral particles (GFP excitation 
maximum: 488 nm, emission maximum: 525 nm).  
As a fluorogenic dye, SiR fluoresces upon binding to a target protein. The equilibrium between 
a non-fluorescent lactonic and fluorescent zwitterion structure is sensitive to hydrophobic 
effects (Lukinavičius et al. 2013). The SNAP-tag was inserted in Gag previously and enabled 
staining of Gag.SNAP in viral particles with SNAP-Cell 647-SiR (Eckhardt et al. 2011). 
Intracellular proteins were previously labeled by transient binding of SiR-coupled inhibitor 
derivatives for cytoskeletal filaments F-actin and microtubule (Lukinavičius et al. 2014).  
In this study, SiR was coupled to the PR inhibitor RTV, which specifically binds to the active 
site of HIV-1 PR, as described before. SiR-RTV was shown to fluoresce upon binding to the 
PR active site due to conformational changes in SiR depending on the environment. Different 
linkers were tested concerning their influence on fluorogenicity of the probe upon binding to 
active HIV-1 PR, as well as unspecific background signal.  
 
4.3.5 Single virus tracking at assembly sites 
 
In this study, laser scanning confocal and TIRF microscopy were applied to image fluorescently 
labeled purified virus-like particles (VLPs) and assembly sites at the plasma membrane of 
HeLa Kyoto cells.  
 
Confocal imaging scans the probe point-by-point with a xy-resolution of about 200 nm and a 
z-resolution of 500 nm (sample penetration). This reduces the time-resolution and increases 
cellular background (Balagopalan et al. 2011). TIRF microscopy is a widefield imaging-based 
technique, where light is directed towards the sample in a critical angle and therefore reflected 
at the glass surface. The evanescent wave of the reflected light can penetrate the sample for 
about 200 nm (Mattheyses et al. 2010). EMCCD-camera-based detection allows sensitive, 
high time resolution imaging with a z-resolution of 200 nm. Therefore, TIRF microscopy was 
applied for live-cell imaging of the assembly process to detect increasing numbers of punctae 
over time.  
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4.4 Aim of the work 
 
Regulation of Gag proteolysis with respect to virus assembly is critical, but time and site of 
maturation initiation are currently unclear. The duration of the process and its structural 
intermediates are also unknown. Most analyses of PR activity were performed in vitro and 
therefore studied independent of viral assembly (Konvalinka et al. 2015).  
The aim of this project was the time-resolved detection of proteolytic activity, Gag processing 
and formation of active PR during the viral assembly process by live-cell fluorescence 
microscopy.  
With the aim to monitor HIV-1 PR activity in parallel to virion assembly by live-cell microscopy, 
I designed a Förster resonance energy transfer (FRET)-based PR sensor. For this, a FRET 
pair of autofluorescent proteins Clover and mScarlet was linked via a PR cleavage site and 
fused to the viral protein r (Vpr) to mediate recruitment to viral assembly sites and particle 
incorporation.  
Different tags were inserted in Gag that indicate processing and conformational changes in the 
viral protein. Specifically, a bimolecular fluorescence complementation assay was designed to 
generate a fluorescent signal upon proteolytic cleavage of Gag. Next, a fluorogenic dye 
applicable for super-resolution microscopy was ultilized to resolve changes in spatial 
distribution of Gag to discriminate mature and immature viral particles. Lastly, changes in 
fluorescence lifetime of the fluorescent protein eCFP depending on localization in the Gag 
lattice or free diffusion in the viral particle were measured. 
Furthermore, specific labeling of active HIV-1 PR by a fluorogenic inhibitor was explored. This 
innovative approach combines the fluorogenic properties of SiR with the specificity of RTV to 
active HIV-1 PR.  
Together, these sensors were applied to shed light in the dynamic coordination of viral 
assembly and HIV-1 PR activity.  
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5 Materials and Methods 
 
5.1 Materials 
 
5.1.1 Laboratory Equipment 
 
Name  Company  
 
Bacterial Shaker Multitron Pro 
 
Infors HT, Bottmingen, Switzerland 
C1000 Touch Thermal Cycler  BioRad, Hercules, USA  
Centrifuge Avanti J-26 XP Beckman Coulter, Brea, USA 
CFX 96 Real Time PCR detector (for SG-
PERT)  
BioRad, Hercules, USA  
Flow cytometer FACS AriaTM  BD Biosciences, Heidelberg, Germany 
Flow cytometer FACS Canto HTS  BD Biosciences, Franklin Lakes, USA  
Gel iX Imager (Agarose gel UV-imager)  INTAS Science Imaging, Göttingen  
Hamilton® TLC syringe: 10 μl, 26s ga, 
needle, fixed  
Hamilton, Reno, USA  
Heraeus Megafuge 40R Centrifuge Thermo Scientific, Waltham, USA 
H-TIRF inverted Eclipse Ti2 microscope Nikon Instruments Inc., Melville, USA 
Ice Maker AF 103 Scotsman, Sprockhövel 
Incubator C200 Labotect Labor-Technik-Göttingen, Rosdorf 
L8-70M Ultracentrifuge with SW28 and 
SW32 rotor  
Beckman Coulter, Brea, USA  
Leica DMIL Led Fluorescent Microscope Leica Microsystems, Wetzlar 
Leica TCS SP2 laser scanning confocal 
microscope  
Leica Microsystems, Wetzlar  
Leica TCS SP8 laser scanning confocal 
microscope  
Leica Microsystems, Wetzlar  
LiCor Odyssey Imager CLx LiCor Bioscience, Lincoln, USA  
Light Microscope ELWD 0.3 T1-SNCP Nikon Instruments Inc., Melville, USA 
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Microbiological Cabinet Envair, Emmendingen 
Microwave for Agarose gels Sharp, Cologne 
NanoPhotometer Implen, Munich 
PCR FlexCycler2 Analytik Jena, Jena 
Plate Reader Inifinite M200 Pro Tecan, Männedorf, Switzerland 
Roller Mixer SRT6 Stuart, Staffordshire, UK 
SDS-PAGE electrophoresis chamber Mighty 
small 
Hoefer, Almstetten 
Semi-Dry Blotter Fastblot B32 Whatman Biometra, Göttingen 
Spectrofluorometer FP-8500 Jasco, Pfungstadt 
Speed Vac  H. Saur, Reutlingen  
STED system 775nm  Abberior Instruments GmbH, Göttingen 
Thermomixer, Eppendorf, Thermomixer® 
comfort 
Eppendorf, Hamburg 
TL-100 Ultracentrifuge with TLA 45 rotor 
(Tabletop)  
Beckman Coulter, Brea, USA  
TLC Glass chamber  Desaga, Wiesloch  
Vortex Genie 2 Scientific Industries, Bohemia, USA 
Warming Cabinet Memmert, Schwabach 
Water Filtering System Stakpure, Niederahr 
Waterbath MP Julabo, Seelbach 
XS40025 Deltarange Weight Scale Mettler Toledo, Gießen 
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5.1.2 Reagents 
 
5.1.2.1 Chemicals and consumables 
 
 
Agarose NEEO     
Ammonium persulfate (APS)    
Acrylamide 30 %  
 
Carl Roth, Karlsruhe 
Sigma Aldrich, St. Louis, USA 
 
Applichem, Karlsruhe  
 
β-Mercaptoethanol  Sigma-Aldrich, St. Louis, USA  
 
Blasticidin  Thermo Scientific, Waltham, USA  
 
Bromophenol blue  Chroma, Fürstenfeldbruck  
 
BSA 100x  NEB, Ipswitch, USA  
 
Blotting paper  3 MM Chr, Whatman, Dassel, 
Germany 
  
DMSO  Merck, Darmstadt  
 
DNA ladder 1 kb Plus  Thermo Scientific, Waltham, USA  
 
dNTP Set  Thermo Scientific, Waltham, USA  
 
Dulbecco’s Modified Eagle Medium (DMEM)  Invitrogen, Karlsruhe  
 
Ethanol (99 %) (EtOH)  Zentralbereich INF, Heidelberg  
 
Fetal Calf Serum (FCS)  Biochrom, Berlin  
 
FluoroBrite DMEM 
 
Thermo Scientific, Waltham, USA  
 
Fugene HD 
 
Roche, Basel, Switzerland 
 
Gel Loading Dye, Purple (6x) for DNA  New England Biolabs, Ipswich, USA  
 
GlutaMAX Supplement  Thermo Scientific, Waltham, USA  
 
Isopropanol  Sigma-Aldrich, St. Louis, USA  
 
LI-COR Blocking Buffer  LI-COR Bioscience, Lincoln, USA  
 
Methanol (MeOH) Sigma-Aldrich, St. Louis, USA  
 
Nitrocellulose membrane  Protran, Schleicher & Schull/Whatman, 
Dassel, Germany 
Name    Company  
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PageRuler prestained  Thermo Scientific, Waltham, USA  
  
Penicillin Streptomycine (PenStrep)  Thermo Scientific, Waltham, USA  
  
Reaction tubes (0.5-2ml) 
 
RNAse Inhibitor, Ribolock  
 
Sarstedt, Nümbrecht 
 
Thermo Scientific, Waltham, USA  
 
Serological pipettes 
 
Sarstedt, Nümbrecht 
 
Single Channel Pipettes, PIPETMAN 
classicTM (10-1000 µl) 
 
Sodium Acetate  
 
Gilson, Middleton, USA  
 
 
Sigma-Aldrich, St. Louis, USA  
 
Sodium Chloride  Sigma-Aldrich, St. Louis, USA  
 
Sodium dodecyl sulfate (SDS)  Applichem, Karlsruhe  
 
Sodium Pyruvate (100 mM)  Thermo Scientific, Waltham, USA  
  
Sulfuric acid  Fluka, Steinheim  
 
Tetramethylethylenediamine (TEMED) Sigma Aldrich (St. Louis, USA) 
  
Tris[(1-benzyl-1H-1,2,3-triazol-
4yl)methyl]amine  
 
Sigma-Aldrich, St. Louis, USA  
Triton X-100  Sigma-Aldrich, St. Louis, USA  
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5.1.2.2 Protease Inhibitors 
 
Ritonavir 
 
 
Lopinavir 
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Darunavir 
 
SiR-C2-RTV 
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SiR-C4-RTV 
 
SiR-C6-RTV 
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5.1.2.3 Reagent Systems (Kits) 
 
Plasmid Plus Midi Kit    Qiagen, Hilden 
NucleoBond MaxiPrep Kit   Macherey-Nagel, Düren 
NucleoSpin Gel and PCR purification Kit Macherey-Nagel, Düren 
 
5.1.2.4 Buffers and Solutions 
 
Acrylamide Stock:   30 % Acrylamide 
    0.15 % Bisacrylamide 
 
PBS (10x):   142.4 g Na2HPO4 · 2H2O 
    27.6 g NaH2PO4 · H2O 
    819 g NaCl 
ddH2O to 10000 ml 
 
4x Resolving Buffer:  1.5 M Tris (pH 8.8) 
    0.4 % SDS 
 
4x Stacking Buffer:  0.5 M Tris (pH 6.8) 
    0.4 % SDS 
 
Running Buffer:  1 g SDS 
    3.03 g Tris 
    14.4 g Glycine 
    ddH2O to 1000 ml 
 
Resolving Gel:  17.5 ml Acrylamide Stock 
    7.5 ml 4x Resolving Buffer 
    5 ml H2O 
 
3x Sample Buffer:  150 mM Tris HCl, pH 6.8 
    6 % w/v SDS 
    30 % Glycerin 
    0.06 % Bromophenol Blue 
    10 % β-Mercaptoethanol 
 
Stacking Gel:   15 ml Acrylamide Stock 30:0.8% 
    25 ml 4x Stacking Buffer 
    60 ml H2O 
 
Sucrose solution (20 %): 10 g Sucrose 
dd PBS to 50 ml 
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TAE Buffer (50x) pH 8.3: 0.1 M EDTA 
    1 M NaAc 
    2 M Tris 
 
TBS-T (10x) pH 7.5:  175.32 g NaCl 
    121.14 g Tris 
    10 ml Tween 
    dd H2O 2000 ml  
 
Western Blot blocking 30 % LI-COR buffer (v/v) 
buffer:    dd TBS-T 
 
Western Blot   0.3 M Tris 
Transfer Buffer 1:  20 % Methanol 
    dd H2O 1000 ml 
 
Western Blot    0.025 M Tris 
Transfer Buffer 2:  20 % Methanol 
    dd H2O 1000 ml 
 
5.1.2.5 Growth Media 
 
5.1.2.5.1  Cell culture media 
 
Adherent cells: Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % heat-
inactivated FCS, and 1 % penicillin/streptomycin. 
Suspension cells: Roswell Park Memorial Institute medium (RPMI 1640) supplemented with 
10% heat-inactivated FCS, and 1% penicillin/streptomycin. 
Imaging medium: Fluoro-Brite supplemented with 10 % FCS (v/v), 4 mM GlutaMAX, 2 mM 
sodium pyruvate, 20 mM HEPES pH 7.4, 100 U/ml penicillin, 100 μg/ml streptomycin 
  
5.1.2.5.2 Bacterial growth media  
 
LB:    5 g/l NaCl  
10 g/l Tryptone  
5 g/l Yeast extract 
 
add H2O and adjust to pH 7.2, autoclave 
 
LB agar plates:  12.5 g/l agar 
    LB 
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For selection, Ampicillin (0.1 mg/ml) or Kanamycin (0.1 mg/ml for liquid culture and 0.06 mg/ml 
for plates) was added to the medium. 
  
5.1.2.6 Nucleic acids 
 
5.1.2.6.1  Oligonucleotides for site-directed mutagenesis 
      
Construct 
 
 
Inserted  
Protein 
 
Restriction  
Enzyme 
 
Direction 
 
 
5'-3' Sequence 
 
  
mScarlet.Vpr mScarlet AgeI  for CGCTACCGGTATGGTGAGCAAGGGC 
  
BsrGI  rev GACTTGTACAGCTCGTCCATGCCGC 
Clover-
mScarlet.Vpr 
 
NaeI for AGAGCCGGCGTGAGCAAGGGCGAGGCAG 
Clover-
mScarlet.Vpr 
 
XhoI rev GCCGGCTCTAGTTTGGAG 
 
Clover.Vpr Clover AgeI  for CGCTACCGGTATGGTGAGCAAGGGCGAGG 
  
BsrGI  rev CGACTTGTACAGCTCGTCCATGCC 
Clover-
mScarlet.Vpr 
 
XbaI for GCTTCTAGAATGGTGAGCAAGGGCGAG 
MA-eCFP MA-eCFP NheI for GATATAGCTAGCATGGGTGCGAGAGCGTCGG 
  
XhoI rev GGTGCTCGAGTCACTTGTACAGCTCGTCCATGCCG 
 
5.1.2.7 Plasmid DNA 
 
Name Description Source 
 
mScarlet.Vpr 
Clover.Vpr 
Clover-mScarlet.Vpr 
 
sfGFP1-10.Vpr 
pCHIV 
 
 
pCHIV SNAP 
 
 
pCHIV eGFP 
 
 
 
mScarlet coupled to viral protein r 
Clover coupled to viral protein r 
Clover linked to mScarlet via PR cleavage 
site and coupled to viral protein r 
Clover coupled to viral protein r 
pcDNA3.1 derived, non-infectious HIV-
1proviral construct, lacking LTRs and parts 
of Nef 
pCHIV derived; SNAP tag inserted in Gag at 
MA C-terminus with cleavage site between 
CA 
pCHIV derived; eGFP tag inserted in Gag at 
MA C-terminus with cleavage site between 
CA 
 
This work 
This work 
This work 
 
This work 
Lampe et al. 
(2007) 
 
Eckhardt et al. 
(2011) 
 
Lampe et al. 
(2007) 
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pCHIV iClip 
 
 
pCHIV isfGFP11 
 
 
pCHIV N-Venus 
 
 
pCHIV C-Venus 
 
 
pCHIV PR D25N 
 
pCHIV PR D25N eGFP 
 
 
pCHIV Gag only 
Gag eGFP 
 
pCHIV Pol SNAP 
 
pCHIV NC-RT 
 
pCHIV NC-RT eGFP 
 
 
 
pCHIV eCFP 
 
 
pCHIV ieCFP 
 
 
MA-eCFP 
 
eCFP 
 
pCHIV derived; Clip tag inserted in Gag at 
MA C-terminus with cleavage site between 
MA and CA 
pCHIV derived; sfGFP11 tag inserted in Gag 
at MA C-terminus with cleavage site between 
MA and CA 
pCHIV derived; N-terminal domain of Venus 
tag inserted in Gag at MA C-terminus with 
cleavage site between CA 
pCHIV derived; C-terminal domain of Venus 
tag inserted in Gag at MA C-terminus with 
cleavage site between CA 
pCHIV derived; D25N active site mutation in 
PR 
pCHIV derived; eGFP tag inserted in Gag at 
MA C-terminus with cleavage site between 
CA and D25N active site mutation in PR 
pCHIV derived; stop in transframe region 
Rev-independent full-length gag gene clone 
fused to EGFP in pEGFP-N 
pCHIV derived; SNAP tag inserted in Pol at 
IN C-terminus  
pCHIV derived; PR cleavage site mutations 
between NC and RT 
pCHIV derived; PR cleavage site mutations 
between NC and RT, eGFP tag inserted in 
Gag at MA C-terminus with cleavage site 
between CA 
pCHIV derived; eCFP tag inserted in Gag at 
MA C-terminus with cleavage site between 
CA 
pCHIV derived; eCFP tag inserted in Gag at 
MA C-terminus with cleavage site between 
MA and CA 
MA coupled to eCFP in pcDNA 3.1 vector 
 
eCFP in pcDNA 3.1 mammalian expression 
vector 
 
Hanne et al. 
(2016) 
 
This work 
 
 
AG Müller 
 
 
AG Müller 
 
 
Hanne et al. 
(2016) 
AG Müller 
 
 
AG Müller 
Hermida-
Matsumoto and 
Resh (2000) 
 
This work 
 
This work 
 
 
 
AG Kräusslich 
 
 
This work 
 
 
This work 
 
Invitrogen 
 
 
 
5.1.2.8 Enzymes 
 
GoTaq Hot Start DNA Polymerase  Promega, Madison, USA  
Pfu Polymerase  Promega, Madison, USA  
Phusion High Fidelity DNA Polymerase  New England Biolabs, Ipswich, USA  
Restriction Endonucleases  New England Biolabs, Ipswich, USA  
T4 DNA Ligase  
HIV-1 protease wt 
New England Biolabs, Ipswich, USA 
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HIV-1 protease D25N AG Jan Konvalinka, Prague, Czech 
Republic 
AG Jan Konvalinka, Prague, Czech 
Republic 
 
5.1.2.9 Antibodies and dyes 
 
5.1.2.9.1  Antibodies 
 
Name Source Application Dilution 
Sheep anti HIV-1 CA 
Rabbit anti HIV-1 MA 
Rabbit anti GFP 
Rabbit anti Vpr 
Secondary antibodies 
conjugated with 
IRDye700/800 
H.-G. Kräusslich, Heidelberg 
H.-G. Kräusslich, Heidelberg 
H.-G. Kräusslich, Heidelberg 
H.-G. Kräusslich, Heidelberg 
Rockland, Limerick, USA 
WB 
WB 
WB 
WB 
WB 
1:5000 
1:3000 
1:1000 
1:1000 
1:10000 
 
5.1.2.9.2  Dyes 
 
Name Source Application Dilution 
SNAP-Cell® SiR 
 
 
SiR-Clip 
New England Biolabs, 
Ipswich, USA 
 
K. Johnsson, Heidelberg 
Live-cell imaging 
 
 
Live-cell imaging 
1:1000 
 
 
1:1000 
 
 
5.1.3 Software 
 
ChemDraw     PerkinElmer, Waltham, USA 
FACS Diva Software    B&D, Becton Dickinson, San José, USA 
Fiji Laboratory for Optical and Computational 
Instrumentation (LOCI), University of Wisconsin-
Madison, Madison, USA 
i-controlTM Software     Tecan, Männedorf, Switzerland 
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Image LabTM Software   Bio-Rad Laboratories, Hertfordshire, UK 
Image StudioTM Lite    LI-COR Bioscience, Lincoln, USA  
Imaris 9     Bitplane AG, Zurich, Switzerland 
Microsoft Office    Microsoft, Redmond, USA 
NIS Elements     Nikon Instruments, Melville, USA 
Serial Cloner Software   Serial Basics, France 
Snap Gene Viewer    GSL Biotech LLC, Chicago, USA 
Pymol      Schrödinger, Japan 
 
5.2 Methods 
 
5.2.1 Biochemical methods 
 
5.2.1.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blotting 
 
Samples for SDS-PAGE were boiled in protein sample buffer at 95°C for 10min for cell lysates 
and 5min for particle lysates.  
Resolving Gel Preparation: 2.9 ml Acrylamide Stock 
    1.25 ml Resolving Buffer 
    0.825 ml H2O 
    41 µl APS (10 % w/v)  
    8.5 µl TEMED 
 
Stacking Gel Preparation: 2 ml Stacking gel mix 
    50 µl APS (10 % w/v) 
    5 µl TEMED 
    20 µl Bromophenol blue 
 
10 µl samples were loaded on a 17.5 % crosslinked polyacrylamide gel and electrophoresis 
was performed at 25 mA/60cm2 gel for 60 min. Subsequently, the proteins were blotted onto 
nitrocellulose membranes using a semidry blotter with 43 mA/60cm2 membrane for 60 min. 
Membranes were blocked in 30 % LI-COR blocking buffer/TBS-T for a 30 min and were 
incubated with primary antibodies overnight at 4 °C (dilutions are indicated in 5.1.2.9.1). 
Subsequently, membranes were washed three times with TBS-T for 15 min and incubated with 
secondary antibodies conjugated to IRDye700/800 (1:10.000; Rockland, Limerick, USA) in 30 
% LI-COR blocking buffer/TBS-T at RT for 1 h. Membranes were washed three times with 
TBS-T for 15 min and fluorescent signals were detected using a digital infrared scanner (LI-
COR, Lincoln, USA). For quantitative signal detection, the Odyssey Image Studio software 
was used (LI-COR, Lincoln, USA). 
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5.2.1.2 Spectrofluorometry 
 
Due to the fluorogenic properties of SiR, the characterization of SiR-C6-RTV fluorescence was 
performed with the Spectrofluorometer FP-8500 (Jasco, Pfungstadt). The following buffers 
were prepared: 1 mg/ml BSA in PBS, 0.1 % SDS in PBS, PBS and absolute Ethanol; they were 
filtered with a sterile Rotilabo® filter (0.22 µm pore size) prior to use. For spectrofluorometric 
analysis, inhibitors were prediluted to 40 µM in DMSO. 200 nM SiR- C2/C4/C6-RTV were 
analyzed in 150 µl buffer. For the titration, HIV-1 PR or HIV-1 PR D25N were added in 50 nM 
and 100 nM steps. 1 µM DRV was added for inhibitor displacement. Excitation spectra were 
recorded at emission 675 nm and excitation ranging from 250-660 nm. Emission spectra were 
set to excitation at 635 nm and emission to 645-749 nm. Emission and excitation bandwidth 
were 5 nm, response time 0.5 s and sensitivity was set to high. Data interval was 2 nm with a 
scan speed of 500 nm/min without auto gain. Light source was a Xenon lamp. For time lapse 
measurements, excitation was set to 650 nm and emission to 675 nm with a data interval of 1 
s for 1 h. 
 
5.2.2 Cell biological methods 
 
5.2.2.1 Cell culture 
 
HEK293T cells are human embryonic kidneys cells transduced with the large T antigen 
(ATCC). HeLa Kyoto cells were derived from Human papillomavirus-related endocervical 
adenocarcinoma passaged in a laboratory in Kyoto, Japan. 
Adherent cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) high glucose, 
supplemented with 10 % FCS and 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were 
maintained at 37 °C with 5 % CO2 and 95 % humidity. 
Passaging of the cells was performed every 3-4 days. For this, cells were washed with PBS 
and detached from the glass surface by 0.05% Trypsin/EDTA in PBS. Cells were resuspended 
in medium and diluted 1:20. 
5.2.2.1.1 Transfections 
 
HEK293T cells were transfected with 1 mg/ml polyethylenimine (PEI) 24 h after seeding. Cells 
were transfected with 3:1 PEI:DNA. Plasmid DNA was added to Roswell Park Memorial 
Institute Medium (RPMI) 1640 without supplements. PEI was added, the mixture was vortexed 
and incubated for 30 min, before dripping it gently on the cells. In a 6 well format, 2µg DNA 
were transfected per well with a 1:1 molar ratio of labeled and unlabeled viral constructs. Vpr 
constructs were transfected in a 1:10 molar ratio with the viral constructs. 
HeLa Kyoto cells were transfected with Fugene HD 24 h after seeding. Transfection agent was 
added to serum-free RPMI 1640 and incubated for 5 min at RT. The solution was gently mixed 
with DNA and incubated for another 15 min, before being carefully dropped on cells. In an 8 
well labtek format, 50 ng DNA were transfected per well with a 1:1 molar ratio of labeled and 
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unlabeled viral constructs. Vpr constructs were transfected in a 1:10 molar ratio with the viral 
constructs. 
5.2.2.2 SNAP and Clip stain 
 
600 nM SNAP-Cell 647-SiR or 1 µM SiR-Clip were incubated with cells for 45 min at 37 °C. 
For STED measurements, cells were washed with imaging medium for 30 min and imaged 
subsequently. 
5.2.2.3 Staining of cells with fluorogenic PR inhibitor  
 
HeLaK cells were incubated with 1 µM SiR-C2/C4/C6-RTV in imaging medium 20 min prior to 
imaging.  
5.2.2.4 Flow cytometry 
 
Flow cytometry was used in this study to survey cells expressing the FRET-based sensor in 
combination with different viral constructs.  
 
Prior to measurement, the cells were prepared as follows: the cells were first harvested and 
centrifuged for 5 min at 1,500 rpm and 4 °C to remove growth medium. Subsequently, the cells 
were resuspended in 1 ml PBS and centrifuged again. The supernatant was then removed, 
and the cells were resuspended in 1 % FCS (in PBS). Finally, the cells were analyzed using 
the BD FACSCanto HTS flow cytometer. The scattered light caused by the passing cells is 
then analyzed to give information about the size (forward scatter, FSC) and complexity 
(sideward scatter, SSC) of the cells and thereby allows distinguishing between dead and living 
cells and between different cell types. Cells expressing fluorescent proteins were detected by 
excitation with a blue laser (488 nm) and a red laser (561 nm) depending on the optimal 
excitation peak of the corresponding fluorophore. Filter sets were also chosen to match best 
with the optimal emission peak of the corresponding fluorophore. 
 
5.2.2.4.1  FACS-based FRET assay 
 
The proteins to be analyzed were Clover and mScarlet (Lam et al. 2012; Bindels et al. 2017). 
Clover acts as the donor fluorophore, as it emits light at 515 nm following excitation at 488 nm. 
The energy is subsequently transferred to mScarlet, the acceptor molecule, leading to the 
emission of light at 520 nm. While FRET was formerly analyzed by fluorescence microscopy, 
the FACS-based FRET assay takes advantage of measuring FRET efficiencies by flow 
cytometry.  
To analyze intracellular HIV-1 PR activity by applying the FACS-based FRET assay, HEK293T 
cells were co-transfected with plasmid DNA encoding the FRET-based sensor in combination 
with different viral constructs. Following 24 h of incubation, the cells were prepared for flow 
cytometric analysis (see 5.2.2.4). For each FRET measurement, five different controls were 
prepared. Cells transfected with pCHIV were used to identify the proportion of viable cells and 
cells exclusively expressing Clover.Vpr or mScarlet.Vpr were used to exclude false-positive 
FRET signals. Cells expressing Clover.Vpr and mScarlet.Vpr acted as a negative control, while 
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cells expressing Clover-mScarlet.Vpr and pCHIV PR D25N acted as a positive control for 
FRET. Cells expressing Clover-mScarlet.Vpr and pCHIV wt were treated with 5 µM of LPV, 
EFV, NNRTI11, NNRTI26 and measured for decrease on FRET+ cells. Cells expressing 
Clover-mScarlet.Vpr and pCHIV dimer PR served as positive control for intracellular PR activity 
(Kräusslich, 1998). Emitted signals were detected by flow cytometry using the 488 nm laser to 
excite Clover and the 561 nm laser to excite mScarlet. Clover signals were subsequently 
detected using a 530/30 filter, while mScarlet signals were detected using a 575/25 filter. To 
measure FRET signals, the cells were excited with the 488nm laser and the resulting signals 
were detected using a 575/25 filter. 
 
5.2.3 Molecular biological methods 
 
5.2.3.1 Bacterial transformation and plasmid amplification 
 
For plasmid preparation and cloning, the chemo-competent E. coli strain DH5α was used. For 
working with retroviral DNA the E.coli Stbl2 was used because of its low recombination rates.  
Dh5α: Gibco, genotype: F− 80dlacZM15 (lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 - thi-1 gyrA96 relA1 28 5.  
Stbl2: Invitrogen, genotype: F- mcrA Δ(mcrBChsdRMSmrr) recA1 endA1 lon gyrA96 thi 
supE44 relA1 λ- Δ(lac-proAB). 
50 µl of bacteria were thawed on ice and mixed with 100-500 ng of the desired plasmid DNA. 
The cells were then kept on ice for 10 min to allow the plasmid DNA to attach to the bacterial 
cell wall. Afterwards, the cells were heat-shocked for 45 s at 42 °C. The cells were mixed with 
500 µl LB medium without antibiotics (see 5.1.2.5.2) and then incubated at 37 °C for 60 min 
while shaking at 350 rpm. Afterwards, the bacterial suspension was spread onto agar plates 
(see 5.1.2.5.2) supplemented with appropriate antibiotics to select bacteria containing the 
desired plasmid DNA. The agar plates were then incubated at 37 °C overnight. 
5.2.3.2 Preparation of plasmid DNA from bacterial mini cultures 
 
For small-scale isolations of plasmid DNA from bacterial mini cultures, the alkaline lysis method 
was conducted as follows: 1 ml of the bacterial mini cultures were cultivated in LB with 
antibiotics and shaken over night at 37 °C. The next day, cultures were centrifuged for 3 min 
at 13.000 rpm, the supernatant was removed, and the cell pellet was resuspended in 200 µl 
buffer S1 (Quiagen, Hilden). To lyse the bacterial cells, 200 µl of buffer S2 were added and 
the solution was briefly mixed. Afterwards, 200 µl of buffer S3 were added to neutralize the 
solution and the sample was incubated on ice for 5 min. The samples were then centrifuged 
for 10 min at 13,000 rpm and 4 °C. The pellet was subsequently discarded while the 
supernatant was vigorously mixed with 480 µl isopropanol to precipitate the DNA. The samples 
were again centrifuged for 10 min at 13,000 rpm and 4 °C and the supernatant was discarded. 
Next, the DNA pellet was washed with 1 ml 70 % ethanol and the samples were centrifuged 
for 5 min at 13,000 rpm and 4 °C. The supernatant was discarded, and the plasmid DNA pellet 
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was dried at 55 °C. Finally, the isolated plasmid DNA was resuspended in 30 µl deionized H2O 
and digested with HindIII and PstI to control for infectious HIV-1 plasmid DNA (see 5.2.3.5). 
5.2.3.3 Gene amplification by polymerase chain reaction (PCR) 
 
In this study, the Q5 DNA Polymerase was used for molecular cloning, as it has proof-reading 
ability. Specific primers (see 5.1.2.6.1) were used including a short sequence complementary 
to the template DNA and a restriction site to allow subsequent cleavage of the PCR product 
by restriction endonucleases. The reaction mix was prepared as follows: 0.5 µl template DNA 
was mixed with 3 µl 10 mM dNTP mix, 0.75 µl forward primer, 0.75 µl reverse primer, 5 µl 10X 
Q5 buffer with MgCl2, 0.25 µl Q5 DNA Polymerase and made up to 50 µl with deionized H2O. 
Generally, 35 cycles of amplification were conducted to obtain sufficient amounts of PCR 
product. The thermal cycling profile is shown. 
Step Temperature Time Cycles 
Initial denaturation 96 °C 5 min 
 
Denaturation 96 °C 1 min  
30x Annealing 52 °C 1 min 
Extension 72 °C 1.5 min 
Final Extension 72 °C 10 min 
 
Storage 4 °C hold 
 
 
5.2.3.4 Agarose gelelectrophoresis 
 
At first, 1 % agarose gels were prepared by dissolving agarose powder in 1xTAE buffer (see 
5.1.2.4). 6 µl Midori Green were added to 50 ml agarose solution. After polymerization of the 
gel, 20 µl control digested plasmid DNA or 50 µl of digested plasmid for ligation and 7µl of a 
DNA ladder 1 kb Plus were transferred into the sample wells. Electrophoresis was conducted 
at 90 V for approximately 30-45 min. To visualize the DNA fragments, the agarose gel was 
exposed to UV light at 254 nm, while DNA was excised from preparative gels under 360 
nm illumination.  
5.2.3.5 DNA digest and ligation 
 
To enable further processing of particular DNA molecules recovered by gel electrophoresis, 
the desired DNA was extracted from the agarose gel using the NucleoSpin Gel and PCR 
Clean-up kit as recommended by the manufacturer. The DNA was finally eluted from the silica 
filter by adding deionized H2O. 10 µl deionized H2O were used to elute smaller DNA fragments 
like PCR products, while 20 µl were used to elute larger molecules like vector DNA. 
Diagnostic restriction digests were conducted by mixing 2 µl 10x Cutsmart buffer, 0.5 µl of 
each restriction enzyme, 2 µg DNA and deionized H2O to a total volume of 20 µl. The samples 
were then incubated for 30 min at 37°C. For molecular cloning, 2 µl of 10x Cutsmart buffer 
were mixed with 1 µl of each restriction enzyme, 2-10 µl of DNA and deionized H2O to obtain 
a total volume of 20µl. 0.5 µl of alkaline phosphatase was additionally added after 5 min to 
prevent recircularization of the linearized vector DNA that was digested with only one enzyme.  
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For ligation reactions, 100 ng (determined by Nano Drop) of digested and purified vector 
was mixed with the digested and purified insert in a 1:3 ratio vecor:insert. Subsequently, 2 
μl of 10x T4 ligase buffer and 0.1 μl of T4 DNA ligase was added, reactions were filled up 
with water to 20 μl and incubated over night at 4 °C. 5 μl were used for transformation of 
bacteria (see 5.2.1). 
5.2.4 Cloning procedures 
 
5.2.4.1 Cloning by PCR 
 
Inserts were amplified via PCR as described in 5.2.3.3 with primers listed in 5.1.2.6.1. 
Following amplification, fragments were purified with the NucleoSpin Gel and PCR Clean-up 
kit as recommended by the manufacturer. Vectors and PCR products were digested using 
appropriate restriction enzymes for 2h at 37°C and loaded on a 1% agarose gel. Following 
running for 30 min at 80V, bands were cut out during brief UV illumination and DNA was 
extracted from the gel. Gel extraction and the following ligation were performed as described 
in 5.2.3.5. 
5.2.4.2 Subcloning 
 
For construction of pKHIVieCFP, pKHIV and pNLC-43ieCFP were digested by BssHII and SphI for 
2 h at 37 °C, the constructs were loaded on a 1 % agarose gel and run for 30 min with 80 V. 
After brief UV illumination, the bands were cut out and purified with the NucleoSpin Gel and 
PCR Clean-up kit as recommended by the manufacturer. Gel extraction and the following 
ligation were performed as described in 2.2.3.5. 
Subcloning of the ieCFP in pCHIV context was performed by digestion of pKHIVieCFP and 
pCHIV with AgeI and ClaI for 2h at 37°C. The following steps were conducted as described 
above. 
For the cloning of pCHIV NC-RT, DNA fragment was designed with the following sequence 
and synthesized by Geneart: 
               ApaI 
aaattgcagggcccctaggaaaaagggctgttggaaatgtggaaaggaaggacaccaaatgaaagat 
                                    aat(I)/ggt(G)                  atc(I) 
tgtactgagagacaggctaattttttagggaagatctggccttcccacaagggaaggccagggaattttcttcagagcagaccag
agccaacagccccaccagaagagagcttcaggtttggggaagagacaacaactccctctcagaagcaggagccgatagac
aaggaactgtatcct 
          atc(I)/+gct(A) 
ttagcttccctcagatcactctttggcagcgacccctcgtcacaataaagataggggggcaattaaaggaagctctattagataca
ggagcagatgatacagtattagaagaaatgaatttgccaggaagatggaaaccaaaaatgatagggggaattggaggttttatc
aaagtaagacagtatgatcagatactcatagaaatctgcggacataaagctataggtacagtattagtaggacctacacctgtca
acataattggaagaa 
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                                                          att(I)/+gct(A) 
atctgttgactcagattggctgcactttaaattttcccattagtcctattgagactgtaccagtaaaattaaagccaggaatggatggc
ccaaaagttaaacaatggccattgacagaagaaaaaataaaagcattagtagaaatttgtacagaaatggaaaaggaagga
aaaatttcaaaaattgggcctgaaaatccatacaatactccagtatttgccataaagaaaaaagacagtactaaatggagaaaa
ttagtagatttcagag                                                                               SbfI 
aacttaataagagaactcaagatttctgggaagttcaattaggaataccacatcctgcagggttaaaac 
 
Here, all PR cleavage sites between NC and RT were mutated to impair PR autoprocessing. 
In a first step, pCHIV and the oligo were digested with ApaI and SbfI. The cloning protocol was 
performed as described above. 
pCHIV contains 2 ApaI cleavage sites. Therefore, this fragment needed to be inserted after 
exchanging the NC-RT domain. In a second step, the NC-RT containing viral construct was 
digested by ApaI. Then the ApaI fragments of pCHIV and pCHIV eGFP were inserted by a 
second ligation. This way, pCHIV NC-RT and pCHIV NC-RT eGFP were constructed (see 
table). 
Plasmid 
number 
Vector Insert Plasmid name Antibiotics 
Resistance 
1147 pVpr.eGFP x 
AgeI/BsrGI 
PCR Citrine x 
AgeI/BsrGI 
pCitrine.vpr K 
1149 pVpr.eGFP x 
AgeI/BsrGI 
PCR Clover 
xAgeI/BsrGI 
pClover.vpr K 
1182 eGFP.Vpr x 
AgeI/XhoI 
PCR CD4 Split GFP 
1-10 x AgeI/XhoI 
Split GFP 1-10. Vpr K 
1183 eGFP.Vpr x 
AgeI/XhoI 
PCR CD4 Split GFP 
11 x AgeI/XhoI 
Split GFP 11. Vpr K 
!1209 663 x MluI/XbaI PCR GFP11 linker 
Mlu/Xba 
pNLC.isfGFP11linker A 
!1210 663 x MluI/XbaI PCR linker GFP11 
Mlu/Xba 
pNLC.ilinkersfGFP11 A 
!1211 663 x MluI/XbaI PCR GFP11 
Mlu/Xba 
pNLC.isfGFP11 A 
1286 pKHIV  x 
BssHII SphI 
1209 x BssHII SphI pKHIV.isfGFP11linker A 
1287 pKHIV  x 
BssHII SphI 
1210 x BssHII SphI pKHIV.ilinkersfGFP11 A 
1288 pKHIV  x 
BssHII SphI 
1211 x BssHII SphI pKHIV.isfGFP11 A 
1292 416  x BssHII 
SphI 
1209 x BssHII SphI pKHIV.isfGFP11linker 
(PR-) 
A 
1293 416  x BssHII 
SphI 
1210 x BssHII SphI pKHIV.ilinkersfGFP11 
(PR-) 
A 
1294 416  x BssHII 
SphI 
1211 x BssHII SphI pKHIV.isfGFP11 (PR-) A 
1295 528  x AgeI ClaI 1286  x AgeI ClaI pCHIV.isfGFP11linker A 
1296 528  x AgeI ClaI 1287  x AgeI ClaI pCHIV.ilinkersfGFP11 A 
1297 528  x AgeI ClaI 1288  x AgeI ClaI pCHIV.isfGFP11 A 
1298 1127  x AgeI 
ClaI 
1292  x AgeI ClaI pCHIV.isfGFP11linker 
(PR-) 
A 
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1299 1127  x AgeI 
ClaI 
1292  x AgeI ClaI pCHIV.ilinkersfGFP11 
(PR-) 
A 
1300 1127  x AgeI 
ClaI 
1294  x AgeI ClaI pCHIV.isfGFP11 (PR-) A 
1344 1149x Age/Xho PCR mScarlet 
Age/Xho 
mScarlet.Vpr K 
1364 pKHIV x 
BssHII/SphI 
1341 x BssHII/SphI pKHIV iCFP A 
1365 1162 x BsrGI 1345 x BsrGI Clover-mScarlet.Vpr K 
1370 528xAge/Cla 1364 x Age/Cla pCHIV iCFP A 
1451     NC-RT Oligo 
(Geneart) 
A 
1453 528xApaI 1451xApaI pCHIV NC-RT A 
1454 355xApaI 1451xApaI pCHIV NC-RT eGFP A 
 
5.2.5 Virological methods 
 
5.2.5.1 Preparation of virus-like particles (VLPs) 
 
3x107 293T cells were seeded in a T175 flask 24 h prior to transfection using the PEI method. 
70 μg pcHIV or a 1:1 mixture of pcHIV and a fluorescently tagged variant thereof were 
transfected per flask. Supernatants were harvested app. 40-48 h post transfection, cleared by 
brief centrifugation at 1500 rpm for 5 min at 4°C and subsequently filtered through 0.45 μm 
filters. 32 ml of supernatant were layered upon a 6 ml sucrose cushion (20 % sucrose (w/w) in 
PBS) and pelleted in the ultracentrifuge at 28’000 rpm for 2 h at 4 °C with a SW32 rotor. The 
pellet was the resuspended in 50 μl of PBS. For smaller preparations, 293T cells were seeded 
in 6-well plates at 3x105 cells/well transfected with 2 µg DNA and pelletation performed in a 
table-top ultracentrifuge at 44’000 rpm for 45 min-1 h. The pellet was the resuspended in 20 μl 
of PBS. 
5.2.5.2 SNAP labeling of VLPs 
 
600 nM SNAP-Cell 647-SiR was incubated with VLPs in PBS for 45 min at 37°C. 10 µl VLPs 
in PBS were attached to an 8 well labtek for 30 min at RT and washed twice with PBS. For 
imaging, 200 µl PBS were added to each well. 
 
5.2.6 Imaging methods 
 
5.2.6.1 Total internal reflective fluorescence microscopy (TIRF)  
 
TIRF live cell imaging was performed at a Ti2 Microscope (Nikon, Düsseldorf) with an Apo 
TIRF 60x Oil DIC N2 (NA 1.49) objective and 1.5x zoom. A 488-640 dual filter was used for 
GFP and SiR measurements. The TIRF angle was adjusted manually. The microscope was 
equipped with an Andor DU-897 X-11099 EMCCD camera (Andor, Belfast, Ireland). For live-
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cell imaging, cells were kept at 37 °C with 5 % CO2. For timelapse experiments, cells were 
imaged every 5 s for 2-4 h. 
5.2.6.1.1 Förster resonance energy transfer (FRET) 
 
A 405-488-561-640 quadruple filter was used for FRET measurements. DD was detection of 
Clover signal after excitation with 488 nm, AA measured mScarlet signal with 561nm excitation 
and DA detected mScarlet fluorescence after 488 nm excitation. 
5.2.6.1.2 Fluorescence recovery after photobleaching (FRAP) 
 
The 405-488-561-640 quadruple filter was used for FRAP measurements as well. Here, only 
DD and AA signals were detected (see 5.2.6.1.1). Then, 561nm laser was increased to 100 % 
laser power and a region of interest was illuminated for 2 s. Afterwards, DD and AA signals 
were measured again. 
5.2.6.2 Laser scanning confocal microscopy 
 
Confocal imaging was performed with a Leica SP8 TCS DLS microscope (Leica Microsystems, 
Wetzlar) with a 63x/1.4 HC PL APO CS2 Oil objective with HyD detectors. Imaging settings 
were 1024x1024 pixels acquired with 400 Hz bidirectional and 5x zoom for particles, 2x zoom 
for cells. GFP was excited with the Argon laser at 488 nm and detected at emission 496-567 
nm, 633 nm with the HeNe laser and emission at 650-750 nm. 
5.2.6.2.1 Förster resonance energy transfer (FRET) 
 
Particles were excited with 488 nm and emission detected at 489-550 nm (DD) and 570-631 
nm (DA) and 561 nm excitation with the DPSS yellow laser and emission at 570-631 nm (AA). 
5.2.6.3 Stimulated emission depletion (STED) 
 
STED imaging was performed at a λ = 775 nm STED system (Abberior Instruments GmbH, 
Göttingen, Germany), using a 100 x Olympus UPlanSApo (NA 1.4) oil immersion objective 
with 590 and 640 nm excitation laser lines at room temperature. Nominal STED laser power 
was set to ~ 60 % of the maximal power of 1200 mW with 10 ms pixel dwell time and 15 nm 
pixel size. 
5.2.6.4 Fluorescence lifetime imaging microscopy (FLIM) 
 
eCFP lifetime imaging was performed on a home-built setup by the AG Lamb (Munich). 
Particles and cells were excited with a pulsed λ = 445 nm laser with 1-2 µW laser power as 
measured before the microscope stand. Fluorescence was detected at λ = 479±40 nm at an 
MPD single-photon counting module without prior polarization selection. Laser powers were 
adjusted with a count rate of about 10-30 kHz at the detector. Single frames were acquired 
with a pixel size of 60 nm and a total field of view of 30x30 µm in 5 s. 80 frames were acquired 
per field of view at at least three different positions per sample. Phasor analysis of lifetime data 
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was performed by the AG Lamb. For live-cell imaging of late stage cells, 30x30 µm fields were 
imaged in 5000 ms with 500 lines and 80 frames. For timelapse experiments, cells were 
imaged with 5 s breaks between frames for 720 frames. Atto425 was used as reference for the 
phasor plot with a lifetime of t = 3.0 ns. The focus was set close to the surface and 
measurements were performed 6 times for 60 s with 5.8 µW laser power. 
 
5.2.7 Image analysis 
 
5.2.7.1 Image processing 
 
Microscopy images were processed with Fiji (Laboratory for Optical and Computational   
Instrumentation (LOCI), University of Wisconsin-Madison, Madison, USA). Camera offset was  
measured in an area without cells or particles and subtracted from the whole image. Local 
background subtraction was carried out with the rolling ball method with varying size of 5-50 
pixels. A median filter of 1 pixel was applied to smoothen the signal. A mask was created using 
the channel with the strongest signal and the particle picker was applied to the mask to detect 
particles with the size of 4-40 pixels. Signal intensities of the detected particles were exported 
for the separate channels.  
5.2.7.2 FRET analysis 
 
To measure the FRET signal, the separate channels were first multiplied with the mask and 
then all values were divided by 255 using the Fiji Image calculator. Then, the FRET values 
were generated by dividing I (DA) by I (DD). The values were exported by applying the detected 
particles to this image. 
5.2.7.3 Acceptor bleaching 
 
The bleached area was cropped and a mask was generated in the GFP channel. Again, the 
particles were detected, and the signal intensity was measured for the Clover and mScarlet 
signal pre and post bleaching. The formula applied was: (I(post)Clover-
I(pre)Clover)/I(post)Clover. 
5.2.7.4 FRAP analysis  
 
To measure the signal of mScarlet, ROIs were manually drawn on assembly sites and the 
signal intensity over time was extracted. Recovery was calculated by: (I(recovery)mScarlet – 
I(bleach)mScarlet)/I(pre)mScarlet. 
5.2.7.5 Co-localization analysis 
 
Mean signal intensities were measured for all detected particles. A signal threshold was set 
for a positive signal in each channel. % colocalization was determined by positive signal 
overlap for each particle. 
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5.2.7.6 Single assembly sites kinetics (Tracking via Imaris) 
 
Newly formed particles at the plasma membrane were tracked with Imaris and signal intensities 
were grouped for assembly kinetics. The GFP/Clover channel was mostly used for tracking. 
Diameters of detected punctae at the plasma membrane were measured and set to a 
maximum of 0.6 µm. Background subtraction was not applied, since background subtracted 
files as described in 5.2.7.1 were analyzed. Minimal quality was set to detect early events and 
track duration was set to at least 10 min. Maximum distance between spots was set to 1 µm 
and 2 gaps were allowed. The signal intensity profiles over time were examined and grouped 
for exponential, linear, linear endpoint and mess. Exponential and linear endpoint tracks were 
exported for all channels. 
5.2.8 Statistical analysis 
 
Signal intensities were plotted using GraphPad Prism and exponential functions were fitted to 
the data. This way, the assembly kinetics were determined. 
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6 Results 
 
6.1 Fluorescence-tagged virus-like particles can be visualized in fluorescence 
microscopy 
 
The aim of this thesis was the detection of HIV-1 PR activity and active PR during the viral 
assembly process by fluorescence microscopy. Viral particles were tagged with fluorescent 
proteins to visualize the assembly process and nascent virus particles. Different targets for 
fluorescent tags previously identified to be tolerated in viral particle formation and incorporation 
into the viral particle were applied here: fluorescent proteins were coupled to the accessory 
protein Vpr, and Gag was tagged in between its MA and CA domains (Müller et al. 2004, 
McDonald et al. 2002). Various fluorescent proteins based on GFP, mCherry or SNAP 
(Eckhardt et al. 2011) were explored to establish virus derivatives tailored to the different 
applications. 
Proteins incorporated into particles by coupling them to the viral protein r (Vpr) included 
mCerulean (Ex: 433 nm; Em: 475 nm), Citrine (Ex: 516 nm; Em: 529 nm), mScarlet (Ex: 569 
nm; Em: 594 nm), and Clover (Ex: 505 nm; Em: 515 nm) (Fig. 13A). Alternatively, fluorescent 
proteins were introduced into the structural polyprotein Gag between MA and CA: eCFP (Ex: 
433 nm; Em: 475 nm), eYFP (Ex: 513nm; Em: 527 nm), mCherry (Ex: 587 nm; Em: 610 nm), 
and eGFP (Ex: 488 nm; Em: 507 nm) (Fig. 13B). Virus particles harboring these fusion proteins 
were imaged by confocal microscopy. Punctate fluorescent signals corresponding to virus-like 
particles (VLPs) were detected in all cases. The apparent diameter of approximately 300 nm 
resulted from the diffraction limit of light microscopy as introduced in 4.3. Microscopic 
appearance of the samples was comparable for all fluorescently labeled VLPs and 
independent of the location of the tag. This allowed further tests of the fluorescent tags 
concerning their applicability for double labeling of VLPs and assembly sites at the plasma 
membrane. 
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Fig. 13: Virus-like particles can be visualized via incorporated fluorescent proteins. A: Schematic model of 
the indicated fluorescent proteins coupled to Vpr andconfocal images of the corresponding purified virus-like 
particles depicted in pseudocolor LUT. HEK 293T cells were co-transfected with pCHIV wt and pVpr.FP in a 1:10 
molar ratio. Supernatant was harvested at 48 hpt and concentrated via ultracentrifugation through a 20% sucrose 
cushion. VLPs were resuspended in PBS, adhered to an 8-well labtek chamber slide and imaged by LSC. Scale 
bar 2 µm. B: Schematic model of stated fluorescent proteins in Gag, introduced between the MA and CA domain. 
Below, confocal images of corresponding purified virus-like particles depicted in pseudocolor LUT. HEK 293T cells 
were co-transfected with pCHIV wt and pCHIVfluorescent protein in a 1:1 molar ratio. Further sample preparation as 
described in A. Scale bar 2 µm. 
 
In order to allow for analyses combining a FRET pair (Clover-Ruby or Citrine-Cerulean) tagged 
to Vpr with a label within Gag, the panel of fluorescence tags was expanded with the self-
labeling SNAP-tag (Reymond et al. 2011). SNAP was inserted in Gag and labeled with SNAP-
Cell 647-SiR, a dye emitting in the far-red range (Eckhardt et al. 2011). For co-localization 
analyses, SNAP-Cell 647-SiR labeled Gag was combined with Clover.Vpr (Fig. 14A) by co-
transfection of producer cells. For VLPs purified from the tissue culture supernatant of co-
transfected cells, single and double labeled VLPs were detected (Fig. 14B). Double labeled 
particles and assembly sites at the ventral plasma membrane of HeLa Kyoto cells were 
identified by co-localization of SNAP-Cell 647-SiR and Clover (Fig. 14B, C, right panel).   
Signal co-localization of both tags and established imaging of assembly sites by TIRF 
microscopy allowed proceeding to live-cell imaging. 
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Fig. 14: Double labeling of viral particles and assembly sites. A: Schematic model of fluorescent proteins 
introduced into Gag, inserted between the MA and CA domain or coupled to Vpr. B: Confocal images of 
concentrated virus-like particles carrying Gag.SNAP and Clover.Vpr. HEK 293T cells were co-transfected with 
pCHIV wt, pCHIVSNAP and pClover.Vpr in a 1:1:10 molar ratio. Supernatants were harvested 48 hpt and 
concentrated via ultracentrifugation through a 20 % sucrose cushion. VLPs were resuspended in PBS and stained 
with 600 nM SNAP-Cell 647-SiR for 30 min, followed by adhesion to an 8-well labtek and imaging by LSC. Scale 
bar 2 µm. C: TIRF images of assembly sites at the ventral plasma membrane. HeLa Kyoto cells were co-transfected 
with pCHIV wt, pCHIVSNAP and Clover.Vpr in a 1:1:10 molar ratio and 24 hpt stained with 600nM SNAP-Cell 647-
SiR for 30 min prior to imaging by TIRF microscopy. Scale bar 10 µm.  
 
6.2 Live-cell imaging of the viral assembly process 
 
In order to correlate PR activation with the viral assembly process by live cell imaging, I first 
set out to establish a baseline for analysis of HIV-1 assembly at the plasma membrane using 
the newly generated virus derivatives. In this study, laser scanning confocal (LSC) and total 
internal reflection fluorescence (TIRF) microscopy were applied to image fluorescently labeled 
purified VLPs and assembly sites at the plasma membrane of HeLa Kyoto cells (Fig. 14, 15).  
Confocal imaging scans the sample point-by-point with an xy-resolution of approximately 200 
nm and a z-resolution of 500 nm (Fig. 15A, upper panel, Balagopalan et al. 2011). TIRF 
microscopy is a widefield imaging-based technique, where light is directed towards the sample 
in a critical angle and therefore reflected at the glass surface. The evanescent wave of the 
reflected light can penetrate the sample for approximately 200 nm (Fig. 15A, lower panel, 
Mattheyses et al. 2010), which restricts observation to the ventral plasma membrane and 
strongly reduces background from intracellular labeled proteins. Here, Gag SNAP expressing 
pCHIV were labeled live with SNAP-Cell 647-SiR dye added to the cell culture supernatant 
(Fig. 15B, C).  
For purified VLPs adhered to a glass surface, both imaging techniques showed comparable 
results concerning detection of signal and background (Fig. 15B). For imaging of living cells, 
the SNAP-Cell 647-SiR dye was present during the measurement, therefore a higher 
nonspecific background signal was detected in both imaging techniques (Fig. 15C). Viral 
proteins are expressed in the cytoplasm and assembled at the plasma membrane. For LSC 
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microscopy, the cytoplasmic signal of Gag SNAP-Cell 647-SiR is too intense to allow the 
detection of assembly sites at the plasma membrane of HeLa Kyoto cells (Fig. 15C, upper 
panel).  
For TIRF microscopy, the influence of cytoplasmic background was decreased significantly 
(Fig. 15C, lower panel), so that viral assembly sites at the ventral plasma membrane of HeLa 
Kyoto cells were clearly visible over the cytoplasmic background. Therefore, TIRF microscopy 
was applied for live-cell imaging of the viral assembly process. Analysis of fluorescently labeled 
assembly sites concerning their assembly kinetics was conducted next to validate our system 
by comparison to published values. 
 
 
Fig. 15: LSC and TIRF microscopy of SNAP-Cell 647-SiR labeled particles and assembly sites. A: Schematic 
model of confocal (upper panel) and TIRF (lower panel) microscopy sample illumination. B: Concentrated virus-like 
particles imaged by LSC (upper panel) and TIRF (lower panel) microscopy. HEK 293T cells were co-transfected 
with pCHIV wt and pCHIVSNAP in a 1:1 molar ratio. Supernatant was harvested 48 hpt and concentrated via 
ultracentrifugation through a 20 % sucrose cushion. VLPs were resuspended in PBS and stained with 600 nM 
SNAP-Cell 647-SiR for 30 min, followed by adhesion to an 8-well labtek and imaging by LSC. Scale bar 2 µm. C: 
Assembly sites at the ventral plasma membrane of co-transfected HeLa Kyoto cells imaged by confocal (upper 
panel) and TIRF (lower panel) microscopy. HeLa Kyoto cells were co-transfected with pCHIV wt and pCHIVSNAP in 
a 1:1 molar ratio and 24 hpt stained with 600 nM SNAP-Cell 647-SiR for 30 min prior to imaging by TIRF microscopy. 
Scale bar 10 µm.  
 
For validation of our live-cell imaging system, HeLa Kyoto cells were transfected with pCHIV 
expressing fluorescent tags coupled to Vpr or inserted into the structural protein Gag in 
between the MA and CA domain. Results obtained with the newly generated virus derivatives 
were compared with published work from our group obtained with pCHIVeGFP using different 
microscopy setups and a different tracking algorithm (Ivanchenko et al. 2009; Lampe et al. 
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2007) to verify accuracy of imaging and quantification methods and test for a potential influence 
of the tags on virus assembly behavior. 
Late stage virus-producing cells characterized by large patches of assembled particles at the 
plasma membrane were employed to adjust the focal plane and the TIRF angle. Laser 
intensities were optimized to detect early assembly sites and to minimize phototoxicity. 
Nascent virus-like particles were detected as plasma membrane punctae. Cells showing very 
few punctae on the plasma membrane, were imaged for 2 h. Over this time period, an 
increasing number of assembly sites was detected, reaching hundreds of punctae (Fig. 16). 
Assembly sites were defined by an increase in signal intensity over time due to accumulation 
of tagged proteins at the site.  
Imaging by TIRF microscopy was optimized concerning cell viability and prediction of cells to 
start the assembly process in the course of this work. Imaging media and laser intensities were 
varied, and strong cellular Gag expression was identified as signal for subsequent viral 
assembly. Fig. 16 shows micrographs of exemplary cells expressing HIVSNAP and stained with 
SNAP-Cell 647-SiR (Fig. 16A) or expressing untagged HIV together with Vpr.Clover (Fig. 16B). 
The assembly process at the plasma membrane was captured over a time course of 2 h. In 
accordance with previous studies using HIVeGFP (Ivanchenko et al. 2009), a gradual increase 
in the number of assembly sites occurred mainly within the first 50-60 min of observation 
illustrated by the frames displayed in Fig. 16. This period was selected for further analysis.  
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Fig. 16: Live-cell imaging of the assembly process at the plasma membrane of HeLa Kyoto cells by TIRF 
microscopy. A: Time lapse measurement of Gag.SNAP assembly at the plasma membrane of HeLa Kyoto cells. 
HeLa Kyoto cells were co-transfected with pCHIV wt and pCHIVSNAP and stained at 16 hpt with 600 nM SNAP-Cell 
647-SiR 30 min prior to imaging. Cells were imaged every 5 s for 1-2 h. Images show individual frames recorded 
for a representative cell at the indicated times after the start of the observation. B: Live imaging of Clover.Vpr 
recruitment to the plasma membrane of HeLa Kyoto cells. HeLa Kyoto cells were co-transfected with pCHIV wt and 
pClover.Vpr in a 1:10 molar ratio. At 16 hpt, cells were imaged every 30 s for 1-2 h. Images show individual frames 
recorded for a representative cell at the indicated times after the start of the observation. Scale bars: 10 µm. 
 
Next, the assembly dynamics were analyzed and compared with data published previously for 
the assembly of HIVeGFP under similar conditions (Ivanchenko et al. 2009). Detection of punctae 
and analysis of signal intensity of individual punctae over time was performed by tracking with 
Imaris. Imaris is a commercial software applied here to detect spots and track them over time 
and was found most robust compared to methods previously applied in this group (Ivanchenko 
et al. 2009; Rahman et al. 2014). At early time points of observation (< 20-50 min), assembly 
sites were well separated and could easily be tracked. The continuous formation of new 
assembly sites resulted in spatial crowding, hampering tracking of punctae at later time points.  
In order to determine whether Gag.SNAP (which had not yet been analyzed in live-cell 
assembly experiments), and Vpr (which is indirectly recruited to the viral assembly site) 
accumulate at nascent budding sites with similar kinetics than previously observed for 
Gag.eGFP, I performed quantitative analysis of assembly kinetics. Tracks with a minimum 
length of 10 min, displaying a clear increase in intensity over time were selected for these 
analyses. A total of 150 tracks from two independent experiments were averaged, and the 
mean intensity over time was fitted to a saturating single exponential equation. Fig. 17 shows 
data obtained for cells expressing HIVSNAP (Fig. 17A) and Clover.Vpr, which is indirectly 
recruited to viral assembly sites by interaction with the p6 domain of Gag (Fig. 17B). Each 
signal was normalized to the maximum intensity of the assembly site. For HIVSNAP, a curve fit 
yielded a rate constant of 0.002935±0.002041 s-1. This was comparable to assembly kinetics 
of HIVeGFP (~5*10-3 s-1; Ivanchenko et al., 2009). Accumulation of Clover.Vpr at HIV-1 assembly 
sites occurred with a rate of 0.00608±0.008681 s-1, slightly faster than the kinetics of labeled 
Gag. 
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Fig. 17: Assembly kinetics of pCHIVSNAP and pCHIV with pClover.Vpr. A: Plot of mean signal intensity over time 
of assembly sites of pCHIVSNAP transfected HeLa Kyoto cells stained with SNAP-Cell 647-SiR described in Fig. 
16A. Mean value and SD of Gag.SNAP fluorescence intensity over time, exhibiting saturating exponential assembly 
kinetics. n=50 assembly sites from 2 cells with exponential fit (red line) and mean rate constant. B: Plot of mean 
signal intensity over time of assembly sites of pCHIV with pClover.Vpr transfected HeLa Kyoto cells depicted in Fig. 
16B. Mean value and SD of Clover.Vpr fluorescence intensity over time, exhibiting saturating exponential assembly 
kinetics. n=150 assembly sites from 2 cells with exponential fit (green line) and mean rate constant. 
 
Fluorescent labeling of VLPs and assembly sites was established and allowed visualization of 
the viral assembly process by live-cell imaging. Virus derivatives used in this work were shown 
to exhibit assembly kinetics comparable to previously established values. This provided an 
essential basis for live-cell analysis of viral assembly site formation in parallel to PR activation 
or activity. 
The aim of this project was the detection of HIV-1 protease (PR) activity and active PR during 
viral assembly. Therefore, different FRET, FLIM and PR-inhibitor-based fluorescence sensors 
were generated and characterized to assess their applicability for live-cell imaging.  
 
6.3 Design of sensors to detect HIV-1 PR activity during viral assembly 
 
Different sensors were designed to enable detection of proteolytic processing by fluorescent 
microscopy. They were based on physical characteristics of fluorescent proteins that changed 
depending on HIV-1 PR. Sensors depict PR activity, so it could be measured despite the 
resolution limit of fluorescent microscopy. Three different processes were detected: (i) 
proteolytic processing of an external sensor (ii) Gag processing and (iii) formation of active PR.  
 
6.3.1 An external FRET-based sensor was specifically cleaved by HIV-1 PR 
 
For a FRET-based analysis of PR activity, the autofluorescent proteins Clover and mScarlet 
were coupled via an HIV-1 PR cleavage site (corresponding to the cleavage site between MA 
and CA) and linked to Vpr to allow its incorporation into viral particles (Fig. 18A). Proteolytic 
cleavage of the FRET-based sensor was to detect the enzymatic activity of HIV-1 PR. 
Clover acted as the donor fluorophore. In an uncleaved sensor, the energy upon excitation is 
transferred to mScarlet, the acceptor fluorophore, leading to acceptor signal emission (Lam et 
al. 2012, Bindels et al. 2017). This is only possible when the spatial distance between the 
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acceptor and donor fluorophores is small (<10 nm). Upon proteolytic processing, the 
fluorescent proteins dissociate, and FRET is no longer possible due to the increase in steric 
distance (Fig. 18A).  
 
To confirm incorporation in the viral particle and HIV-1 PR-specific cleavage of the FRET-
based sensor, concentrated VLPs were lysed and detected by immunoblot with antisera 
against Vpr and CA simultaneously (Fig. 18B).  
Endogenous Vpr has a molecular mass of 14 kDa and was detected in all VLPs (Fig. 18B, left 
panel). As controls, Clover (Fig. 18B, lane 1, donor only) and mScarlet (Fig. 18B, lane 2, 
acceptor only) were coupled to Vpr separately. Both constructs had a size of 41 kDa. Co-
transfection of pClover.Vpr and pmScarlet.Vpr (Fig. 18B, lane 3) served as FRET negative 
control. In this experiment, lower amounts of VLPs were produced for this sample, causing 
weaker bands in the western blot (Fig. 18B, left and right panel). All controls and uncleaved 
sensor (Fig. 18B, lane 4) were packaged into viral particles containing catalytically inactive 
(D25N) PR. Therefore, no Gag processing was observed (Fig. 18B, lane 6-9). Full-length Gag 
has size of 55 kDa. Uncleaved sensor was detected at 70 kDa (Fig. 18B, lane 4). An unspecific 
degradation product of the FRET-based sensor was observed with a size of 35 kDa (marked 
by *). PR-specific cleavage of the sensor and Gag was observed for the sensor and wild-type 
pCHIV (Fig. 18B, lane 5, 10). A specific band for the cleaved FRET-based sensor was detected 
at 42 kDa (Fig. 18B, lane 5), as expected for mScarlet.Vpr, and for CA at 24 kDa (Fig. 18B, 
lane 10). 
 
Incorporation in the viral particle and HIV-1 PR-specific cleavage of the FRET-based sensor 
was confirmed by immunoblot analysis. Next, changes in the FRET signal upon proteolytic 
processing of the sensor was analyzed in purified VLPs by LSC microscopy. 
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Fig. 18: Sensor incorporation and analysis of PR dependent sensor and Gag cleavage in virus-like particles 
(VLPs). A: Scheme of PR dependent FRET sensor cleavage. Clover and mScarlet are linked by the PR cleavage 
site found between MA and CA in Gag (right). B: 293T cells were co-transfected with pCHIV PR D25N or wt and 
pFRET-based sensor or control constructs. 48 hpt, supernatants were harvested and concentrated via 
ultracentrifugation through a 20 % sucrose cushion, followed by immunoblot analysis using antiserum raised against 
HIV-1 Vpr and CA. D donor, A acceptor, D + A describes co-transfection, D-A depicts the FRET-based sensor. * 
represents an unspecific degradation product. 
 
To assess the changes in the FRET signal due to proteolytic processing, purified VLPs were 
analyzed by fluorescence microscopy. Nascent viral particles were previously shown to contain 
FRET-based sensor cleaved by HIV-1 PR; therefore, a PR-specific FRET signal change would 
verify the applicability of the sensor for further live-cell imaging analysis. For confocal imaging 
of VLPs, control and sensor constructs were co-transfected with wild-type and Gag.SNAP 
pCHIV in a 1:1 ratio (Fig. 19). Gag.SNAP was labeled with SNAP-Cell 647-SiR to identify virus 
particles. Here, virus particles were verified by the SNAP-Cell 647-SiR signal (Fig. 19A, 5th 
column).  
 
The first column of Fig. 19A depicts Clover signal after excitation with 488 nm (DD = Donor 
excitation/Donor emission), the second displays signal of mScarlet fluorescence after 488 nm 
excitation (DA = Donor excitation/Acceptor emission). In the third column, mScarlet signal was 
measured with 561 nm excitation (AA = Acceptor excitation/Acceptor emission). FRET images 
and values were calculated by DA/DD (Fig. 19A, 4th column, B, C). In Fig. 19A, FRET values 
are depicted by the LUT fire. Low FRET values (0.0) are depicted in blue, high FRET values 
(1.4) are displayed in yellow. Mean FRET values and SD were calculated analyzing 500 
particles per sample (Fig. 19B). The frequency distribution of FRET values of the uncleaved 
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sensor (D25N PR), was compared with FRET values after PR specific cleavage of the sensor 
in a wild-type pCHIV (Fig. 19C).   
 
VLPs containing the donor only (Clover.Vpr) were imaged to determine the bleed through of 
the donor into the DA channel (Fig. 19A, upper row). No unspecific signal was detected in the 
acceptor channel (AA). A mean FRET value of 0.05±0.023 was calculated for ~ 500 particles, 
suggesting a weak bleed through of the donor in the DA channel (Fig. 19B). Co-transfection of 
pClover.Vpr and pmScarlet.Vpr with pCHIV enabled detection of unspecific FRET signal due 
to molecular crowding of the fluorescent proteins, named FRET negative control. Donor (DD) 
and acceptor (DA and AA) signals were detected in the particles (Fig. 19A, second row). The 
mean FRET value increased threefold to 0.14±0.13 in ~ 500 particles (Fig. 19B). The sensor 
in VLPs containing catalytically inactive PR (D25N mutation at the active site) remained 
uncleaved and was used to determine the maximum FRET value. Fluorescence signal was 
detected in all channels (Fig. 19A, 3rd row). Mean FRET values of 0.65±0.31 were calculated 
in ~ 500 particles (Fig. 19B). The histogram shows a gaussian distribution of FRET values for 
the particles (Fig. 19C). For the sensor in VLPs containing the wild-type PR, fluorescence 
signal was detected in all channels as well (Fig. 20A, 4th row). A mean FRET value of 0.32±0.31 
was determined (Fig. 19B), which is a 50% lower mean FRET signal compared to catalytically 
inactive D25N PR. Correspondingly, a clear shift of FRET ratio distribution to low values was 
detected in the population of VLPs carrying wild-type PR (Fig. 19C). Approximately 80% of the 
population exhibited FRET values below 0.2.  
 
Analysis of PR-dependent FRET changes in purified VLPs revealed a clear discrimination of 
cleaved and uncleaved FRET-based sensor. For further analysis, the optimal amount of 
incorporated sensor concerning proteolytic processing was tested by titration experiments. 
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Fig. 19: Analysis of PR dependent FRET signal changes in virus-like particles (VLPs). A: 293T cells were co-
transfected with pCHIV PR D25N or wt and pCHIVSNAP in a 1:1 ratio and FRET-based sensor or control constructs 
(1:30 ratio). 48 hpt, supernatants were harvested and concentrated via ultracentrifugation through a 20 % sucrose 
cushion. Concentrated VLPs were attached to 8-well labtek and imaged by LSC microscopy. Donor signal intensity 
was measured upon Donor excitation (DD), Acceptor signal intensity was analyzed for Donor (DA) and Acceptor 
(AA) excitation. FRET values were calculated by dividing signal intensity measured in DA by DD: I(DA)/I(DD). Scale 
bar 2 µm. B: Quantification of mean FRET values in VLPs. Mean and SD of 500 particles per sample are shown. 
Statistical analysis via unpaired two-tailed t-test (p<0.0001). C: Frequency analysis of mean FRET values of 
indicated viral particles (n=500). I Intensity. 
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High Vpr amounts in VLPs have been found to impair Gag processing (Lampe et al., 2007). 
Therefore, amounts of incorporated sensor needed to be controlled for an optimal proteolytic 
cleavage of sensor and Gag.  
Molar ratios of sensor plasmid to pCHIV were titrated in the range of 1:0.66 to 1:60. As a 
negative control for sensor and Gag processing, the sensor was co-transfected with a pCHIV 
derivative expressing catalytically inactive PR (D25N mutation at the active site). pCHIV wt 
was transfected alone as control for optimal Gag cleavage. VLPs were purified from 
transfected cells, lysed and analyzed by immunoblot with antisera raised against recombinant 
GFP (reactive against all GFP derivatives, including Clover and eCFP) and HIV-1 CA (Fig. 
20A). Specific bands corresponding to Clover and CA were detected in the presence of a virus 
comprising wild-type PR. Signal intensities of bands representing uncleaved sensor and 
Clover, or uncleaved Gag derived precursor and CA, respectively, were quantitated to 
determine the degree of processing (Fig. 20B). Figure 20 B displays the relative degree of 
cleavage in % for each sample. A maximum relative Gag cleavage of 80% was determined in 
the absence of sensor. Lower amounts of sensor (up to a molar ratio of 1:9 sensor plasmid to 
pCHIV) did not affect relative Gag processing; increasing sensor concentrations reduced Gag 
processing efficiency and resulted in suboptimal sensor cleavage. An optimal sensor cleavage 
was achieved with a molar ratio of 1:13, while Gag processing was highest for a molar ratio of 
1:30. The molar ratio 1:30 was used for all other productions of VLPs (Fig. 18, 19) and further 
analysis in HEK293T cells. 80% cleavage of the FRET-based sensor was in line with the 
population size exhibiting FRET values below 0.2 (Fig. 19).  
Since HIV-1 specific processing of the FRET-based sensor was confirmed in VLPs, it was next 
applied to test the influence of various probes on intracellular HIV-1 PR activity. 
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Fig. 20: Effect of sensor plasmid titration on bulk processing efficiency. A: 293T cells were co-transfected 
with the plasmid expressing the FRET-based sensor and pCHIV at the indicated molar ratio. At 48 hpt, supernatants 
were harvested and concentrated via ultracentrifugation through a 20% sucrose cushion, followed by immunoblot 
analysis using antiserum raised against GFP and HIV-1 CA. * represents an unspecific degradation product typically 
observed for proteins comprising red fluorescent proteins. B: Quantitation of median signal for sensor and Gag 
processing products from immunoblots using Image Studio light software. 
 
PR-dependent cleavage of the sensor in cells was observed by flow cytometry to investigate 
manipulation of intracellular PR activity (Fig. 21). Sensor and control plasmids were co-
transfected with pCHIV in HEK293T cells (1:30). Cell harvest and FACS FRET analysis were 
conducted 24 hpt. The sensor was co-transfected with HIV-1 pCHIV comprising wt PR, PR 
D25N and a constitutively active PR (dimer PR) (Kräusslich et al. 1998). Unlabeled pCHIV 
without addition of sensor was used as control. FACS-FRET was employed to detect drug 
mediated changes in intracellular PR activity – inhibition of proteolytic activity by PR inhibitors, 
or enhancement of intracellular PR activity by NNRTIs that stabilize the GagPol dimer. 
Therefore, cells transfected with the sensor plasmid and wild-type pCHIV were additionally 
treated with the protease inhibitor Lopinavir (LPV, 5 µM) or non-nucleosidic reverse 
transcriptase inhibitors (NNRTI) e.g. Efavirenz (EFV, 5 µM). 
Live cells were gated for further analysis of fluorescence intensity (Fig. 21A). Double positive 
cells were further analyzed for their intensity in the FRET channel (Fig. 21B). Clover only and 
mScarlet only controls were utilized for laser compensation setting (Fig. 21A). Results from 
this experiment are summarized in Figure 21 C. When the sensor plasmid was co-transfected 
with a virus derivative carrying an inactive PR (pCHIV PR D25N), 99,5% FRET positive cells 
were measured by FACS FRET (Fig. 21C). Weak intracellular PR activity was detected upon 
co-transfection of pClover-mScarlet.Vpr with wild-type pCHIV. In this case, the FRET positive 
population decreased to 81±4% (Fig. 21C). The constitutively active PR decreased the FRET 
positive population to 28.8 ± 8.5 % (Fig. 21C). These values indicated that the FACS based 
system can be used to monitor changes in intracellular PR activity. DMSO (inhibitor solvent 
control) had no influence on PR activity and yielded comparable FRET values to untreated 
cells expressing wild-type HIV (Fig. 21C). Premature PR activation induced e.g. by EFV 
decreased the amount of FRET+ cells due to intracellular PR activity by 17.5 ± 9% compared 
to wild-type (Fig. 21C). LPV rendered the PR inactive (Fig. 21C). Different NNRTIs were tested 
to determine their effect on intracellular PR activity. NNRTI 11 activated PR strongly, 
decreasing the FRET positive population to 53.33 ± 4.66 (Fig. 21C). NNRTI 26 did not impact 
PR activity and was comparable to wild-type values with 79.05 ± 10.08 % FRET positive cells 
(Fig. 21C). These exemplary results confirmed the suitability of the system for determining the 
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influence of compounds on PR activity in virus producing cells. Since the central aim of this 
work was dynamic analysis at individual assembly sites, however, bulk measurements were 
not further pursued. 
 
 
 
Fig. 21: Quantification of intracellular HIV-1 PR activity by FACS FRET. A: HEK293T cells were co-transfected 
in with the -FRET-based sensor and pCHIV containing wt PR, PR D25N and constitutively active PR. Additionally, 
HIV-1 wt expressing cells were treated with PR inhibitor LPV, as well as RT inhibitors EFV, NNRTI 11 and NNRTI 
26 [all 5 µM]. 24 hpt, cells were analyzed by flow cytometry. Samples were gated for donor and acceptor double 
positive populations. B: Intracellular donor signal intensity was plotted against FRET signal (DA) to detect shift of 
population upon proteolytic processing of the sensor. C: Quantification of FRET positive cells. Mean and SD from 
4 independent experiments.  
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To validate the FRET potential of the sensor for live-cell imaging by TIRF microscopy, acceptor 
bleaching experiments were conducted at the HIV-1 budding sites on the plasma membrane 
of HeLa Kyoto cells (Fig. 22). In an uncleaved sensor, energy is transferred from the donor to 
the acceptor fluorophore (Fig. 22B). The amount of transferred energy can be determined by 
quantification of donor signal increase upon acceptor bleaching (Fig. 22B, C). Plasmids 
pClover.Vpr (donor control) or pClover-mScarlet.Vpr (reporter) were co-transfected with pCHIV 
encoding either HIV-1 PR D25N or wild-type PR (Fig. 22A). The left panel depicts donor (Fig. 
22A, 1st column) and acceptor signal (Fig. 22A, 2nd column) before acceptor bleaching, while 
the right panel indicates signals recovered after bleaching. The bleached area is marked by a 
rectangle. The increase in donor signal was quantified by measuring its intensity at the 
bleached site before and after acceptor bleaching and inserting these values in the equation 
in Fig. 22C. Clover.Vpr showed an unspecific donor signal increase of 6 ± 7% (Fig. 22D) upon 
bleaching. Sensor expressed together with wild-type HIV-1 PR (and thus presumed to be 
largely processed to Clover and mScarlet.Vpr) displayed a donor signal increase of 8 ± 7%, 
comparable to the Clover.Vpr control, while donor signal intensity in the uncleaved FRET-
based sensor was increased by 27 ± 13% upon acceptor bleaching. This led to an estimated 
FRET potential at HIV-1 budding sites of approximately 20 %. This potential allowed a 
discrimination of changes in the FRET signal by TIRF microscopy and FRET measurements 
were therefore pursued further.  
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Fig. 22: Maximum FRET efficiency detected by increase of donor signal intensity upon acceptor 
photobleaching. A: HeLa Kyoto cells were co-transfected with pClover.Vpr and pClover-mScarlet.Vpr and pCHIV 
carrying wt or D25N PR. At 24 hpt, acceptor bleaching was conducted at the plasma membrane with 561 nm laser. 
Images were detected prior to and directly after bleaching. Scale bar 5 µm. B: Scheme of acceptor bleaching 
technique. C: Equation for donor signal quantification.  D: Quantification of donor signal increase. Mean and SD in 
red. n=50 patches of 5 cells measured in 2 independent experiments. Statistical analysis via unpaired two-tailed t-
test (p<0.0001).  
 
In the uncleaved sensor, Clover and mScarlet are present in a 1:1 molar ratio. This enabled 
me to analyze fluorescence signal recovery after photobleaching (FRAP) of the acceptor by 
using the area of Clover signal as an intramolecular control. In principle, this system could be 
applied to distinguish between cell associated and released viral particles on the plasma 
membrane of cells. Released viral particles are incapable of replenishing fluorescent sensor 
molecules, while assembly sites allow exchange of proteins with the cytoplasmic reservoir and 
therefore should exhibit fluorescence recovery.  
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The sensor was co-transfected into HeLa Kyoto cells with a proviral plasmid encoding either 
wt PR or PR D25N. The acceptor fluorophore mScarlet was bleached, and the signal intensity 
was measured with a frame rate of 1 min for 30 min (Fig. 23A). Relative fluorescence intensity 
at the assembly sites was quantified and plotted over time. Fluorescence intensity measured 
outside the bleached area did not change. Within the bleached region, a very slow gradual 
increase of mScarlet fluorescence intensity was observed at all previously fluorescent sites, 
indicating that all spots and patches comprised budded particles as well as particles still 
connected to the plasma membrane and/or accumulated new assembly sites over the course 
of the experiment. Fluorescence recovery in this region at 30 min after photobleaching was 
calculated using the equation shown in Fig. 23C, yielding a total recovery of 14.93 ± 7 %, 
suggesting that a substantial proportion of particles in the area was already released at the 
time of bleaching. More precise tracking of individual assembly sites at an early stage of 
budding site formation should be considered for future experiments. 
 
 
Fig. 23: Fluorescence recovery after photobleaching detected by TIRF microscopy. A: HeLa Kyoto cells were 
co-transfected with clover only and the sensor in the respective pCHIV carrying wt or D25N PR. 24 hpt, acceptor 
bleaching was conducted at the plasma membrane with 561 nm laser and fluorescence recovery measured at 1 
frame/min for 30 min. The figure shows frames recorded at the indicated times after photobleaching. Scale bar 5 
µm. B: Plot of relative mScarlet fluorescence intensity normalized to signal before bleaching and signal increase 
after bleaching. Mean in black and SD in gray. C: Formula for recovery quantification. Quantification of mScarlet 
recovery, mean and SD of n=50 clusters of 5 cells. 
 
Finally, the applicability of the Clover-mScarlet.Vpr sensor for live-cell imaging was determined 
by analysis of FRET measurements at the assembly sites of HeLa Kyoto cells by TIRF 
microscopy. Plasmids expressing Vpr fused to the donor alone or the sensor were co-
transfected with pCHIV either expressing HIV-1 PR D25N or wild-type PR into HeLa Kyoto 
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cells (Fig. 24A). Signal intensities were measured for donor upon donor excitation (DD), 
acceptor after acceptor excitation (AA) and acceptor after donor excitation (DA). FRET values 
were calculated by dividing signal intensities of DA by DD (Fig. 24B). The frequency distribution 
of the calculated FRET values from 4-500 individual sites (area of 4-40 pixels) was analyzed 
for each sample (Fig. 24C).  
Bleed through of the donor into the DA channel yielded a mean FRET value of 0.16±0.04 (Fig. 
24B, C, upper panel) comparable to the mean value obtained for purified mature VLPs (Fig. 
19). The positive FRET control, i.e. sensor expressed in the presence of HIV-1 PR D25N 
yielded FRET values of 1.1±0.29. Analysis of the frequency distribution of intensities indicated 
two populations (Fig. 24B, C, middle panel). This could depict different FRET efficiencies 
between cells. Co-expression of the Sensor with HIV-1 encoding wild-type PR yielded a lower 
FRET value of 0.59±0.19. Relative occurrence illustrated the shift of the population to lower 
FRET values, but additionally reveals two populations (Fig. 24B, C, lower panel). 
This signal change was expected to be sufficient to detect proteolytic cleavage of the FRET-
based sensor during viral assembly. Time-lapse measurements of the assembly process of 
Clover-mScarlet.Vpr featured assembly kinetics comparable to Clover.Vpr, but no change in 
FRET signal over time was observed (data not shown). Therefore, additional approaches were 
conducted to accomplish detection of proteolytic activity during the formation of viral particles. 
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Fig. 24: PR dependent FRET changes detected at HIV-1 Gag assembly sites by TIRF microscopy. A: HeLa 
Kyoto cells were co-transfected with either Donor only or the sensor with pCHIV expressing wt or D25N HIV-1 PR. 
24 hpt, late assemblies at the ventral plasma membrane were imaged by TIRF microscopy. Donor signal intensity 
was detected after Donor excitation (DD), while Acceptor signal intensity was measured upon Donor (DA) and 
Acceptor (AA) excitation. B: FRET ratios were calculated by I(DA)/I(DD). Ratio images are depicted with the LUT 
fire. Scale bar: 1 µm. C: Histograms depicting the relative frequency of mean FRET values at individual sites (area 
4-40 pixels) on the plasma membrane in %. 400-500 clusters from 5 cells were analyzed per condition. 
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6.3.2 Internal labeling of Gag for detection of Gag processing as a marker for PR 
activity 
 
Different tags were inserted in Gag to observe Gag processing during viral assembly: (i) split 
fluorescent proteins, that fluoresce upon proteolytic cleavage of Gag, (ii) a fluorogenic dye that 
can be applied to super-resolution microscopy and resolve changes in spatial distribution, and 
(iii) eCFP, that features changes in its fluorescent lifetime depending on localization in the Gag 
lattice or free diffusion in the viral particle. 
 
6.3.2.1 Split fluorescent proteins and insertion in Gag does not enable distinction of mature 
and immature VLPs 
 
Fluorescent proteins are able to reassemble from its two complementary non-fluorescent 
fragments, which allows detection of fluorescence signal due to specific protein-protein 
interactions (Kerppola 2006, 2008). For the purpose of detecting gag processing, non-
fluorescent split subdomains of the fluorescent protein Venus (Hernandez und Sandri-Goldin 
2011) (Fig. 25A) were separately inserted as internal domains between the MA and CA domain 
of Gag, with the rationale that constraint induced by the Gag lattice should prevent their 
association into a complete fluorophore (Fig. 25). Release of the fluorophore subunits by PR 
mediated processing should enable them to interact and thus result in recovery of 
fluorescence.  
 
Immature VLPs containing both modified Gag proteins were produced in presence and 
absence of the HIV-1 PR inhibitor LPV. In contrast to the assumption that fluorescence 
recovery was prevented by constraining the split domains in an immature lattice, these 
particles were observed to display strong fluorescence (Fig. 25B). Albeit relative fluorescence 
signal intensities measured for immature VLPs (20.9±2.9) were somewhat lower that those 
measured for mature particles produced in the absence of LPV (30.8±5.5) respectively, these 
data indicated that molecular interactions between moieties contained in Gag could already 
occur in the unprocessed state (Fig. 25E) indicating high inherent flexibility of the assemblies.  
 
We therefore explored a different positioning of the split subunits, with one moiety expressed 
as part of Gag and the other attached to the accessory protein Vpr, which is not part of the 
Gag lattice. Super-folder GFP (sfGFP) was split in subunits β1-10 and β11, which have been 
described to reconstitute in the absence of fusion partners mediating their interaction 
(Cabantous et al. 2005; Cabantous und Waldo 2006). β11 was inserted in Gag in between MA 
and CA flanked by PR cleavage sites (MA-CA) on each site, which should allow free diffusion 
of b11 in the particle after proteolytic processing. Flexible linkers were attached N- or C-
terminally of β11. β1-10 was coupled to Vpr for incorporation in the viral particle by interaction 
with the C-terminal p6 domain of Gag (Fig. 25C). This approach was based on the assumption 
that β1-10 and β11 should not interact in the immature particle due to the location of β11 at 
the N-terminus of Gag in the tight immature lattice and β1-10 in the particle interior. 
pCHIV expressing β11 with or without linkers was co-transfected with pβ1-10.Vpr in HEK 293T 
cells grown in the presence or absence of LPV (Fig. 25D). Analysis of mean signal intensity 
per particle revealed an impact of linkers on the recovered fluorescence signal, with linkers 
allowing for more efficient reconstitution of the fluorophore (mean intensities in mature articles 
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of 43.0±9.1 or 37.8±8.2, as compared to 22.8±1.4 in the absence of linker). However, no 
significant difference in fluorescence intensity between immature and mature particles was 
observed for any of the three variants (Fig. 25F). Again, these results indicated that the 
assemblies produced using these variants did not comprise a regularly packed Gag lattice, 
providing flexibility for fluorophore interactions even in the absence of processing. The split 
fluorophore approach was thus deemed unsuitable for the investigation of Gag processing and 
not further pursued. 
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Fig. 25: Maturation of viral particles not detectable with split systems of fluorescent proteins. A: Schematic 
model of Venus split in N- and C-terminal domains. After proteolytic processing of Gag, Venus domains can form 
the fluorescent protein. B: 293T cells were co-transfected with and pCHIVC-Venus and pCHIVN-Venus in a 1:1 ratio 
together with pCHIV wt (1:1:2 molecular ratio) in duplicates. 1 sample was treated with 2 µm LPV. 48 hpt, 
supernatants were harvested and concentrated via ultracentrifugation through a 20% sucrose cushion. 
Concentrated VLPs were attached to 8-well labtek and imaged by LSC microscopy. Confocal images of 
corresponding purified VLPs depicted in pseudocolor LUT. Scale bar 2 µm. C: Schematic model of split sfGFP 
system. sfGFP11 is inserted between MA and CA, while sfGFP1-10 is coupled to Vpr for incorporation. Only freely 
diffusing sfGFP11 upon proteolytic processing can form a fluorescence sfGFP. D: 293T cells were co-transfected 
with and pCHIVfGFP11 and pCHIV wt in a 1:1 ratio together with sfGFP1-10.Vpr (1:10 molecular ratio) in duplicates. 
1 sample was treated with 2 µm LPV. 48 hpt, supernatants were harvested and concentrated via ultracentrifugation 
through a 20% sucrose cushion. Concentrated VLPs were attached to 8-well labtek and imaged by LSC microscopy. 
Confocal images of corresponding purified virus-like particles depicted in pseudocolor LUT. Scale bar 2 µm. E: 
Quantification of mean fluorescence intensity of Venus signal per VLP ± LPV. Mean and SD of 1500 particles. F: 
Quantification of mean fluorescence intensity of sfGFP signal per VLP ± LPV with different locations of a flexible 
linker on sfGFP11. Mean and SD of stated number of particles. 
 
6.3.2.2 Changes in localization of fluorescence tags in Gag can be visualized by STED 
microscopy 
 
For the reasons outlined above, all measurements were performed using TRIF microscopy, 
visualizing particles accumulating at the ventral membrane of the cell and the glass coverslip 
over a time period of 1-2 h after onset of assembly site formation. The morphology of particles 
formed under these conditions has never been analyzed. In order to investigate whether 
proteolytic processing does occur under these conditions, I made use of the observation of 
Hanne et al. (2016) that the resolution of STED super-resolution microscopy allows for 
discrimination of immature and mature HIV-1 particles. The high laser power of the STED laser 
beam results in rapid photobleaching and phototoxicity, which prevents application of this 
approach to live-cell analyses of maturation. However, it should be suitable to investigate the 
maturation status of cell-associated particles in still images. 
Hanne et al. had used HIV-1 derivatives carrying a SNAP-tag or the closely related Clip-tag 
(Reymond et al. 2011) flanked by two PR cleavage sites (Figure 26A). Expression of the virus 
in the presence or absence of the PR inhibitor LPV yielded immature or mature particles, 
respectively. Characterization of purified particles stained with SiR-SNAP or SiR-Clip, 
respectively, by STED nanoscopy revealed a ring-like pattern for immature virions, in which 
the stained tag was present as part of the semi-spherical immature Gag shell. Proteolysis of 
the polyprotein should result in random distribution of the released tag within the virion. 
Accordingly, mature particles were indeed found to display a ‘blob’ or spot-like morphology 
(Hanne et al. 2016).  
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I wanted to make use of this system established for isolated particles, applying it to the analysis 
of assembly sites at the ventral membrane of virus expressing cells. 
First assessment of pCHIViClip was conducted in purified VLPs as described by Hanne et al., 
2016 to validate the system. Immature VLPs were produced in the presence of LPV, wild-type 
particles without additives. Images were acquired using an Abberior STED microscope in 
diffraction limited (confocal) and STED mode (Fig. 26B). In confocal microscopy, immature 
(+LPV) and mature (-LPV) samples were both detected as spots (Fig. 26B, left column). STED 
microscopy revealed a ring structure for immature VLPs imaged in the focal plane (Fig. 26B, 
upper row, middle and right column). Wild-type VLPs depicted a few rings, but mostly blob 
structures (Fig. 26B, lower row, middle and right column). Line profiles were analyzed to 
compare full width half maximum (FWHM) values of immature (Fig. 26D) and mature (Fig. 26E) 
particles measured for confocal and STED microscopy. For confocal microscopy, FWHM of 
261±31 nm was quantified for mature and 250±16 nm for immature VLPs (Fig. 26C). Immature 
ring structures imaged by STED microscopy revealed the distance of the peaks depicted in 
Fig. 27D of 109±28 nm, while blobs were measured to have a FWHM of 74±14 nm.  
Since these results were in line with the published data (Hanne et al. 2016). pCHIViClip could 
now be applied for visualization of mature and immature viral structures at the plasma 
membrane of HeLa Kyoto cells. 
 
Fig. 26: Discrimination of mature and immature virus-like particles by STED microscopy. A: Schematic model 
of Clip tag inserted between the MA and CA domain in Gag, flanked by PR cleavage sites. In an uncleaved state, 
it is part of Gag and can be observed as ring-like structure. After proteolytic processing, it freely diffuses in the 
particle and is detected as a blob. B: Confocal and STED images of immature (+LPV) and mature (-LPV) purified 
VLPs stained with SiR-Clip and zoom of STED image. HEK 293T cells were co-transfected with pCHIViClip and 
pCHIV wt in a 1:1 molar ratio and either untreated or treated with 2 µm LPV. Supernatant was harvested 48 hpt and 
concentrated via ultracentrifugation through a 20 % sucrose cushion. VLPs were resuspended in PBS and stained 
with 1 µm SiR-Clip for 45 min at 37°C, followed by adhesion to an 8-well labtek II and imaging by STED microscopy. 
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Scale bar 0.5 µm. C: Measured diameter of viral particle by taking the peak width at half maximum of the line profile 
for confocal images and the blob, and by measuring the peak distance of the ring structure. D: Line profile of 
immature VLP (+LPV) with confocal and STED measurement. E: Line profile of mature VLP (-LPV) with confocal 
and STED measurement.  
 
Live-cell imaging of the pCHIViClip stained with SiR-Clip was conducted at the plasma 
membrane of HeLa Kyoto cells grown in presence or absence of LPV for imaging of immature 
and mature released viral particles and assembly sites (Fig. 27, 28). Due to the confined space 
between the plasma membrane and the glass surface, released viral particles remained 
trapped and could therefore not be distinguished from assembly sites. In confocal microscopy, 
viral particles could not be resolved at this point (Fig. 27B). As we zoomed in on the plasma 
membrane with STED microscopy, we observed the whole plasma membrane covered by 
assembly sites and what appeared to be piles of released particles trapped underneath the 
cell (Fig. 27B). Cells grown in the presence of LPV displayed exclusively ring-like structures 
(Fig. 27A, C, upper panel). In contrast, both ring- and ‘blob’-like structures were observed for 
untreated cells, indicating that processing does occur. featured ring- and blob-like structures 
(Fig. 27A, C, lower panel). The high density of structures prevented detailed analysis, however. 
These findings clearly show that late stages of virus production are unsuitable for live-cell 
microscopy and patches have to be excluded from tracking analyses. 
Earlier time points of viral assembly were analyzed by imaging of cells displaying fewer 
particles on the plasma membrane. This might pinpoint the timing of Gag processing in relation 
to the state of assembly. 
 
Fig. 27: Virus-like particles ± LPV assemble at the plasma membrane of HeLa Kyoto cells. A: Schematic 
model of Clip tag inserted between MA and CA in Gag, flanked by PR cleavage sites. In an uncleaved state, it is 
part of Gag and can be observed as ring-like structure. In the processed state, it freely diffuses in the particle and 
is detected as a ‘blob’.  B: Confocal image of assembly sites and trapped particles at the plasma membrane of 
HeLa Kyoto cells stained with SiR-Clip. HeLa Kyoto cells were co-transfected with pCHIViClip and pCHIV wt in a 1:1 
molar ratio and either untreated or treated with 2 µm LPV. 24 hpt, cells were stained with 1 µm SiR-Clip for 45 min 
at 37°C and washed for 30 min prior to imaging by STED microscopy.  Scale bar 15 µm. C: Zoom of assembly sites 
and trapped particles stained with SiR-Clip detected by STED microscopy. Scale bar 2 µm. 
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Live-cell imaging of the pCHIViClip stained with SiR-Clip was conducted at the plasma 
membrane of HeLa Kyoto cells in presence of LPV for imaging of immature released viral 
particles and assembly sites (Fig. 28). Here, GagiClip is a component of the Gag lattice and 
should be detected as a ring-like structure in the viral particle, as described for the VLPs (Fig. 
28A). The focal plane of the assembly sites was located with an overview confocal image (40 
µm x 40 µm) (Fig. 28B). A smaller area (5 µm x 4 µm) was selected and imaged by confocal 
and STED microscopy concurrently (Fig. 28C). Late assembly sites or accumulations of 
released viral particles were detected as big patches by confocal microscopy (Fig. 28C, upper 
row). STED imaging of the same area of interest revealed individual particles and assembly 
sites that were detected as ring-like structures in the focal plane (Fig. 28C, lower row). Zoom 
ins are depicted for a clearer illustration of the ring-like structures (Fig. 28C, lower row, right 
panel). 
STED imaging at viral assembly sites enabled discrimination of immature late buds and 
released viral particles. Therefore, this system is further applied to the analysis of wild-type 
assembly sites in the absence of LPV.  
 
Fig. 28: Immature viral particles assemble at the plasma membrane of HeLa Kyoto cells. A: Schematic model 
of Clip tag inserted between MA and CA in Gag, flanked by PR cleavage sites. In an uncleaved state, it is part of 
Gag and can be observed as ring structure. B: Confocal image of immature (+LPV) assembly sites and trapped 
particles at the plasma membrane of HeLa Kyoto cells stained with SiR-Clip. HeLa Kyoto cells were co-transfected 
with pCHIViClip and pCHIV wt in a 1:1 molar ratio and treated with 2 µm LPV. 24 hpt, cells were stained with 1 µm 
SiR-Clip for 45min at 37°C and washed for 30 min prior to imaging by STED microscopy. Scale bar 10 µm. C: Zoom 
of assembly sites and trapped particles stained with SiR-Clip detected by confocal and STED microscopy and zoom 
ins as stated. Scale bar left: 2 µm, middle: 1 µm and right: 0.5 µm.  
 
The analysis of transfected HeLa Kyoto cells in the absence of LPV was conducted as 
described for the immature assembly sites (Fig. 29). During the assembly process, late viral 
buds will be detected as ring-like structure, while proteolytic cleavage of Gag produces 
particles containing freely diffusing Clip-tag which should be captured as a compact “blob” (Fig. 
29A). An overview image of the focal plane was measured by confocal microscopy (Fig. 29B). 
Upon higher magnification (zoom ins), areas that resembled patches in confocal microscopy 
revealed individual particles by STED imaging (Fig. 29C). Immature ring structures were 
detected in combination with mature blobs. This indicated the asynchronous assembly of viral 
particles on one cell and depicted stages of assembly and budding (ring structures) and mature 
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viral particles (blobs), indicating that processing does indeed occur under the conditions and 
in the time frame used in our experiments. 
Hanne et al., 2016 visualized maturation of purified viral particles upon PR activation. This 
process was locally blocked in the field of view after imaging of viral particles by STED 
microscopy. Although the mature and immature structures were resolved at assembly sites by 
STED microscopy, measuring dynamic processes of PR activity during the viral assembly 
could not be accomplished with this system. 
 
 
Fig. 29: Virus-like particles assemble at the plasma membrane of HeLa Kyoto cells in the absence of LPV.  
A: Schematic model of Clip tag inserted between MA and CA in Gag, flanked by PR cleavage sites. In a cleaved 
state, it freely diffuses in the particle and is detected as a blob.  B: Confocal image of wt (-LPV) assembly sites and 
trapped particles at the plasma membrane of HeLa Kyoto cells stained with SiR-Clip. HeLa Kyoto cells were co-
transfected with pCHIViClip and pCHIV wt in a 1:1 molar ratio. 24 hpt, cells were stained with 1 µm SiR-Clip for 45 
min at 37 °C and washed for 30 min prior to imaging by STED microscopy. Scale bar 10 µm. C: Zoom of assembly 
sites and trapped particles stained with SiR-Clip detected by confocal and STED microscopy and zoom ins as 
stated. Scale bar left: 2 µm, middle: 1 µm and right: 0.5 µm. 
 
 
6.3.2.3 Changes in fluorescence lifetime of eCFP in Gag can be visualized by FLIM 
microscopy 
 
Close interaction of two molecules of the fluorescent protein eCFP result in a process called 
homo-FRET that can be measured by changes in the fluorescence lifetime of the protein (FLIM, 
(Suhling et al. 2015)). We tested, whether this property can be exploited as a readout for Gag 
processing. For this, eCFP was inserted in Gag in between the MA and CA domains (Fig. 30). 
The fluorophore was either flanked by two PR cleavage sites to allow for free diffusion in the 
particle upon proteolytic processing (ieCFP), or only by a C-terminal processing site, resulting 
in retention at the membrane bound MA domain after processing. and merely rearrange on the 
viral membrane after PR dependent cleavage (eCFP) (Fig. 30A). In the immature state, the 
fluorophore is part of the Gag lattice in both cases.  
This project is a collaboration with the AG Lamb (Munich). They designed a system for imaging 
with laser scanning confocal (LSC) microscopy combined with Time-Correlated Single Photon 
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Counting (TCSPC). FLIM data is analyzed in the phasor space by observing clustering of pixels 
values in specific regions (Digman et al. 2008). For further information, see Materials and 
Methods. 
To test specific PR dependent processing of pCHIVieCFP and pCHIVeCFP, they were co-
transfected with a wild-type pCHIV in a 1:1 ratio in the presence and absence of LPV. VLPs 
were purified from the supernatant of virus-producing HEK293T cells and analyzed by 
immunoblot with antisera detecting GFP and its derivatives or CA. For pCHIVieCFP and 
pCHIVeCFP ± LPV, Gag.eGFP was detected with both antisera (~80kDa) (Fig. 30B, lane 2, 4, 
6, 8). Proteolytic processing was detected for both constructs in the absence of LPV. 
pCHIVieCFP produced free eCFP (~27kDa), as well as CA (~24kDa) (Fig. 30B, lane 1 and 5). 
For pCHIVeCFP, GFP antiserum detected a band ~40kDa, depicting MA-eCFP (Fig. 30B, lane 
3). Processed CA was displayed precisely as for pCHIVieCFP (~24kDa) (Fig. 30B, lane 7). The 
designed constructs were proteolytically cleaved in the expected products of free eCFP and 
MA-eCFP. Therefore, they were assumed functional and applicable for further analysis.  
Next, the fluorescence lifetime of mature and immature pCHIVieCFP and pCHIVeCFP in purified 
VLPs was determined. 
 
 
 
Fig. 30: Analysis of proteolytic processing of Gag.ieCFP and Gag.eCFP by immunoblot. A: Schematic model 
of eCFP tag inserted between MA and CA in Gag. It is either flanked by PR cleavage sites (ieCFP) or just one 
cleavage site between the protein and CA (eCFP). B: 293T cells were co-transfected with pCHIVieCFP or pCHIVeCFP 
and pCHIV wt in a 1:1 molar ratio and either untreated or treated with 2 µm LPV. 48 hpt, supernatants were 
harvested and concentrated via ultracentrifugation through a 20% sucrose cushion, followed by immunoblot 
analysis using antiserum raised against GFP and HIV-1 CA.  
Results  77 
 
 
Purified VLPs were analyzed by Fluorescence Lifetime Imaging Microscopy (FLIM) in 
collaboration with the AG Don Lamb (Department of Physical Chemistry, LMU Munich) (Fig. 
31). Purified HIVieCFP and HIVeCFP particles produced in presence or absence of LPV were 
imaged and depicted in false colors in relation to the fluorescence lifetime determined (Fig. 
31A). Frequency analysis revealed a gaussian distribution of fluorescence lifetime values for 
the particles. Immature particles showed comparable lifetime for both virus derivatives of 1.9-
2.4 ns, with a peak at 2.23 ns or 2.18 ns (Fig. 31A, B, left panel). In both cases, localization of 
the fluorescent tag in Gag resulted in interaction of the proteins within the rigid immature lattice, 
which in turn led to low eCFP FLIM values. Mature HIVeCFP particles displayed increased 
fluorescence lifetime values of 2.2-2.8ns (Fig. 31A, B, upper panel), consistent with enhanced 
mobility of mature MAeCFP at the viral membrane. The mean fluorescence lifetime of all 
particles shifted from 2.23 ns to 2.41 ns. Strong overlap of the populations depicted by 
frequency analysis prevented distinction of immature and mature particles with the pCHIVeCFP 
construct due to the shift of ~0.2 ns (Fig. 31B, upper panel).  
PR dependent cleavage of Gag in HIVieCFP led to a shift of mean fluorescence lifetime from 
2.18 ns obtained for articles prepared in the presence of LPV to 2.57 ns for particles produced 
in the absence of LPV. (Fig. 31A, B, lower panel). A broadening of the values detected from 
2.4-3.0 ns and a clear separation of particles in two populations was observed in this case. 
The distribution of one population corresponded to the one obtained for particles generated in 
the presence of LPV, the other displayed higher fluorescence lifetimes, indicating the co-
existence of immature and mature particles in these samples. (Fig. 31B, lower panel). Since 
these results indicated that FLIM measurements were suitable to discriminate between mature 
and immature particles, we proceeded to live-cell measurements. 
 
 
Fig. 31: Measurements of fluorescence lifetime of eCFP in purified VLPs. A: Confocal images of pCHIV 
containing eCFP and ieCFP in presence (immature) and absence (wild-type) of LPV. 293T cells were co-transfected 
with pCHIVieCFP or pCHIVeCFP and pCHIV wt in a 1:1 molar ratio and either untreated or treated with 2 µm LPV. 48 
hpt, supernatants were harvested and concentrated via ultracentrifugation through a 20% sucrose cushion, followed 
by imaging with LSC microscopy combined with Time-Correlated Single Photon Counting (TCSPC). The lifetime 
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ranging from 1.9-3.0 ns is depicted by the LUT jet. Scale bar 5 µm. B: Particle lifetimes were extracted using phasor 
analysis. Frequency distribution analysis of mean lifetime values of indicated viral particles. n=500 particles.  
 
After validation of the system, fluorescence lifetime measurements of eCFP constructs were 
then conducted in HeLa Kyoto cells expressing the viral constructs to assess the expected 
differences in fluorescence lifetime due to proteolytic processing (Fig. 32).  
 
First, lysates of transfected cells were analyzed by immunoblot using antisera against GFP 
and MA (Fig. 32B). The cleaved eCFP moiety detected by the GFP antiserum displayed a 
slightly higher electrophoretic mobility than free eCFP due to an attached linker in the vector. 
Lysates from cells expressing MA.eCFP displayed the expected signal at ~40 kDa reactive 
with both antisera; an additional band at ~25 kDa detected with the αGFP serum likely 
represented an intracellular degradation product . Gag.eCFP was also detected with both 
antisera, displaying an apparent molecular mass of ~80 kDa. As expected, untreated cells 
transfected with the viral constructs displayed mainly free MA (17 kDa) and eCFP (27 kDa), 
while only precursor proteins were detected upon LPV treatment.  
We then proceeded to record FLIM images of eCFP expressed in different contexts in HeLa 
Kyoto cells 24 hpt. As a baseline, we first measured free eCFP expressed in the cytosol by 
focusing on the central plane of the cell. This yielded a mean fluorescence lifetime of 2.8-2.9 
ns (Fig. 32A, upper left panel), comparable to literature values (3.0 ns; Kremers et al., 2006). 
In order to determine whether fusion of eCFP to the MA domain of Gag by itself influenced the 
fluorescence lifetime of the fluorophore, we performed comparative measurements with cells 
expressing a MA.eCFP fusion protein. Compared to eCFP alone, cytosolic MA.eCFP showed 
a shorter lifetime of 2.4-2.5 ns (Fig. 32A, upper right panel), comparable to the value obtained 
for mature HIVeCFP VLPs (Fig. 31A, upper right panel). This might be due to clustering of the 
proteins in the cytoplasm induced by MA, or the influence of MA on the tag itself. Assembly 
sites at the plasma membrane of HeLa Kyoto cells expressing pCHIVieCFP in the presence of 
LPV exhibited a shorter lifetime of 1.9-2.4 ns (Fig. 32A, lower left panel). These values were 
in line with measurements of immature VLPs (Fig. 31A, left panel). Viral buds in cells producing 
pCHIVieCFP exhibited longer lifetimes (~2.5 ns) for small punctae (area of 4-40 pixels), but bright 
patches featured a lifetime comparable to the immature sites (1.9-2.4 ns; Fig. 32A, lower right 
panel).  
 
PR-dependent differences in fluorescence lifetime of eCFP at assembly sites on the plasma 
membrane were observed for still images. Quantification of fluorescence lifetime at single 
assembly sites was conducted to determine the exact changes in fluorescent lifetime induced 
by proteolytic processing of Gag.ieCFP.  
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Fig. 32: Measurements of fluorescence lifetime of eCFP in HeLa Kyoto cells. HeLa Kyoto cells were 
transfected with eCFP and MA-eCFP and co-transfected with pCHIVieCFP and pCHIV wt in a 1:1 molar ratio, either 
untreated or treated with 2 µm LPV. 24 hpt, cells were either imaged by LSC microscopy combined with TCSPC or 
lysed for immunoblot analysis. A: Confocal images of cytoplasmic eCFP and MA-eCFP, as well as assembly sites 
and trapped particles of pCHIV containing ieCFP in presence (immature) and absence of LPV. Fluorescence 
lifetimes were extracted using phasor analysis. The lifetime ranging from 1.9-3.0ns is depicted by the LUT “jet”. 
Scale bar 5 µm. B: Lysates of cells transfected with the indicated constructs were separated by SDS-PAGE and 
analyzed by detected by quantitative immunoblot (Li-Cor) using the indicated antisera. 
 
Fluorescence lifetime of HIVieCFP assembly sites expressed in the presence or absence of LPV 
was quantified for individual punctae (area of 4-40 pixels) and the relative frequency 
distribution was plotted (Fig. 33). For cells grown in the presence of LPV, a gaussian 
distribution of lifetimes in the range of 1.8-2.2 ns was observed (Fig. 33, left panel); the 
distribution of intensities was comparable between different cells. For cells grown in the 
presence of LPV, the population shifted to higher lifetimes (2.0-2.4 ns, Fig. 33, right panel), but 
these values were still lower than the lifetimes measured for purified mature VLPs (2.57 ns, 
Fig. 31). A possible explanation for this discrepancy is that the cellular background influenced 
the measurement. Alternatively, the time point chosen for recording was not optimal. 
Therefore, cells were next monitored over a longer time period. 
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Fig. 33: Lifetime distribution comparing immature (+LPV) and mature (-LPV) assembly sites at the plasma 
membrane of HeLa Kyoto cells. A: HeLa Kyoto cells co-transfected with pCHIVieCFP and pCHIV wt in a 1:1 molar 
ratio were either untreated or treated with 2 µm LPV. At 24 hpt, cells were imaged by LSC microscopy combined 
with TCSPC. Fluorescence lifetimes of eCFP were extracted by phasor analysis. The lifetimes ranging from 1.8-3.0 
ns are depicted using the LUT “jet”. Scale bar 5 µm. B: Frequency distribution analysis of mean lifetime values. The 
histograms summarize data for 50 individual sites per cell for two cells per condition. 
 
The plasma membrane of a pCHIVieCFP expressing cell was observed for two hours and images 
were acquired every 30 min (Fig. 34). 80 frames were obtained for each timepoint to sum up 
the amount of photons at each spot. Fluorescence lifetimes of all sites at the plasma membrane 
were analyzed in bulk and the frequency distribution over time was analyzed. At the onset of 
observation (0 min), about 30 particles were detected, displaying a mean fluorescence lifetime 
of 2.0-2.4 ns (dark blue line). 30 min later, ~70 particles were observed and the values spread 
from 1.8-2.4 ns (30 min, light blue line). The shift to lower lifetimes might indicate molecular 
crowding due to Gag lattice formation at the budding site. After 1 h, the number of detected 
particles did not change, but the amount of particles with lower lifetime increased (60 min, 
green line). After 90 min, an increase of particle numbers was observed. The distribution of 
fluorescence lifetime stayed 1.8-2.4 ns, with a maximum at 2.0 ns (red line). After 2 hours, the 
peak of the population shifted to 2.2 ns (120 min, purple line). In summary, whereas an 
increase in particle number was observed over time, a shift of the population to longer 
fluorescence lifetime was not detected in these bulk analyses. 
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Fig. 34: Lifetime distribution of assembly sites during particle formation over time. A: HeLa Kyoto cells were 
co-transfected with pCHIVieCFP and pCHIV wt in a 1:1 molar ratio, either untreated or treated with 2 µm LPV. At 24 
hpt, cells were imaged by LSC microscopy combined with TCSPC for 80 frames every 30 min over 2 h. 
Fluorescence lifetimes of eCFP were extracted using phasor analysis. The lifetime ranging from 1.8-3.0 ns is 
depicted by the LUT “jet”. Scale bar 5 µm. B: Frequency distribution analysis of mean lifetime values of spots over 
80 frames obtained at the indicated time points after the start of observation. 
 
Next, imaging was performed at a higher time resolution in order to allow single particle 
tracking for a more detailed observation of changes in fluorescence lifetime (Fig. 35). The 
plasma membrane of pCHIVieCFP transfected HeLa Kyoto cells was imaged every 5s for 2h 
(Fig. 35A). Assembly sites were tracked by me using Imaris, and the fluorescence lifetime at 
individual sites was calculated by Chen Quian (AG Lamb). Tracking of individual assembly 
sites revealed a signal intensity increase of Gag.eCFP with the typical saturation exponential 
assembly kinetics as described earlier (Fig. 35B, red lines), but only minor changes in 
fluorescent lifetime over time were observed for a small number of tracks analyzed (4/ 100) 
(Fig. 35B, blue lines). This may at least in part be due to the fact that Gag clustering during the 
assembly process should lead to a decrease of fluorescence lifetime; this would obscure an 
increase due to proteolytic processing, if both processes coincide.  
The findings from live-cell imaging were in line with the bulk analysis but did not allow an 
estimation of proteolytic processing of Gag during the assembly process. Further optimization 
of the imaging and analysis is needed to improve this approach. Attempts to diminish 
phototoxicity and reduce cellular background are being discussed. This is currently ongoing in 
collaboration with the Lamb group. 
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Fig. 35: Changes in eCFP fluorescence lifetime during viral assembly. Time lapse measurement of Gag.ieCFP 
assembly at the plasma membrane of HeLa Kyoto cells. HeLa Kyoto cells were co-transfected with pCHIVieCFP and 
pCHIV wt in a 1:1 molar ratio. 24 hpt, cells were imaged by LSC microscopy combined with TCSPC with a frame 
rate of 0.2 s-1 over a period of 2 h. The figure shows frames captured at the indicated time points. Scale bar 5 µm.  
B: Fluorescence lifetimes were extracted using phasor analysis and plotted over time for single tracks (blue lines) 
in parallel to the respective eCFP fluorescence intensity (red lines). Phasor analysis was performed by Chen Quian, 
LMU Munich.  
 
6.3.3 Design of fluorogenic HIV-1 PR inhibitors to specifically visualize the active PR 
 
A different, innovative approach tested in this work was the detection of formation of active 
HIV-1 PR during the viral assembly process via a fluorogenic inhibitor derivative. The PR 
inhibitor Ritonavir (RTV) that binds to the active site of the PR dimer was coupled to the 
fluorogenic dye silicone-rhodamine (SiR) (Fig. 36). SiR exists in a spironolactonic form that is 
non-fluorescencent, as well as in a fluorescenct zwitterionic conformation (Fig. 36A). The 
equilibrium between a non-fluorescent lactonic and fluorescent zwitterion structure is sensitive 
to hydrophobic effects (Lukinavičius et al., 2013). The conformation depends on the 
environment; therefore, fluorescence efficiency is strongly altered by binding to a target. RTV 
is a PR inhibitor which binds strongly to mature HIV-1 PR, but with much lower affinity to the 
PR moiety of the unprocessed GagProPol precursor (Humpolíčková et al. 2018). 
Here, I explored whether binding of a RTV-SiR derivative to the active site of HIV-1 PR would 
allow detection of the formation of active HIV-1 PR by a fluorescence signal (Fig. 36B). 
Different carbon linkers were tested for optimal fluorogenicity of SiR, carrying either two (SiR-
C2-RTV, Fig. 37A), four (SiR-C4-RTV, Fig. 38A) or six (SiR-C6-RTV, Fig. 39A) carbon 
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molecules. All compounds were synthesized by our collaborators Jiří Schimer and Jan 
Konvalinka (IOCB Prague). 
 
 
Fig. 36: Design of a fluorogenic probe to detect active PR. A: SiR adopts an open or a closed conformation 
depending on the environment of the molecule. It was coupled to PR inhibitor Ritonavir specifically bind the active 
site of HIV-1 PR. B: Principle of the assay: Binding of SiR-RTV to the mature HIV-1 PR should result in enhanced 
fluorescence. PR structure adapted from from PDB ID: 3el1. C: Structure of SiR-RTV. Different probes with varying 
linkers were tested. 2-carbon, 4-carbon and 6-carbon linkers were used in this study. The compound with a 4-
carbon linker is shown here. 
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6.3.3.1 Specific fluorogenicity of the probes was validated by spectrophotometry 
 
First, in vitro binding experiments were conducted to determine fluorogenicity of the three 
probes and the effect of specific interaction with HIV-1 PR. 200 nM SiR-C2-RTV (Fig. 37), SiR-
C4-RTV (Fig. 38) and SiR-C6-RTV (Fig. 39) were analyzed by spectrophotometry. SiR 
fluorogenicity depends on the hydrophobic environment of the probe. Ethanol (EtOH) enforces 
a closed, non-fluorescent conformation, while SDS drives it to the zwitterionic fluorescent form. 
This was validated by excitation spectra. Relative fluorescence intensity at 675nm was 
recorded upon excitation in the range of 250-660 nm (Fig. 37B, 38B, 39B). While a small peak 
at 280 nm was detected for the sample in EtOH, no emission was detected at 650nm, the 
expected emission maximum of SiR (blue line). When samples were measured in PBS/0.1 % 
SDS maximum excitation was observed from 630-650 nm (orange line). The turn-on of the 
probes was measured by recording emission spectra. Emission was detected in the range of 
645-749 nm upon excitation with 635 nm (Fig. 37C, 38C, 39C). Measurements of the probe in 
EtOH or PBS/0.1 % SDS were performed as negative and positive controls, respectively. While 
only very low fluorescence signal was detected for EtOH (blue line), the highest emission 
intensity for all probes was measured in 0.1 % SDS in PBS (orange line).   
Unspecific fluorescence signal due to unspecific protein binding was tested by adding 0.1 
mg/ml BSA in PBS to the probes (pink lines). SiR-C2-RTV (Fig. 37C) and SiR-C4-RTV (Fig. 
38C) exhibited high unspecific turn-on in these control measurements, while SiR-C6-RTV (Fig. 
39C) showed only a weak signal intensity increase under these conditions.  
Next, 600 nM purified HIV-1 PR was added to the probe in 0.1 mg/ml BSA in PBS (dark red 
lines). The addition of wild-type HIV-1 PR did not increase the fluorescence signal of SiR-C2-
RTV compared to the BSA control (Fig. 37C). With SiR-C4-RTV, fluorescence was turned-on 
almost to the maximum signal obtained for 0.1% SDS in PBS (Fig. 38C). A strong specific 
fluorescence signal was also detected for SiR-C6-RTV (Fig. 39C). As a control, purified HIV-1 
PR with the active site mutation D25N was mixed with the probes (green lines). Purified HIV-
1 PR D25N also formed a dimer, but was catalytically inactive, therefore it controlled for 
specificity of the probes to active HIV-1 PR. This D25N mutation impaired RTV binding to the 
active site, because the aspartyl carboxy groups are necessary to activate the H2O molecule 
obligatory for binding of RTV to PR (Konvalinka et al. 2015). None of the probes displayed an 
increase in fluorescence above the nonspecific protein background in this case, validating PR 
active site specificity of the observed signal. Interestingly, the unspecific signal detected in 
0.1mg/ml BSA in PBS was decreased by the addition of PR D25N to SiR-C2-RTV and SiR-
C4-RTV (Fig. 37C, 38C).  
To further validate specificity of probe binding, an excess (1 µM) of a different PR-inhibitor 
(Darunavir; DRV) with stronger binding affinity to the HIV-1 PR active site compared to RTV 
was added for a competition experiment. (Fig. 38C, 39C, grey line) (Dierynck et al., 2007). This 
resulted in a decrease of fluorescence signal to the background level (Fig. 38C, 39C, pink line), 
indicating displacement of the SiR-RTV probes from the active site. Additionally, emission 
signal at 675 nm after excitation with 650 nm was measured over time after 1 µM DRV was 
added (Fig. 37D, 38D, 39D). Fitting of the decay curve to a single exponential decay equation 
yielded rates of 0.08258 s-1 for SiR-C2-RTV, for SiR-C4-RTV 0.05374 s-1 and for SiR-C6-RTV 
0.1809 s-1. These apparent rates indicated a much higher off rate for the compounds than the 
koff of 8.1 x 10-4 s-1 determined for RTV alone (Dierynck et al., 2007), but detailed kinetic 
measurements in vitro were not yet performed. Modification of RTV by coupling to the dye did 
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influence its kinetics. While the apparent rates observed were in a similar range, the slowest 
displacement was observed for SiR-C6-RTV indicating better PR binding.  
For visualization, the fold signal increase was normalized to EtOH (Fig. 37E, 38E, 39E). SiR-
C2-RTV and SiR-C4-RTV exhibited a strong turn-on of ~50-fold and 60-fold, while SiR-C6-
RTV only showed a turn-on of 35-fold in 0.1 % SDS in PBS (Fig. 37E, 38E, 39E). Additionally, 
the unspecific turn-on of SiR-C2-RTV and SiR-C4-RTV was ~25-fold compared to only 3-fold 
for SiR-C6-RTV. When the signal intensity increase was normalized to values detected for 0.1 
mg/ml BSA in PBS (Fig. 37F, 38F, 39F), the maximum turn-on in 0.1 % SDS in PBS was just 
2.3-fold for SiR-C2-RTV and SiR-C4-RTV, while SiR-C6-RTV exhibited a ~9-fold signal 
increase. While specific turn-on after addition of PR led to a 7-fold increase for SiR-C6-RTV, 
SiR-C2-RTV only showed 1.2-fold and SiR-C4-RTV 2.2-fold signal increase. Based on these 
in vitro cuvette measurements, SiR-C6-RTV should provide a better signal-to-noise ratio for 
PR detection than the other two compounds. Since cuvette measurements in the presence of 
BSA represent a rather artificial control for non-specific binding compared to the environment 
of virus producing cells on a glass coverslip, side-by-side comparisons were also performed 
using live-cell imaging.  
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Fig. 37: Spectrophotometric analysis of SiR-C2-RTV. A: Structure of SiR-C2-RTV drawn with ChemDraw 
software. B: Excitation spectra of 200 nM SiR-C2-RTV in Ethanol (blue line) and 0.1 % SDS in PBS (orange line). 
Emission signal at 675 nm was detected for the excitation range of 250-660 nm. C: Emission spectra of 200 nM 
SiR-C2-RTV in presence of Ethanol (blue line), 0.1% SDS in PBS (orange line), 0.1 mg/ml BSA in PBS (purple 
line), 0.1 mg/ml BSA in PBS and 600 nM PR D25N (green line) and 0.1mg/ml BSA in PBS and 600 nM PR wt (dark 
red line). Emission signal in the range of 645-749 nm was measured after excitation with 635nm. D: Decrease of 
fluorescence signal detected after addition of 1 µm DRV due to inhibitor displacement. Fluorescence signal was 
measured every 1 s for emission at 675 nm after excitation with 650 nm. The data were fitted using GraphPad Prism 
to a single exponential decay equation (red line), yielding the indicated rate constant. E: Quantification of fold signal 
increase normalized to emission maximum in Ethanol. F: Quantification of fold signal increase of the emission 
maximum normalized to emission maximum obtained in 0.1 mg/ml BSA in PBS. 
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Fig. 38: Spectrophotometric analysis of SiR-C4-RTV. A: Structure of SiR-C4-RTV drawn with ChemDraw 
software. B: Excitation spectra of 200 nM SiR-C4-RTV in Ethanol (blue line) and 0.1 % SDS in PBS (orange line). 
Emission signal at 675 nm was detected for the excitation range of 250-660 nm. C: Emission spectra of 200 nM 
SiR-C4-RTV in presence of Ethanol (blue line), 0.1% SDS in PBS (orange line), 0.1 mg/ml BSA in PBS (purple 
line), 0.1 mg/ml BSA in PBS and 600 nM PR D25N (green line) and 0.1mg/ml BSA in PBS and 600 nM PR wt (dark 
red line). Emission signal in the range of 645-749 nm was measured after excitation with 635nm. D: Decrease of 
fluorescence signal detected after addition of 1 µm DRV due to inhibitor displacement. Fluorescence signal was 
measured every 1 s for emission at 675 nm after excitation with 650 nm. The data were fitted using GraphPad Prism 
to a single exponential decay equation (red line), yielding the indicated rate constant. E: Quantification of fold signal 
increase normalized to emission maximum in Ethanol. F: Quantification of fold signal increase of the emission 
maximum normalized to emission maximum obtained in 0.1 mg/ml BSA in PBS.
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Fig. 39: Spectrophotometric analysis of SiR-C6-RTV. A: Structure of SiR-C6-RTV drawn with ChemDraw 
software. B: Excitation spectra of 200 nM SiR-C6-RTV in Ethanol (blue line) and 0.1 % SDS in PBS (orange line). 
Emission signal at 675 nm was detected for the excitation range of 250-660 nm. C: Emission spectra of 200 nM 
SiR-C6-RTV in presence of Ethanol (blue line), 0.1% SDS in PBS (orange line), 0.1 mg/ml BSA in PBS (purple 
line), 0.1 mg/ml BSA in PBS and 600 nM PR D25N (green line) and 0.1mg/ml BSA in PBS and 600 nM PR wt (dark 
red line). Emission signal in the range of 645-749 nm was measured after excitation with 635nm. D: Decrease of 
fluorescence signal detected after addition of 1 µm DRV due to inhibitor displacement. Fluorescence signal was 
measured every 1 s for emission at 675 nm after excitation with 650 nm. The data were fitted using GraphPad Prism 
to a single exponential decay equation (red line), yielding the indicated rate constant. E: Quantification of fold signal 
increase normalized to emission maximum in Ethanol. F: Quantification of fold signal increase of the emission 
maximum normalized to emission maximum obtained in 0.1 mg/ml BSA in PBS. 
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6.3.3.2 Specific fluorogenicity of the probes detected at HIV-1 assembly sites in HeLa Kyoto 
cells 
 
HeLa Kyoto cells in late stages of viral assembly were treated with 1 µM of the probes for 20 
min and a fluorescent signal specific to the viral buds or released viral particles was detected 
for all compounds (Fig. 40). In agreement with the in vitro measurements (Fig. 37, 38, 39), 
SiR-C2-RTV and SiR-C4-RTV produced a higher unspecific background signal than SiR-C6-
RTV, observed as blurry signal in the area surrounding the transfected cell and the cell surface 
(Fig. 40, middle column). Rigorous cleaning of the glass surface by 0.1 M HF treatment prior 
to cell seeding was essential to avoid excessive background from dye adhering to the glass 
coverslip. Even then, the background signal at the glass surface was higher than in the region 
covered by the plasma membrane. While the fluorescence signal recorded at assembly sites 
was threefold higher for SiR-C4-RTV than for SiR-C6-RTV, the higher unspecific background 
signal obtained with this probe impaired the recognition of specific marks.  
Based on these measurements, SiR-C6-RTV was selected for further live-cell imaging 
experiments. 
 
Fig. 40: PR-dependent SiR-RTV signal detected at HIV-1 Gag assembly sites by TIRF microscopy. HeLa 
Kyoto cells were transfected with pCHIV/pCHIVeGFP expressing wt HIV-1 PR. At 24 hpt cells were treated with 1 
µm of the indicated probes for 20 min prior to imaging. Late assemblies at the ventral plasma membrane were 
imaged by TIRF microscopy. Scale bar: 10 µm. 
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For SiR-C6-RTV, further validation of signal specificity was conducted. Fluorogenic signals at 
assembly sites were determined for virus derivatives with an active PR and compared to 
signals obtained with variants that either lacked GagProPol (Gag only) or carried catalytically 
inactive PR (PR D25N). Testing whether SiR-RTV based detection is really specific for the 
mature form of PR also required a virus derivative capable of forming GagProPol dimers 
comprising a wild-type PR active site but unable to generate mature PR. For this, I constructed 
a variant of pCHIV in which all PR cleavage sites between NC and RT were mutated to impair 
autoprocessing (pCHIVNC-RT). Finally, I used a variant with GagProPol and competed for 
binding of the SiR-RTV probe with 1 µM of the stronger binding PR inhibitor DRV (Fig. 41).  
Pol-SNAP was transfected in a 1:20 molar ratio with pGag.GFP to imitate the Gag to 
GagProPol ratio found in viral particles and cells were stained with SNAP-Cell 647-SiR as a 
positive control. Since the signals detected for SNAP-Cell 647-SiR bound to the SNAP-tag in 
GagProPol exceeded the signals detected for SiR-C6-RTV by 10-20-fold (Fig. 41B), 
measurements had to be performed using different microscope settings. 
Assembly sites at the ventral plasma membrane were observed for all samples (Fig. 41A, left 
column). In contrast, clear specific SiR staining was only visually observed for the sample 
stained for GagProPol.SNAP and for the SiR-C6-RTV stained sample that should comprise 
mature PR in the absence of a PR inhibitor competitor (Fig. 41A, top and bottom row, 
respectively). Quantification of the mean SiR signal at the individual budding sites above 
background was performed and plotted as relative frequency distribution (Fig. 41B). The strong 
SiR signal obtained for GagProPol.SNAP served as a positive control fir SiR fluorescence 
detection (Fig. 41A, B, 1st row). Assembly sites of HIVGag only which lack PR did not exhibit any 
specific signal for SiR-C6-RTV above background (Fig. 41A, 2nd row). Detected mean SiR 
signal intensities (up to 200) were therefore set as threshold for background signal (Fig. 41B, 
2nd graph).  
Assembly sites of virus expressing catalytically inactive PR D25N did not show any specific 
signal for SiR-C6-RTV as well (Fig. 41A, 3rd row). Quantification of signals at individual sites 
revealed a signal distribution comparable to Gag only (Fig. 41B, 2nd, 3rd graph). The absence 
of fluorescent signal for this probe supported the hypothesis that SiR-C6-RTV only stained 
active HIV-1 PR. (Fig. 41A, 4th row). Mean signal intensities were at background level (Fig. 
41B, lower left graph). 
Expression of wild-type pCHIV in presence of DRV lacked specific SiR signal at the assembly 
sites (Fig. 41A, 5th row). Quantified values were comparable to the negative controls (Fig. 41B, 
lower middle graph). This is in line with the competition assay conducted by spectrofluorometry 
measurements (Fig. 39D). 
For assembly sites containing the wild-type HIV-1 PR, a specific signal was observed for SiR-
C6-RTV (Fig. 41A, 6th row). Co-localization was illustrated in the merged image (right column). 
Frequency distribution analysis of quantified SiR signal shows a shift in the population. The 
specific signal increased 3-fold above background (Fig. 41B, lower right graph).  
The specific signal shift rendered SiR-C6-RTV a promising candidate to label active HIV-1 PR 
during the assembly process and was therefore applied to time-lapse measurements of viral 
assembly.  
Results  91 
 
 
Results  92 
 
 
Fig. 41: PR-dependent SiR signal detected at HIV-1 Gag assembly sites by TIRF microscopy. A: HeLa Kyoto 
cells were transfected with pCHIV expressing pCHIV either lacking HIV-1 PR (Gag only), carrying catalytically 
inactive PR (PR D25N), autoprocessing defective PR (NC-RT), and wild-type PR, either untreated or treated with 5 
µM DRV. GFP-tagged and unlabeled pCHIV was co-transfected in a 1:1 molar ratio. 24 hpt, cells were treated with 
600 nM SiR-SNAP or 1 µM of SiR-C6-RTV for 20 min prior to imaging. Late assemblies at the ventral plasma 
membrane were imaged by TIRF microscopy. Images are representative for 10 cells imaged each in 3 independent 
experiments. Scale bar: 10 µm. B: Relative frequency distribution [%] of mean SiR signal intensity at the Gag 
budding site of n=30 cells from 3 independent measurements.  
 
Live cell imaging of pCHIVeGFP carrying wild-type PR was conducted in the presence of 1 µm 
SiR-C6-RTV during the assembly process (16 hpt) over a period of 2-4 hours (Fig. 42). Viral 
assembly sites were tracked to adjust for slight movements of the cell during live-cell imaging 
and mobility of viral particles after release. Analysis of pCHIVeGFP assembly kinetics yielded in 
saturating exponential curves with rate constants as described above (Fig. 17).  
A total of 250 sites from 3 cells that displayed an exponential increase in the Gag.eGFP 
channel was analyzed for fluorescence in the SiR channel. Quantitative analysis of signals in 
the SiR channel was challenging due to the high sensitivity required for these measurements 
– only ~60 molecules of mature PR per site can be expected to be present after completion of 
autoprocessing. Although a specific SiR signal was easily discernible by visual inspection of 
movies, low signal to noise ratio and fluctuations of the signal hindered quantitation of specific 
fluorescence in the SiR channel for a large fraction of assembly sites, but 50 sites analyzed to 
date allowed for such quantitative analysis. Since the pattern of SiR signal appearance differed 
between individual sites, each site was analyzed separately. The three exemplary assembly 
sites displayed in Fig. 42 were chosen based on their lack of mobility and the fact that they 
showed signal intensity increase of Gag.eGFP and SiR-C6-RTV over the period of observation 
(Fig. 42A). The three different patterns of appearance of the SiR signal were observed at these 
sites. In the upper panel, specific signal was detected 2500 s after the onset of assembly site 
formation, while the middle panel already displayed a SiR signal after 1250 s. For the lower 
panel, only a weak SiR signal was detected after 2500 s.  
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According to previously published analyses, HIV-1 Gag assembly takes ~ 10 min, while the 
viral particle is released after ~ 20 min (Ivanchenko et al. 2009). SiR signal increase was 
observed to be either (i) early, (ii) late or (iii) fluctuating. Early signal increase was detected 
after 10-20 min, suggesting PR activation during or at late stages of the viral assembly process 
(Fig. 42A, middle panel, 42C upper and lower panel). Later events were observed after ~ 40 
min, indicating formation of active PR after viral release (Fig. 42A, upper and lower panel, 42C 
middle panel).   
In summary, SiR-C6-RTV was successfully established to allow to monitoring formation of 
active HIV-1 PR during the viral assembly process in a time dependent-manner. The signal 
was not detected at all sites analyzed and the recruitment patterns with respect to the time 
course of assembly site formation differed between individual sites. Further analyses to 
determine the frequency of the different patterns are ongoing. 
 
 
Fig. 42: Live-cell imaging of SiR-C6-RTV fluorescence signal during the viral assembly process. A: Time 
lapse measurement of Gag.eGFP assembly at the plasma membrane of HeLa Kyoto cells. HeLa Kyoto cells were 
co-transfected with pCHIVeGFP and pCHIV wt in a 1:1 molar ratio. At 16 hpt, cells were treated with 1 µM of SiR-C6-
RTV for 20 min prior to imaging. Cells were imaged by TIRF microscopy with a resolution of 0.2 frames/s for 2 h. A 
total of 250 tracks from 3 cells were analyzed. The Figure shows frames from movies recorded at the indicated time 
points for three individual sites that displayed an increase of fluorescence in both channels. Scale bars: 1 µm. B: 
Plot of mean signal intensity of assembly sites of pCHIVeGFP transfected HeLa Kyoto cells. Mean value and SD of 
Gag.eGFP fluorescence intensity over time, exhibiting saturating exponential assembly kinetics. n=250 assembly 
sites from 3 cells with exponential fit and mean rate constant. C: Plot of mean signal intensity of SiR-C6-RTV over 
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time for three representative assembly sites of pCHIVeGFP transfected HeLa Kyoto cells. t=0 represents the first time 
point of assembly site detection (Gag.eGFP signal above background). 
 
 
 
  
Discussion  95 
 
7 Discussion 
 
While the importance of HIV-1 PR processing of Gag is known to be crucial for formation of 
infectious viral particles, the dynamic coordination of viral assembly and PR activity are not 
well understood. Approaches to disengage viral assembly and proteolytic processing, resulted 
in impaired viral infectivity and structural integrity (Mattei et al. 2014, Schimer et al. 2015). In 
this work, novel fluorescence-based probes were designed to detect PR activity and formation 
of active dimerized PR in real-time during the assembly process by fluorescence microscopy 
measurements. 
 
7.1 Visualization of the assembly process by fluorescence microscopy 
 
Our aim was to establish a temporal correlation between PR activation of proteolytic 
processing and the process of particle formation. PR activation and processing might 
theoretically occur during the assembly process, between completion of assembly and 
abscission or even after release has occurred. Previous analyses of Gag assembly kinetics 
had revealed that assembly is completed within an average of 8-9 min, followed by a 
‘stationary’ period of ~ 10 min before particle abscission from the plasma membrane could be 
detected (Ivanchenko et al. 2009). In order to cover the whole process, it is thus necessary to 
observe individual assemblies over a minimum of 30 min following initial detection of the 
assembly with high time resolution. Quantitative analyses require kinetic data from a large 
number of individual assembly sites (> 100), and the appearance of individual sites at the 
membrane of a single cell is asynchronous; consequently, total observation periods in the 
range of 1 h or more are required for meaningful data collection.  
Assembly kinetics were shown to differ between the ventral and lateral plasma membrane. A 
rate constant of k = 5.9 ± 0.4*10-3 s-1 was calculated for saturating exponential curves 
measured at the lateral plasma membrane, which was found to be faster than for the ventral 
plasma membrane (k = 3.49 ± 0.26 *10-3 s-1; Mücksch et al. 2017). At the lateral plasma 
membrane, released particles diffused out of the field of view, so the fluorescence signal was 
lost and later timepoints could not be observed. Additionally, 3D z-stacks needed to be imaged 
to observe assembly at the lateral plasma membrane. Earlier studies revealed similar mean 
rate constants but described similar rate constants for ventral and lateral plasma membrane 
for saturating exponential curves. The complicated 3D imaging and tracking necessary for 
imaging of the lateral plasma membrane might cause variations in the assembly kinetics 
between lateral and ventral plasma membrane (Ivanchenko et al. 2009).  
In order to reduce background from intracellular Gag and sensor proteins and to allow 
observation of viral particles after release, measurements were performed by TIRF microscopy 
at the ventral plasma membrane. In this case, viral particles are trapped between the cell and 
the glass surface, enabling longer time periods of viral detection, but making it more difficult to 
distinguish between late assembly sites and released virions (Ivanchenko et al., 2009, 
Jouvenet et al. 2008, Mücksch et al. 2017). Gag is known to be present as monomers and 
small oligomers in the cytoplasm (Kutluay und Bieniasz 2016; Hendrix et al. 2015). To detect 
Gag recruitment and the plasma membrane during early events of assembly would require 
single molecule sensitivity, that is not reached here. Therefore, no exact timeframes in relation 
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to the onset of the viral assembly process could be determined. This question is currently under 
investigation by our collaborators (AG Lamb, Munich).  
In this study, the formation of newly produced viral particles at the plasma membrane of HeLa 
Kyoto cells was detected over 1 - 2 h by TIRF microscopy. Spots with an area of 4-40 pixels 
were observed to increase in fluorescence intensity over time. The kinetics of fluorescence 
signal intensity increase were analyzed by tracking the assembly sites and measuring the 
signal intensity over time. The observed assembly kinetics with saturating exponential curves 
were found to be comparable to published data (Ivanchenko et al. 2009, Jouvenet et al. 2008, 
Mücksch et al. 2017). Independent of the fluorescence tag, comparable rate constants of 
~3*10-3 s-1 were measured: SiR-SNAP, eGFP or eCFP inserted in Gag showed equal rate 
constants. Vpr.Clover revealed faster kinetics, which may be a result of recruitment of Vpr by 
Gag after the initiation of assembly site formation.  
In the beginning of viral assembly, only few spots were detected on the plasma membrane and 
were therefore easily trackable. Over time, the number increased, and the buds became 
crowded, which complicated the tracking. These sites were excluded from the analysis. 
Trapping of released VLPs underneath the cell allowed the observation of viral particles for a 
longer time period and was utilized to detect later stages of viral particle. However, it 
complicated the discrimination between the viral budding and the pinching off process. To 
resolve this issue, other studies included fluorescently labeled components of the ESCRT 
machinery, which is recruited by Gag to perform the scission off the plasma membrane and 
induce viral particle release (Ivanchenko et al. 2009; Jouvenet 2012). Due to technical 
limitations in the detectable amount of fluorescence channels, these factors were not included 
in this study, but will be considered in future experiments. 
 
7.2 Design of sensors to visualize HIV-1 PR activity during viral assembly by 
fluorescence microscopy 
 
Different sensors were designed to enable the detection of proteolytic activity or formation of 
HIV-1 PR during viral assembly by fluorescence microscopy. They were based on physical 
characteristics of fluorescent proteins that changed depending on HIV-1 PR. Sensors depict 
PR activity, so it could be measured despite the resolution limit of fluorescence microscopy. 
Three different processes were detected: (i) proteolytic processing of an external sensor (ii) 
Gag processing and (iii) formation of active PR.  
 
7.2.1 An external FRET-based sensor was specifically cleaved by HIV-1 PR 
 
Fluorescence-based studies were applied to detect HIV-1 activity since the 1990s. Mostly, the 
measurements were conducted in vitro, e.g. with spectrofluorometry. In those studies, either 
purified proteins or viral particles were subject to proteolytic cleavage by purified HIV-1 PR 
(Baum et al. 1990, Gaber et al. 2012, Müller et al. 2014, Richards et al. 1990). However, 
concentrations of proteins in the cuvette might vary compared to native conditions in viral 
particles and protein accessibility might differ between soluble protein and protein incorporated 
in a viral particle. Therefore, these studies cannot fully be transferred to the viral process.  
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In other studies, different FRET-pairs like mCerulean and mCitrine or GFP and mCherry were 
applied to observe HIV-1 PR activity in cells (Gaber et al. 2012, Yang et al. 2012). mCerulean 
is excited with 405 nm, which was found to increase phototoxicity and is therefore not 
applicable for our approach (Hanne et al. 2016). In this work, fluorescent proteins Clover and 
mScarlet with high brightness and comparable folding kinetics were utilized as FRET pair to 
improve detection of fluorescence signal and reduce effect of maturation time of the proteins 
on FRET signal (Bindels et al. 2017, Lam et al. 2012).  
In our FRET-based sensor, Clover and mScarlet were linked by the cleavage site located 
between MA and CA, defined as an intermediate processing site (Pettit et al. 1994). Sensor 
incorporation was achieved by linking the proteins to Vpr (Lampe et al. 2007). Proteolytic 
processing of the FRET-based sensor by wild-type HIV-1 PR reduced the FRET value by two-
fold in purified VLPs. The FRET-based sensor was found to be not fully cleaved, as assessed 
by immunoblot analysis of purified VLPs. Since immunoblot analysis is a bulk approach, it does 
not allow distinction between a mixture of particles carrying different proportions of cleaved vs. 
uncleaved sensor, which can be caused e.g. by inactive PR in some virions, or a similar degree 
of incomplete cleavage in all particles. Incomplete cleavage might have been caused by 
inactive HIV-1 PR in individual viral particles or by variable amounts of incorporated sensor 
due to unequal incorporation. Furthermore, higher sensor concentration could result in high 
FRET values after PR processing due to molecular crowding even in the case of complete 
processing.  
Previous experiments in our lab indicated that high amounts of incorporated Vpr.eGFP 
impaired Gag processing due to exogenous expression (Lampe et al. 2007). This was in line 
with the titration experiments in this work, which also showed that high amounts of incorporated 
sensor impede Gag processing. 
Others described a FRET-based sensor utilizing YFP and mCherry coupled to Vpr and linked 
with two PR cleavage sites. Still, they observed impeded Gag and external FRET-based 
sensor processing to 55%, probably caused by too high amounts of sensor incorporation (Sood 
et al. 2017). In contrast, the study presented here, Gag processing rates of 80%, comparable 
to wild-type viral particles without exogenous Vpr were reached by careful titration of the FRET-
based sensor in VLPs. 
For the FRET-based sensor, which was incorporated in wild-type viral particles, plotting of the 
frequency distribution revealed a gaussian distribution of FRET values. These may be caused 
by the spatial arrangement of the fluorescent molecules, that influence the energy transfer 
efficiency. Energy transfer is only efficient, when the fluorescent proteins are aligned, so that 
the donor can induce an acceptor dipole. Protein alignment is subject to stochastic variations 
due to rotational diffusion (Vogel et al. 2012); this might lead to these observed variations of 
FRET efficiency.  
Within cells, the co-expression of sensor and wild-type HIV-1 PR caused a two-fold decrease 
of the FRET values upon proteolytic processing of Clover-mScarlet.Vpr, whereas the 
frequency distribution revealed two populations, a mixture of mature and immature particles 
on the plasma membrane. While lower FRET values depict mature viral particles, early 
assembly sites and immature particles contained uncleaved FRET-based sensor and therefore 
result in higher FRET values, as shown for purified VLPs before. This might be due to 
asynchronous viral assembly in and between cells. 
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Due to cell-to-cell variation, cells might present different stages of assembly or the FRET-
based sensor was not entirely cleaved by HIV-1 PR due to higher amounts of exogenous Vpr 
expressed in this cell (Lampe et al. 2007). Nevertheless, this twofold signal change was 
expected to be sufficient to detect proteolytic cleavage of the FRET-based sensor during viral 
assembly, since it was in line with literature (~ 30%; Gaber et al. 2012, Sood et al. 2017). In 
FRET literature, changes in the 5% range are accepted to confirm protein-protein interactions 
(Kuchenov et al. 2016). A FRET-based sensor containing mCerulean and Citrine was 
described to show a 25-35% drop of FRET signal due to HIV-1 PR in cells (Gaber et al. 2012). 
In this work, PR-dependent changes in FRET signal due to proteolytic processing up to 50% 
were detected in VLPs. 
 
Albeit twofold differences in FRET signal in purified immature and mature particles, time-lapse 
measurements did not reveal changes in FRET signal as expected from still images of purified 
VLPs and assembly sites on the plasma membrane of HeLa Kyoto cells. Either, phototoxic 
effects impaired proteolytic activity, the cleavage did not happen in the observed timeframe or 
the process was decelerated. Phototoxic effects describe the side effects of laser excitation, 
that induces reactive oxygen species (ROS), which react with the proteins and can impair their 
functionality (Wright et al. 2002). Since active HIV-1 PR was detected in this study, formation 
of PR itself and therefore autoprocessing did not seem to be impaired. Additionally, TIRF 
microscopy features lower laser power, as well as lower sample penetration. This should 
decrease phototoxic effects and therefore generation of ROS. To test the impact of phototoxic 
effects and the timeframe, cells should be imaged with a fewer frames over a longer period of 
time (2-4 h). To further reduce phototoxicity, ROS could be tackled with scavengers like 4-
hydroxy TEMPO (Żamojć et al. 2014).  
Additional approaches were applied to accomplish the detection of proteolytic activity during 
the formation of viral particles.  
 
7.2.2 Internal labeling of Gag for detection of Gag processing as a marker for PR 
activity 
 
Different tags were inserted in Gag to observe Gag processing during viral assembly: (i) split 
fluorescent proteins, that should fluoresce upon proteolytic cleavage of Gag, (ii) a fluorogenic 
dye that can be applied to super-resolution microscopy and resolve changes in spatial 
distribution, and (iii) eCFP, that features changes in its fluorescence lifetime depending on 
localization in the Gag lattice or free diffusion in the viral particle.  
 
7.2.2.1 Split fluorescent proteins and insertion in Gag does not enable distinction of mature 
and immature VLPs 
 
Fluorescent proteins Venus and sfGFP were split into non-fluorescence subdomains (Hu und 
Kerppola 2003; Cabantous und Waldo 2006), incorporated in Gag between the MA and CA 
domain and designed to fluoresce upon Gag processing. The assumption was that constraint 
of the split subunits as internal part of a polyprotein that assembles into a stable and regular 
lattice (Sundquist und Kräusslich 2012) would prevent or at least hinder their association into 
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a functional fluorophore. PR-dependent Gag processing at one or both ends of the inserted 
subdomain should enable the fluorescent apoprotein to form, resulting in the appearance of a 
fluorescent signal. Upon co-expression of the two subdomains in viral particles, these subunits 
were able to reconstitute the fluorescent apoprotein. Emission of fluorescence signal was 
observed independent of proteolytic processing by HIV-1 PR, indicating that reconstitution of 
the split fluorescent protein subunits could occur within the context of the uncleaved 
polyprotein.  
 
The immature Gag lattice is believed to be immobile and tight. A variable assembly would not 
allow to resolve the overall structure at resolutions as high as 8.8 Å (Briggs et al. 2009; Schur 
et al. 2015). In this case, it seemed that the overall flexibility was higher, or the assembly was 
disturbed by the insertion, but viral particles were nonetheless produced and released. These 
findings indicate that the particle assembly process by itself is robust and tolerates alterations 
of the Gag polyprotein, which are likely to disturb the regular molecular architecture of the 
lattice. Since the approach was found to be unsuitable for the intended purpose, the 
architecture of the resulting virions was not further analyzed. 
 
 
7.2.2.2 Changes in localization of fluorescence tags in Gag can be visualized by STED 
microscopy 
 
Next, changes in localization of fluorescence tags in Gag were visualized by STED microscopy. 
The insertion of the Clip tag in Gag between MA and CA and flanked by PR cleavage sites 
(pCHIViClip), combined with the increased resolution of STED microscopy enabled a 
discrimination of mature and immature viral particles. For purified VLPs, this was shown 
previously (Hanne et al., 2016). Here, pCHIViClip was applied to visualized immature rings and 
mature blob-like structures at the plasma membrane of HeLa Kyoto cells.  
STED microscopy was applied to resolve late stages of viral assembly, that could not be 
visualized by confocal microscopy. Patches, as observed during live-cell imaging of the 
assembly process, were discovered to harbor numerous (~50-100) late budding sites or 
released viral particles trapped underneath the cells. For pCHIViClip expressing wild-type HIV-
1 PR, conformational changes of the tag upon proteolytic processing were detected. A mixture 
of ring- and blob-like structures was observed. Ring-like structures depicted late stages of 
assembly and budding, as well as immature viral particles, while mature particles were 
detected as “blobs”. The resolution enabled distinguishing of individual viral particles even in 
this crowded environment. The presence of ring- and blob-like structures validated the onset 
of proteolytic processing of Gag during this stage of assembly. The mixture also indicated an 
asynchronous assembly of viral particles on one cell. 
Proteolytic activity was reported to be impaired by the phototoxic effects of the STED laser. 
Hanne et al. (2016) visualized maturation of purified viral particles upon PR activation. This 
process was locally hindered after imaging of viral particles by STED microscopy in the field 
of view. Here, 4-Hydroxy-TEMPO was applied to detoxify ROS to reduce phototoxicity and 
improve proteolytic processing (Żamojć et al. 2014).  
Although the mature and immature structures were resolved at assembly sites by STED 
microscopy, measuring dynamic processes of PR activity during the viral assembly was not 
performed with this system. Imaging cells for multiple frames was observed to induce cell 
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death. Time-lapse measurements of assembly sites were discussed to impair Gag processing 
at the imaged site and therefore not pursued further. Now, a new method was described to 
allow nm resolution with a minimal amount of photons (MINFLUX) (Balzarotti et al. 2017). With 
this method, measurements at late stages of assembly might allow the visualization of 
conformational redistribution of the Clip-tag from the ring- to the blob-like structure.  
 
7.2.2.3 Changes in fluorescence lifetime of eCFP in Gag can be visualized by FLIM 
microscopy 
 
FLIM measurements are often applied to measure FRET efficiency, mostly of hetero-FRET 
pairs. The application of hetero-FRET pairs can change the ratio of incorporated fluorescent 
proteins in Gag (Müller et al. 2014). Here, eCFP was utilized for FLIM measurements, because 
it employs homo-FRET, which reduces the influence of protein incorporation (Poëa-Guyonet 
al. 2013). For FLIM measurements, signal intensity can be taken out of the equation, therefore 
this method is more robust than FRET measurements (Suhling et al. 2015). This reduced the 
influence of bleaching on this system. The microscope set-up of our collaborators (AG Lamb, 
Munich) was specifically designed for improved eCFP signal and fluorescence lifetime 
detection. Lifetime quantification algorithms were developed by this group, allowing most 
precise calculations based on phasor analysis (Digman et al. 2008).  
To detect Gag processing, eCFP was inserted in Gag in between MA and CA. It was either 
flanked by PR cleavage sites to freely diffuse in the particle upon proteolytic processing 
(ieCFP) or featured with one clipping site to stay linked to MA and merely rearrange on the 
viral membrane after PR dependent cleavage (eCFP). Molecular crowding of Gag induced 
homo-FRET of eCFP in the Gag lattice, resulting in a decrease of fluorescence lifetime 
(Kremers et al. 2006).  
Proteolytic processing induced an increase of fluorescence lifetime. In VLPs, freely diffusing 
eCFP of pCHIVieCFP featured a two-fold higher increase in fluorescence lifetime than MA-eCFP. 
Molecular crowding of eCFP in the small volume of a VLP did not impact its fluorescence 
lifetime, because values were comparable to freely diffusion of eCFP in the cytoplasm of HeLa 
Kyoto cells. Either, MA induced clustering of the molecules in the cytoplasm, leading to a 
decrease in fluorescence lifetime, or the coupling changed the properties of eCFP. DNA-
origami experiments with controlled formation of MA-eCFP multimers or monomers would 
need to be conducted to shed light on this question.  
Live-cell imaging performed with higher time resolution allowed tracking of individual assembly 
sites. While they revealed signal intensity increase of eCFP with the saturation exponential 
assembly kinetics as described earlier, only slight changes in fluorescence lifetime were 
observed for four out of 100 analyzed tracks. This was in line with the bulk analysis but did not 
allow a detection of proteolytic processing of Gag during the assembly process. Either, 
cytosolic background precluded observation of changed in fluorescence lifetime, or laser 
phototoxicity hindered proteolytic processing of Gag by HIV-1 PR.  
While TIRF measurements were mostly applied to live-cell imaging of viral assembly, FLIM 
measurements were conducted by confocal imaging due to technical restrictions. The 
increased sample penetration of 200 nm to 500 nm, enhanced the influence of cytoplasmic 
background signal (Balagopalan et al. 2011; Mattheyses et al. 2010). This might affect the 
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FLIM measurements and decrease the overall changes that could be detected due to the 
presence of Gag.eCFP in the cytoplasm. Additionally, phototoxic effects might have impaired 
or reduced HIV-1 PR activity. To reduce phototoxicity, ROS could be tackled with scavengers 
like 4-hydroxy TEMPO (Żamojć et al. 2014).  
For the four detected assembly sites, an increase of fluorescence lifetime was observed after 
about 15-20 min. Studies that observed Gag processing after inducing PR activity, report a t1/2 
of 30 min for this process (Mattei et al. 2014; Schimer et al. 2015; Hanne et al. 2016). As 
discussed before, uncoupling of Gag assembly and proteolytic processing might alter PR 
cleavage activity. Detection of Gag processing during the assembly process would suggest 
faster processing in the nascent viral particle compared to the induced measurements. 
Further imaging of time-lapse experiments will be conducted for this project. First, 
measurements will be conducted in presence on 4-hydroxy TEMPO to reduce influence of 
ROS. Alternatively, a TIRF-FLIM set-up should be considered for imaging to reduce 
phototoxicity and cytoplasmic background. An improvement of tracking and lifetime 
quantification is ongoing in collaboration with AG Lamb. 
 
7.2.3 Formation of active HIV-1 PR was detected during the viral assembly process 
 
The last approach tested in this work was the detection of formation of active HIV-1 PR during 
the viral assembly process. The PR inhibitor RTV, which binds to the active site of the PR 
dimer, was coupled to the fluorogenic probe SiR.  
Detection of intracellularly expressed proteins by fusion of the protein of interest to a SNAP- 
or Clip-tag, followed by covalent adduction of a fluorogenic dye like silicone-rhodamine (SiR) 
to the self-labeling tag is well established (Reymond et al. 2011). The equilibrium of SiR 
between a non-fluorescence lactonic and fluorescence zwitterion structure is sensitive to 
hydrophobic effects (Lukinavičius et al. 2013). The dye substrate has been optimized to yield 
high fluorogenicity when bound to SNAP or Clip, and the covalent nature of the resulting 
complex allows for extensive washing to reduce cellular background in live-cell experiments. 
This results in a high sensitivity of detection, which easily allowed to follow assembly of 
Gag.SNAP carrying particles at the cell membrane. Staining of Gag.SNAP and Gag-Clip 
expressing viral particles with SNAP-Cell 647-SiR and SiR-Clip respectively was previously 
described (Eckhardt et al. 2011, Hanne et al. 2016). Labeled Gag was successfully observed, 
because in a viral particle, there are ~2500 Gag molecules. Only ~ 60 PR dimers are 
incorporated per virion; therefore the detection is more challenging (Sundquist and Kräusslich 
2012). 
The innovative concept of intracellular protein labeling by transient binding of a SiR-coupled 
inhibitor derivative has been established for cytoskeletal filaments F-actin and microtubule 
(Lukinavičius et al. 2014). These structures are characterized by a very high number and 
density of monomeric subunits and are therefore frequently used as exemplary targets for the 
validation of novel staining or microscopic approaches. The application of the principal 
approach to a more challenging target had not been described.   
HIV-1 PR in known to be highly affected by mutations and due to its small size (10 kDa), direct 
labeling of PR was not accomplished without impairing virus infectivity, even with small TC-
Discussion  102 
 
tags (Pereira et al. 2011). While tagging PR directly cannot discriminate monomeric PR in 
GagProPol and dimeric active PR, we specifically designed our probe to detect active HIV-1 
PR.  
SiR-RTV was shown to fluoresce upon binding to the PR active site due to conformational 
changes in SiR depending on the environment. Different carbon linkers were tested for optimal 
fluorogenicity of SiR, carrying either two (SiR-C2-RTV), four (SiR-C4-RTV) or six (SiR-C6-
RTV) carbon molecules.  
Detection of emission spectra revealed unspecific turn-on upon addition of 0.1 mg/ml BSA in 
PBS for SiR-C2-RTV and SiR-C4-RTV, while SiR-C6-RTV showed only a weak signal intensity 
increase in the presence of BSA in vitro. A longer linker therefore seemed to increase 
specificity of the probes, while a shorter linker increased maximum fluorescence intensity. It 
should be noted, however, that the addition of BSA in vitro is a rather simplified correlate of 
interactions that may occur in the cytosol of a virus producing cell.   
Although fluorescence signal at assembly sites was threefold higher for SiR-C4-RTV than for 
SiR-C6-RTV, which might have improved early detection of fluorescence signal, the high 
unspecific background signal for SiR-C4-RTV impaired the recognition of specific signals. For 
assembly sites containing the wild-type HIV-1 PR, a specific signal of threefold above 
background was observed for SiR-C6-RTV. Covalent binding of SNAP-Cell 647-SiR to the 
SNAP-tag increased the fluorogenicity by 10-20-fold (Lukinavičius et al. 2013), a 10-fold higher 
SNAP-Cell 647-SiR signal intensity was detected at assembly sites expressing Pol-SNAP 
compared to SiR-C6-RTV. 
Live cell imaging of pCHIVeGFP carrying wild-type PR revealed specific SiR signal at Gag.GFP 
assembly sites in the presence of 1 µM SiR-C6-RTV during the assembly process over 2 – 4 
h. Analysis of pCHIVeGFP assembly kinetics resulted in saturating exponential curves with rate 
constants as described above. According to literature, viral assembly takes ~10 min, while the 
viral particle is released after ~20 min (Ivanchenko et al. 2009).  
To detect formation of active PR during the viral assembly process, SiR-C6-RTV needed to 
remain in the supernatant. While this led to an unspecific background, a specific signal was 
nevertheless detected during viral assembly at the plasma membrane. SiR signal increase 
was observed to be either (i) early, (ii) late or (iii) fluctuating. Early signal increase was detected 
after 10 - 20 min, suggesting PR activation during late stages of the viral assembly process. 
Later events were observed after ~40 min, indicating formation of active PR after viral release. 
Due to high background signal, fluctuations of the SiR signal hindered detection of specific 
fluorescence signals for a large fraction of assembly sites. Detailled quantification of the early 
and late SiR signal during the viral assembly process will be pursued. Overall, SiR-C6-RTV 
was able to detect formation of active HIV-1 PR during the viral assembly process despite the 
small amount of ~60 molecules of active HIV-1 PR in viral particle. The threefold signal 
increase suggests a detection limit of ~20 bound SiR-C6-RTV molecules with this experimental 
set-up.  
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7.3 Future implications of the project 
 
Detection of proteolytic activity during the viral assembly process was not feasible in this study 
but labeling of active HIV-1 PR by a fluorogenic probe was successfully established. In this 
work, I have successfully established time-resolved detection of active HIV-1 PR in relation to 
the Gag assembly process.  
So far, Gag assembly kinetics were used as markers for the stage of viral assembly. The 
determination of exact timing of formation of active PR in regard to viral release was not shown 
but would be a crucial clue concerning further studies of PR activation. Regulation of PR 
activity by its monomeric expression and a likely activation after closing of the viral particle is 
known, but the exact timing in relation to virus release still remains elusive (Konvalinka et al. 
2015). The p6 domain of Gag is known to recruit the cellular ESCRT machinery to facilitate 
scission of the viral particle from the plasma membrane. It interacts with Tsg101 and ALIX, 
which then recruit ESCRT-III. ESCRT‑III has been observed to assemble into spirals at the 
neck of the bud. It has been shown to recruit the AAA ATPase vacuolar protein sorting 4 
(Vps4), which enables membrane scission and recycles ESCRT components after budding 
has been completed (Freed 2015). Timing of ESCRT recruitment in relation to Gag assembly 
was shown previously (Ivanchenko et al. 2009; Jouvenet et al. 2012, Johnson et al. 2018). The 
ATPase Vps4 was reported to appear at the assembly site shortly before scission of the viral 
particle off the plasma membrane. Correlation of Vps4 recruitment and detection of active HIV-
1 PR would reveal the mystery of timing of PR formation before or after virus release.  
A longer linker between the RTV and SiR seemed to improve functionality of both compounds. 
This suggests that a C8 linker may further increase the specificity of the probe. Testing of 
additional probes was beyond the scope of this work but should be approached in the future. 
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8 Abbreviations 
 
λ wavelength 
τ fluorescence lifetime 
°C degrees Celsius 
3D  three dimensional  
a.u. arbitrary units 
A  adenosine  
AA  amino acid  
AIDS  acquired immune deficiency syndrome  
ALIX  apoptosis-linked gene-2 interacting protein 1/X 
APS  ammonium persulfate  
BSA  bovine serum albumin  
bp base pair 
CA  capsid protein  
cART combined antiretroviral therapy 
CCR5 CC chemokine receptor 5 – HIV-1 coreceptor 
CD  cluster of differentiation  
CD4+ T cell  T cell positive for CD4  
CXCR4 CXC chemokine receptor 5 – HIV-1 coreceptor 
DMEM  Dulbecco's Modified Eagle Medium  
DMSO  dimethyl sulfoxide  
DNA  desoxyribonucleic acid  
dNTP  deoxynucleoside triphosphate  
eCFP  enhanced cyan fluorescent protein  
EDTA Ethylenediaminetetraacetic acid 
eGFP  enhanced green fluorescent protein  
em  emission  
EM electron microscopy 
Env  envelope protein  
ER  endoplasmic reticulum  
ESCRT  endosomal sorting complexes required for transport  
EtOH  ethanol  
ex  excitation  
FACS  fluorescence-activated cell sorter  
FCS  fetal calf serum  
FLIM fluorescence lifetime imaging microscopy 
FRAP  fluorescence recovery after photobleaching  
FWHM full width at half maximum 
G  guanine  
Gag group specific antigen 
GFP  green fluorescent protein  
golgi  golgi apparatus  
gp 41 glycoprotein 41(kDa size) 
h  hour  
H2O water 
HBR  highly basic region  
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HIV  human immunodeficiency virus  
hpt hours post transfection 
kb  kilo bases 
KCl potassium chloride 
kDa  kilo dalton  
l liter 
LB-media Luria-Bertani media 
LPV lopinavir 
LTR  long terminal repeat  
LUT  look-up table  
MA  matrix protein  
mCherry  monomeric cherry fluorescent protein  
MeOH  methanol  
mg milligram 
MgCl2 magnesium chloride 
min minutes 
mM  millimolar  
ml  milliliter  
mRNA  messenger RNA  
myr  myristoyl  
NA  numerical aperture  
NaCl sodium chloride 
NC  nucleocapsid protein  
Nef  negative factor  
nm nanometer 
nM nanomolar 
ORF  open reading frame  
p6 protein 6 (kDa size) 
PBS  phosphate buffered saline  
PCR  polymerase chain reaction  
PEI polyethylenimide 
PI(4,5)P2  phosphatidylinositol-4,5-bisphosphate  
PIC  pre-integration complex  
PM  plasma membrane  
Pol  polymerase  
PR  protease  
RNA  ribonucleic acid  
rpm rotation per minute 
RT  reverse transcriptase  
RTC  reverse transcription complex  
s seconds 
SD  standard deviation  
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEM  standard error of the mean  
sfGFP superfolder green fluorescent protein  
SiR silicone rhodamine 
SP1 spacer peptide 1 
SP2 spacer peptide 2 
STED  stimulated emission depletion  
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t  time  
Tat  trans-activator of transcription  
TC-tag tetracystein tag 
TEMPO 
TFR 
tetramethylpiperidinyloxyl 
trans-frame region 
TIRF  total internal reflection fluorescence 
Tsg101 tumor susceptibility gene 101 
U  units  
V volt 
Vif  viral infectivity factor  
VLP  virus-like particle  
Vpr  viral protein r  
Vps4 vacuolar protein sorting protein 4 
Vpu  viral protein u  
w/v weight/volume 
WB western blot 
wt  wild-type  
YFP yellow fluorescent protein 
µg microgram 
µl microliter 
µm micrometer 
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this thesis. 
Barbara Müller conceptualized and supervised the project and provided substantial input on 
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